var title_f9_55_10096="Myelinated nerve fibers";
var content_f9_55_10096=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peripapillary myelinated nerve fibers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 282px; height: 361px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The white color and feathery borders are characteristic findings.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl C Golnik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_55_10096=[""].join("\n");
var outline_f9_55_10096=null;
var title_f9_55_10097="Etoricoxib: International drug information";
var content_f9_55_10097=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Etoricoxib: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Arcoxia (GB, IE, NZ)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Nonsteroidal Anti-inflammatory Drug",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), COX-2 Selective",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pain and inflammation in osteoarthritis, rheumatoid arthritis, and acute gouty arthritis",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adolescents &gt;16 years and Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Osteoarthritis: 30-60 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rheumatoid arthritis: 90 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acute gouty arthritis: 120 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 60 mg, 90 mg, 120 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10381 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D4C8FA2A70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_55_10097=[""].join("\n");
var outline_f9_55_10097=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303434\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978812\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978815\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978811\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821182\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978814\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10381\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10381|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_55_10098="Disseminated superficial actinic porokeratosis 2";
var content_f9_55_10098=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Disseminated superficial actinic porokeratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous macules with peripheral keratotic rims are present on the extremity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_55_10098=[""].join("\n");
var outline_f9_55_10098=null;
var title_f9_55_10099="Cyanide antidote kit: Patient drug information";
var content_f9_55_10099=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cyanide antidote kit: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/16/14598?source=see_link\">",
"     see \"Cyanide antidote kit: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/29/19926?source=see_link\">",
"     see \"Cyanide antidote kit: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F155081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cyanide Antidote Package",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691802",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cyanide poisoning.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702941",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sodium nitrite, sodium thiosulfate, amyl nitrite, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705331",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Amyl nitrite:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694774",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use in your nose only. Keep out of your mouth and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695647",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sit or lie down before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694645",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Crush vial between your fingers. Do not take off the covering.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695098",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hold under your nose for 15 to 30 seconds to breathe in vapor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Sodium nitrite and sodium thiosulfate:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12122 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-04D01F2D42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_55_10099=[""].join("\n");
var outline_f9_55_10099=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155081\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015933\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015932\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015937\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015938\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015935\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015942\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/16/14598?source=related_link\">",
"      Cyanide antidote kit: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/29/19926?source=related_link\">",
"      Cyanide antidote kit: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_55_10100="Reactive arthritis - oral lesions";
var content_f9_55_10100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oral lesions in reactive arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gray plaques are present on the tongue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_55_10100=[""].join("\n");
var outline_f9_55_10100=null;
var title_f9_55_10101="Livedo reticularis in cold agglutinin disease";
var content_f9_55_10101=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F61212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F61212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Livedo reticularis in cold agglutinin disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 452px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHEAdQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxK8iO4MOVP6VU2nHetadQgCEHd39KRLbjJHFcZ7SV0ZgjJwQDTwpAB5BFXLgBQFB4FVSMg4PSkw2HI4Ye9RsMjHHNMyVORTg6sfekimyu4IbmjPtU0gyPeoDxkHOf51aMZOwuRjNIv3hikz6UZ5yBVE3Jc8ZobBpucigHFIdxQSDkE1bgmKjOenpVTfijzQB15prcTehY12zW4i/tCDk8CVR1B9axU3KowT/hWml08e7axweoxwR6Vnzqx3GNfwqnqTGXKLHctC4Ksa2V1uI2xDn58VyUszbiMYIqMb3455p+zTJ+tuOiOhTVyJsqcDPSrt1r0H2b1kPYVy8dqzdSRXp3wq+HP9vSrqWpoyaVC2QD1uGH8I/2c9T+FNUk2QsVOxj+HdO1zViktlpUrxH7sj/Kp98ntXGaszy6pctLjf5jKdpyODj+lfWmrvFpmh3r2y+WsFs5AXgBQp49q+d/h34bTUZvt18heJP9XGf4z3J9hVT5aKchRVTEyVNCeFtGeS18x4DIWIKxZwWHrXRyRX1vt32USIASNwyR+PpWpcR3Wnu8sSrGD0IUnj+lUoNQmmulLSBsDnA/xrzpVHN83Q+jpUI04qJpaZfXc6riC3IAxtWPtXQaZeO0wjuPMjTHy8n8qbZSRFUco0Zx2HX9KsXEeYT+7aNicg7T19cd/wAK5Lxk9EdSSSNO3tN8mYXUOwwCR1+hqe5tDeAxXEO2Rejev0rGjuJ4HQOfMz33c/8A1xXQ2V3HOFJ+Zk5K4wV96563PF7CbaM37P5CuCX4HI/r/jUUsBSFGAV0I5YDr9K3rmNTIrKCDjJyCdwqnNbCGJ/LYhWwVXsKyjNsadzFtVjMgjkBCgEqVORmuI+I3h6G/thc22PtSDdvAxvHvXobRR4MRUrIpJXHf6UlpZLcRlLwLLuOd4J6e1dNKu6MuYwrUo1IuMj5eYsjFHBDDrmk617D8RfAMEkL3+kRyBuWK/3h6149IjxyFJFKsDgg8V7tGsqquj5fEYaVCXkIvAwcVDIpVvapcepocb0x+VbHOxsTevSmyIVOV6UwNjiplf5cHpQIbnI9xTT0NOIxkg0wmgA6ClBwSaaelBOBigBSxJ600Ak0YzTug96AFAA4NB2ge9NwT0p6x45NADQC3HNPEaj3pxIFLv8ApQAAcUo4pN1GaYCkUmOaC1G6kApBFJigmjtTAQ5xgk0hGBxmnnFApAR7setG5T1p7DNRGgB5UdiaKjz70UAeoQlZGcMARnIPvRO2xSOlVrZtoYZOM5qG9uSOO45rkPY2SIZ23Oec1EQduBTPMJ5pTISOOKW4Jkbdagk4PBx9KlJyTTDyT6dqFoTJiLO2Bxk+tM8xifcUjnApq8H61S2M2+geY2ev6UhkcDGf0p2KRlPWmhWG+Y3rQGYg801l/Om5wcYNMQ8s3ckimFz6ml3Bu9NagTHKSSOTUbszkqp49aUZxjmnhQOAOlXEzkymLZQSWySamSFQQAKnwSamtLeW5uY4YI3kmkYIiIMliewq7tmNkjpPhx4X/wCEl8QxwSkrZQjzbhx/dH8P1J4r6PFuLW2jhtYVht41CoijAA9Kxvh/4WTwx4ejtpghv5v3l068/N2UH0H8810/mjODxxjgVrFCZxfxEaWDwVqaop3zxCEHP98hT+hNc14fit9O0SKNMDYoGMVt/FTUEaGysEyCzG4kA6ELwo/M5rz6We4Ee0zFR6E9PavMxt6kuRM93KqVoOo92bGryR7MmNsHPfGKw7XT1kbzNz/LzlT/AEqzblGCmd2dgOF3dvpWhZtsOJUCR4zisF+7jyo9ZRuOt7loNsUZd0bruwa6e0u4vKWJCGRfXOB9PT9K560iimuh0wO5rRML25yuHfkghsEfQVnyJ+o59i9qJztfCs6nPToP5j8an068Xa3mxnPUA/41khJ5Bklgo5DY5/H1qbT5pBOY5k47tiolT91oatY6eRsWxkJ6DIw1R2jPMgklTjPGP0OaswQxyQhScKeSpHb+tWEWKFSpIPYKx4x6V5stNEZt2WhmaiAm1ohtcEjaemfapINtzbdDEQOcevtUd4WyuBviz1HzY+lW4bZpAFRpMHlWPH51cneFmN7akCBJHZJHVg3945zXjXxc8Jra3h1Gyi2wS8sq9FNexyQSJclRkMvqOM+1UNZsv7R06eG6hABHGO/4etb4arKlNNbHJiKKqxsfK75jYhs0gIPSum8XeH5tLuWDRnyiSUOK5UcE19FTmpxuj5qvSdKVmLMuDkdD1qMGp8bxtBquB81WYj6aadTW60XAKQ0ppQPWi4AMKM0Ku480cseTxSmQAAKOnei4EgXaKCaj8xvb8qA574pgOppFO388/pRlT60ANoB4pTjHem44NABuNGTTcYoxQA7dS7zTe1KEb0NIaV9iQNTgRUW0gnOaFY980wZN1pGGelNR+epqTqOM0CIGXnrRUhAzRQB6IuFmkVemP8msy6BaRueO1WLYsJ+TwRiorgZauQ9foVMEdeaXHB5OKHApqmkSHPvTR0p/06mmkUARuPemVK2SDTAKpGbAdKXGO9Haj0AplChc0GMEc4pc4pQSe9MlogeAZ4pjxbQSaujB681UuXDSFR0X9apIiTsRKMU/qfem1LEjSOqoCzsQqgdyelNGI6CJ55FjjR5HchVVBksT0AFfQXwv+Hq+HEj1PVgraw6/InUWwPYf7R6E9q2vhf8AC2Hw1aRahq0Sy61Iu7k5W3B/hUf3vU/lXfNahSSxHHbFbRj1Zm2ZTOuTzz7jmqq7nmkyDgela1zGFI2kZHGK5rW7/wDsvR766PzS8rEuP4zwv681Taim2JLmfKup5j4nnbVPFl7Ism6CJhEm30UY/nk1Vkt4hhkEpPQkitOwiht0iR28yZvmlYjqT1NaDwfbSRFFtVOASK+enWbm5H1+HpezgomHb6RkeYGI5wN1R6rEIsIJAW9c1q3Md0ilI4C3bJ4quuizXSl5EVSP4jUxb5uaT0OhRJ9L0rzIg53FeuUNaAgwwRHLADJRuDj8eaXSrS4tCIy5CDjIORjFb1qivkFlIPVscU5Np3Mno7mZC6W8RxHgEcjuapQ3QWUtGeRkjd/LBrYmt0EhTC7SemeKoGyxcE7Gyf4hjFKnLuNNGlbXpkgizkN1P+Bq9cW/2hFAbapGQfQ+1ZNvGbchhjaRg5HA+o/rU0d5JACFwU3dB0x/h71zVEm9Cb9gkWWymXGHQ9V3YOK1NPLvbghmQKSdrDkVWjdLjaZSF2n5e4NSy3YWUrjPHUnFZSldWCUtLFpWR1YEZGMHjr71S1NQUKkbOO3es+5vninyA3oOarahqxeIE5+UYNVCnLmRDi7nP+INNh1eCaAoGHTcOoP0rwnxHpU2lX7wzAgjocdR2Ne+Q3bO5ZOExk471xHxMskubNblAN8fBPtXrYeq4S5Xsefj6CnG6PKEbnIqOUYfI7804gqxBpWG5PcV6p88Rg03PWlHWkFABS9TSU4DigBCe1JQaVVJNAJXADNOCeuanSPip4YC5+UZ+gqHNI2hScioI+9Ls9BW9Z+H726I8uJsE9663Rfhzd3RBnLRqe+KylWjFXbOqGDnLoebeVQYq9uj+GNpAg+0T7mJ6E1YtfhpprsS7lj2C1i8ZA2/s+Z4T5RJwAatQadLIyjy259q92h8E6dZSMsSRM3YSDmrP/CN2KIN/l7s5AHGDUvGw6GtPLv5meRad4SkuGQO23PtXYW3w+0xFX7VO5LdhXWvpEbsqxPsI/hBFEmnmNSY5mZgOjNWX1hzejPRhgaUVexzY+G2lXQKwyTx+5GRWNr3wmv7S3afT5RcoP4duDXcaTfm2u3EimOQ8cP1rtLLU1CbTJvyOckdfSqnXnT2M6mBpyWiPku/sLixnaK5ieJx1DCoI32mvpT4g+GrHXtLLrGkV6o3I4H3vY1846naSWV3JFKu10YgiuuhiFVR4mKwjo6rYMbuR3oqJJSF6/pRXTdHCzt7d8Oo98UTj5m7GoI3wQfTmrFwSzMeOa4j2FsUpPWoj1qxIBn2qFs/hVEMQN0px57VGODzTgaTAR156039KlPSoyMcgj3poTEHPTrSEil96SqEByBxTSeaceKae1AXEd9oJzVdTzz+NSTngDuTTPSrWxjPccK6r4aac2p+NtKiVdyxy+fJ6BU5yfyrlR1r2j9n/TgsGratIBlitrHn/vpj/Krgrszex9BWeoCaDMpBY/eGMY96XdG+4Eg7D82f8+9cy+oJAQWAMZPKipU1EeeVSaPDDJU8k1texi4mtdPED8qqSM49a8u8RXX9t6o1rYv/AKDbty3eSToSPYV0HjLXGsNJk8ratzP+5ixwRnqfwFchpiTRwLHbxAJwd3c15uY4lwj7OG7PWyvC88vaSWxDfaWbYb5GVAvAC8k1NZXkkYUMp29vTFWZYZbi7PnksgHT1qzc2afZ1H3QOgx1HpXjSmmlGR9Dzaala5lN2oREbJ6Y6UQrOpCBSW6EmtPRbNsYRAB15NbWn6dvmMrKrHpjOMUKUYuzFKcY6GQ1oojDTNg/T+VQvMyOVWQBeMH0H0rZ1W12S7unsKzZbIg71j3MRwCcV0RlGxnF31GCI3fIUAgfeHf2qpcRzQ4MOSn909F+la1hIgVlPyOOueMGn3SRuCWwSOuOlR7Szs9hc2tjLhnEufMBVwOM/wA6SeEIhKKWU9e1RzywwONo4OQOcmozeFF+V/px1rOa1ugkuxntdSRSsiNn29Kml1APFsfg49Kr3U8csocLhh1PSs29A3gwvuGaORN3BstC/YuwyGPqTTpZY5YMudjgcjPGawrgsFJTr71BLf8A7oq/Ycg9a3Ub7ESkadrIsbMrEkH8qxPFMkb6bNGB8u08mkXUQVHzDJ6D1rD8QXzC0dckk5+lbU4tzOStUVjzm4GGP1pqnnNLdH58Z5zzUcZ6ivYWx85O3M7DX++cdO1Npz/eNNpkh2px4FIvJoY5JoAAMmrVvEWI4NR2sTSvhetd14a8PNKgkdQT7is6k1FHXhaDqMy9I0GW6CyOpVM16R4b8K2m1SBuI4ORmpLCzjt3SIkbgefQV22mrbwgO7DCjnHFebXrNLQ92lhowRZ03RoLONdsQY/QcVcmCqGKBOegzULahEWCQsGzzkUy5nVtoGWLcc8hRXn3lL4jqhCw2SBrxgZEwq+h5qVkSFNiPt77T1q1aNGlsEXZg8s1ETwFiAwZj0z2qefWxd9TDvbj7PK3nxnDdM9T+NZ0l8s+Y7dGyOpP8PtiujuTESIzIpfPQ4JHtiqF5HaEHbuQk9NvH4c5FbRlBvVFL0OZuZJTJseXYemDjn35xxWhZ2ZeFMysB0Dg5Rj9exqadIBHty7xjnDt0P8AWobK5iLtG7eQxOAduA/tzwa2lJ8t4jk2Q3tpLbhzJGky9MMeQfTIptvlIme2coI+WVl5X6ip9RsXkUMuN+MblO3d7HsawZ3ntgyXvzqRlGBzt+p6j9a0hLnWpnzHS2+pHZhWDJ/EByBXlfxcsYhcJewgAvw2PWt6DUphJ5gk3L03DGcfhXP+PrsXOmEA5IIJNVRhKNa62OPGxUqTPOAcCim9aK9ax8v8jtyCp5GKm4Ma5PbFSyoHQdC2KhjBCMvORXIeskQuPaoGA9asNng1A3NMlkRJz2xSqenSkb60nQZoESZ9M0N0po6U7nFAxpB7U09etPppH5UCEptL24601u1UJkNweRTCfQ0XJwVNQF/mq47HNJ6k4brX0B8K5Ra+C9OQDDSF5fxJP9AK+eAfT8q+hfDlpLZ+H9NiJHECHnjGRn+tWtBbnXvJu35PDfjVR7loJ48MOeCc9KzY7sqfUA5qPX7jy7ANGAZGG1D6EjrTc1FXZUYcz5UU7m5fWvELH71paZijyeGb+Jv5Vts7RW+FABPoOlYfh2JoYgAOFGM+v/161XAGWMnJ5+lfMYmq6tW7PpsPRVOKiXrSaLyTI4Ck/nVpiH2xpGCWGSc1hRCSRwFJPP8Ak10WixSLKPMUHjk4rN00tTeStqMs4JLZ95icqCSQK1vPWONSSFOM81dcqkQzg5498Vn3yF0GCpHc9atNPoc/NzvUraniQLIMt6DNJGkUkSkyHIHfiqE91LD8jAnHKjHH0qva3IWTaxxnn6H0rVU243L5dB91G6XHOwE8k57VUmutoZGztPv3q5eXMZBJALd8c1kX8kTxFgcFRwT3ob5rJjsUrslzhSN3bPT6fSo4LlMeXKCG6EdaZHdp5gVScY54qtcujygs2GB4Iqne1imxZ2UTNhgSTxjpWbK5V2znYTxj1pbyUQEDjB7iqbTFk7Y9qajoYSnoJdT4IUN9cVj6jkk4PPXPrVi8kC/MCOlZjSmRzXTShpc5p1LDIpWVRv6g1heIr0JGVB5NaGq6glrFliM9h3NcTd3D3Uxkkxz0Fd1Knd8x5uJrWVluQMSxJPehThqVULcKCT7DNXoNOnZCzqUXsSOtddjzCg3UmgCrkdm0k6xJ1JxXXab4XiESPId7HmhK4HFLbyeU0m07V5JNQnrXeeK7NbLRXCKACQK4Sm1YDqPC1h5gWVsYAzzXounkwwbEPzMOw6VyWjKI7G2QA8jJxXY6LaiXBP3hzn0rzq0usj6LCQUII2tG09N2ZWLSHBwO9dBPYBkj8p2UocgE8H61TsojGg2HkdRU81wyJ0bb0OD1rzJVJSlod8W29DRs4Y4kP3fNxy3b8KrXAAJETFc/xH1qO3nVlOwkgDgnjmo5A7yjeBszkZ71GqldmqbvdiW4mVWLgsM9QOv4U+FnSVyyOIxzgnkVqQNG0YUKMd+MVJ5Uh+QwhgehHNONSN9gdQyJnLBZcJljgFlFV5pnXiSIBD2YY/TvW1eLKkK5iUbeMjBrN+0tgpJCsgHbowreE4taoOe6MaS3ldm8sAo3ToT+nOPpVQCaLO2IOB1Rxjn8a1vtcJlXanktu4DDp/StCZI5rch3AdTxt5z+B/8ArVq6sUgbOLu7/wAhmEUht5B/Cen4j0rHn1pomPmRkI+QSPmT8O4rpteslniARtpU8HPB+noawmhghh2XcSshHIxj8fT+VaRlFq6M5LsZF3GsEX220ceSx/eR/wB33rA8T3YmsCVwAxxXRyw28bu+mT7kI5jfkH6+lch4jhMcDbRhC2SPQ10Uo3dzhxd1TZzBopwortsfNo9BJKkqRnHAxTDtLfLznqKnuVCT5X60OU2ZIAbvXIesUZFwT0qBvSrUi8txg5qBxnOaExSRXI60wdaldfSojgNTIuAHrThx0pnoTilHGaQIeKCM0g64pw+vSkURMKQipCOhppGOeKollO9z5SnsDWfuNalyu63cdxyKyCevatIHLV0ZueEtNbWvEumaailjcTojD/Zzk/oCa+sriytWIVAoVV2r9AMCvDf2dNGF54mvNUmRjFYwFUIHHmPx1+m4j6V7rdISsiqrYU9vWtl3ITOdvdNbG9SpY8lc1gfPezJCgJWPKhj+prb1y4a0iVQSJ5chT/dHc/4VV0+3ECxkfMx/hHXFeVmNflXs0z1cvo3/AHsiaK2NpGDgsTxxUkUcl2wDLtizzxTtQlmhjjVQFJ7deK19LDRwK5RSD15rxOZqNz3L+7cmsbGIBWAC9iD1q/BaEgFcbO2O1MhBlk4Oc/MfQVcy4jAB6e2M/WnFvqc8pyZDNIsIKvycfeHQVl3OqR5HzJ8oPy46067V3lBZmyf4SOvvWdfWvH3Tg8nAzmuiEE3qaRiupVurgMyspJVugPaoWgWZVwGR88nJNIskVuoeQAtnGCea01lhkXKxsCOeTitpy5EW3Yw5opojtkJGejA9aqS2kzqzYygrfuts6jdgehrJ1COeNGaDovBGcHFYqpdhzdTEeAo4ZxlfUGqN6PKO7lgKtSyyO3yMAT69Ko3rvtIKnJ4zXQlrqRLR3ZmXVx5+CN3ToKqvcMoAHT3NXGiAX5VA9SKz7xBHyDxn8zXTGKeiOSrKyK17KXB9qxr+/S1i6kyHooo1fUdp8m3OXP3j6e1Z8Fg8x3SAsx9a64U7aHmVazvZGLdvLdSGSVizE9PSoxA3cYFdSNFfAwvNINFlJAC5OfSt1pscThd3Y/wpbyCMo0anJ4OK2L7S1ALO9a2h6ZLCisyDKrxmmalDI0yrsJ5A6VomyeVFbStAijxOyDefWup0zSxNIiKQu49T3FT2tsRaoz/Iir82eTXVeEtNe4he7kTAYbY/YVpEwmzyv4uWD2Wkxh8YMqjI9K8jPWvob9oOyEXhKzlQfKLhUP5GvnmpnuENUemaRGGSAADhAf0rstOAibIO3jqa47QpF8i3ck/6sZ/KulhmBUMSRjjGeK8XEXvY+nw+sUb1reFbjYXzu6H1q9JEZEJZgTjpngVi6dCDKJZGyeuPStSKTfJwU29NuetcrVnodqW1i5YLEuFYjd/d/rWhJGgwTyo9+lZUihXDpBjHcH+VOMtwIyQvynt3zUOHM7o1tc2I5Y1GFYjPTmmXE5jIYPlwffn64rO02OWV4zK5XnO2tTULaMhWjU5HPGB/+uqVJJ6kNJMfG8s2DKM5HVeCaguLeFmLZ7YwRtx78dPqKihvLlJlG/CHjBqfUZpI7N3UKwHJ296JRcZWQONmYV9pTkboJ1dM5CE9Px/xrNt7uawfZIC8fXk5K/41bkv0mCpFhSTyucc/41Rv4Z1RjsyD1yMkD0rpSVrTGlrqT3c0F3DlXKE8cDH8q5TUlu4JCobKnPyHoR+H+FdLYWEco3h9rA5wai1rT187zVJZTjIqqXJF2CavojjrOBHnUxK0UjclCPlb6GsvxzatHaLKgwpPIrs7uxe32SxFHBOSP7v4f1qHxhYxXfhi4k/iVdw+ta+15ai7HHiofuWjxbOKKXAzzRXpWZ8tqeiXPzKD/EDj6iq2N3API9a0bmMNGdgzwKyixyQR9DXJc9Ynl+ba2MHoRVaRefpV1iJLZMAZXg1UkGCePen1BkDgk1E6kAnFTtz0FMIGMHFMzsVz1o6d80rimj3607CHE57U4HOKYDwaUHgUmNDj9KCOOKOSOaOOmKQMYV9sisi5h8qdgRweRW1gela3hHwy/i3xLp+kRAjz5PnYfwIOWb8BVw3Masbo94+AOhrp3w8imkjInvna6bPdei/oP1Ndqs8duJHlKrGAWduwA71pW8EdlbPDbxbbeCHZGB3UDaB+AFec+N9SRxHpsZ/eN88/bA6hT9eta1qipQ5iMPSdWfIjIuLo6rqU94FOZDtiQ9I0HT8e9bVkohiDZBPc4rLsnjtLfKc/1NXraXeyDGQfvFa+WrOVRuTPqIU+SKitkaEsSTyoWDb1GPoKtxK0XDKQnQ4PX8KovMY5FVCcd61LWQSQBGY4PXiphB2KaaRdtJlXIiC7m5x3pjy4fAbBLYIB6VDLJ5AUBcM/C4H6mq5nCTB3TGD+dbKBnbW5dVWJZQQWB61XuovMjCltgB7jrVuOZGK4GM9eP0qldyI0hj5I6/Ss7tMSbbOVv7dhdHLblz1BrQtfLxwecbeeppNQSNlwxOM54rBFy0VxlQwI464rod6sbG9+ZG3dKdw3EqfQd6pahKrIV3HPU0F5WbcoLKDnGOgrLv7uTzCsfOO+KyjT1MykkTSOWYjnr2PtVW/VECru+Y5rVUqVJLASEdCMZrH1AKR3B5xzXTBtysZzlco3DrgqvIA61yPiC+cEQxf6xu4/hFdFIGWB2kztUEk1ztnZPc3L3EwOXOQD2HavRoU9bnmYqdtCrpOllyrSDLeldVaaVtVXdQB16dKsaXaquAR05yK30VdnzgFc12I865kLYJgkAe1aGmadHu8x0pIwWlAUnrjFb9pbcAdWzzimtSWyWxs4iRGwAJ71K/h4S3gQJlQRlvQ1t6XpXmuHYcgcH1rpoYY7VCzFQkaF+a1SMXK2x57rViHvrbT4BwxVCV9e9d/baebSGOGEL5Ua7V9xXKWiq3iSK6fJ25bn1612P9ox8FztT0qjJ3ZxnxN0SPXPCl9p0rCNlHmRyH+Fl5H4dvxr5JuYXgmkikxuVsEg5Bx6Gvrr4hSi60ySG2fd5inLDjHGK+ZdT0x4JnjlTocZxWVSRpSp3Vjd8LsJtEhPdcpW9Zzbdinr9a5nwfiOK6tzwAd4FbUasZx5fXtXBUim3c+hwknyK510NwjRopON3FblhaxouQw45y3rXJW0MkLCYnnsK6G1mk2LtTgDvXm1VbY9BG3GUJCu65HTFX1jjcBmVSw71gWwNw+WyoBrRiSSBjsfePpmsOXzNLFuRmhOUClPXHOao3swkZthTzMcseKszGR4wJFAOeGU9azp4Iw4Zw+W429R9a7qMVbURLaad5kqkTc9dobrVu70iaWAqHYxegJFV7K3eOZmZd6jjmuw01beeHOT5vfJrOvNwd+g5ytqeX6vok8MXmWxZ3HVT1NZltrksCiK6QkDjJ616nrtoiRM5DFRx8nWvPtVsopXw0eST1xjNVTrRqx94cffV0UDqSRziVDiNuvpWnNdxSWqsFJBGSKzzoJdP3LlTjgf/WrOuori1IR0Kqp7fd/LtVuMZbCvZnQw2scsG4/MuOnp+Ncp4wuPsmizJuyrAqorasLpgOXbn1Ncp8Q2H2QAcgc1FGLdS0jlxc/cZ5eepopjcnpRXtnytz2CawFvEptlPlqu0rnccVzsqL5jK3bpWxpGqG80K2cH95t2uR1GKztTj2yhgOCPzri+1ZnowldEcI2Ag4Pf602627QVGDTbdvvKe4yKZMe/btVXNLET8jtmmHp2p56e9IQDyBVXIehAwz1xUbCpiBnGKa1UQQqeeacDx0pH9qbmk0O5KDS96jU9qeD+dIBwr2r9myyP2vW9SKJlI0to2Yd2OTt/Ac143Z2013cR29rEZZpGCoijJJPSvrjwL4dg8MeGbTT7dAtxsE13L1LOV5P1/lWlKN3cyrSSVjW1u/t9J0m6uLnasFvGXdgeWPQD88D8a8KlNxqEk9/dgq8zFmGemTwB7DpXZ/ErUPt17b6PC+beFhPcMOmf4VP8/wAq59kRyFZh5YFcOOr3moLoeplWH5Y+0l1INOjabgltinAz0HvXRafH5kjbHBXp0wM1W02zMqFkbCkYC9ABW9plm8Q4UkZwVA6V5NSaeiPWlJJDxZ+ZGoOEY981amtnhiLxjOOoHWtZLRFcMWIYikuiiwsxcEHqR/hRTmzm9o2zn4BNtOWGQfvNxmn+aiuGkVXTPSpWnQ3EqRjCKBtOOD9az9R2s5ZNoKitlqy07my0a+UDFkA479qyr2FxMxG4KSOelRi8VEQM3IHOOakmvVdAwfP1rmneBGsWVJB8rJKnHv61haq8EcahY23cnd3q7qUpAO0AZ6cnmsDUJi6sSpDk4GBmtqN73NEy/p16GhwzBhnnFJLLCzN+7AI4waw1RoiDzuY8k8VPEDuLuWJXkDrWkqet0Zta6E19LEmQVIIFYFxcBiRt4zgE1d1CSSRuhCkVnGMHGV4rqpQSV2RIg1FlNosKEsZDg+4p1hZjfnHAHWo7hGN4hC/Io/DmteM4QAKMgY4r0qUbI8PEz5pjFTCfKCCTVmMmPahG49zikUblwM9e9aVpZGRlJXOenvWqRg5JDbCz81i44HY12Oi6VvIZ0O0DJzUGl2C5wV4HIB9a620hSKPoeR0PatFEwnMntrVI428vgd8Cl+ypdW9yzIWIQY9sVIXwhTBJ/Sr2mqDazYUAkYxVmZwYi8m+ErjBHGBS3cjK5TkgcitHVYSJn6Dt1rLd+CzDkcUmNGZqBzhDjpk5NcB4i0uN3chc55zXe3WNrOwwxOSK5bV5NxcIowOprN6m8NDz+xtvsuoEjowxwK27JB9oDMuVA7VHHD5moLxgZrZ+zqEZs/lXn4iVnY9rBax1LEEqzypsU/lXQRbdiqQCwrnrI7CNi7gOpHWt+ymjjw7kb+wPNebVi+h6iWhpRW6KgIByeSBVuFUEgKoQT15qAypJGHZiQP7tSwToQSUYj2rntIaT3NE26GI7j5Zb+ICq7wxebggYHG4cZ/Co5JcoCrEg9R6CpNPl81lKbmVj/EMYrogmlcFcsLp8TwgJgN6HmpYYpbUZXCsPbitCCKEuGQgPUt7GGiKsfm9qyda/usn2nRmJqOojy8rgMOoIzmskyR3Mm2RMN/exWzc2GYgGQ4x1NZK27wk+UM49eeKUZRSsjWFktC2bJPIAaMMV5BFc/r9tbz2zSRAiRc53DkV0dnfAEo/3R7GsfXnhNyGU7lYEHnpUwlLnJkcHagIG3DnOcVyvj+bNmpz1NdROjrduwDbM4zXBfEW4H2yC0U5Ma7m57mvaowvJM8vG1OWm2zj8ZopwHFFdx8/c6jwbctmW1DYB/eKPXsa6PUATEO4X1rg9HufsmpwSk4XdhvoeteguEZTz8pHp1rlrK0rnZQldWMhSA4yMH2psg5I7CiZSpGexxTpBwOeCKSOkh9KbyB9KXg9ulH51SEyPnOeaa/HrUh+tMcZqkQ0QsM0xh04qXFMHLUxDVPNSKeR04qI49a9O+CXgGXxTrCajexhdGspAXLDImcdIx/Wi1yZS5dWdf8DfA8kEZ8Q6jGY3ZcWyN12nq2PU9K9d1K8h0rTrm7nIMcKliAcZI7D8eK2GeKCARRxxIijCjHTHpXl/xP1Detrp0Zz5jebIB/dHQfiefwrWpJUoORjSi69RI4xppLye4mkYfaJmMkrehPb8OlaGm6eZHVi2VHfHU1XsrdN8cYfDH52HfHvW+kqwoEjwvv2r5upUbd11PrILkjyxNSwgC5AHI4rYs0zIF+8euewrFivI3gHl5MnfHetnS5R5eZc7+2K4+STepjUuX5oCSxUnP1rPltQC7sCuD0zkYq7dGaVWYqojyAFHU08rlMMQSvb0+tapuK0MOaxy14skEwIBCE7h6YqLEdyf4fMPXnIq/qB4bHfjpWVAcOSpx7gc10OV43R0Rely41mPszMMDaPzNY0zOmQ2DnGOMVrh38o/KzZPOKoTypErAsNp6ZGa51O+5MZPqU5LSVcFiCB2Jpk1pHPGvnYB/lUk19uGEGSvbNVLy73wgq21x1FXFybBtjLi3j8pcxnjgMDWdeMI02xgA/3qvrOTburIWk9D0qheusgUKhBPUV000+oGaySO+3acYzkiny248pflIY8VdVGEa4TJOOT3qVk3HaVywHOK6YayUTCvPki2ZjwpFAuBns3enuYRGHTBYnkdDU17BtQOnOcDHpTbWBJyRLEGA4z0r17WPnr31J7ONZHBY9+cetdTY2mNpHy5HpzVG302HYhVR1zx6V0mm2ihF3H7veriZyZcs0AK7EwF6nvW3AqYV8k54wefzqlBFhdx29PXGasjGfkJrQyY+VVSUE9B3BrU03DbuBgj9Kyzlvkf5jn061o2Jw4OSVHBFAmc9rkI89iRlvc1zMjLuIx8p4OT1rs/EcY85UDckdfSuN1LDSny+UHcDqaTBGVrAaFN2fkYda5W9QohIyQf1ruWPnRxxsoZAP4qz9U05DCzIOMZPtUtXNoSSZ57bENduxx8o+nNWhcDftOWDdqZdw+RIyqOW/lV+2tVMKs64yOteVibc12fQYJWgi/ZLhFVIwHbqavpbbgTJ970FO0q2V414bI6H1rW2iFdpUFj6ivNnU1sj0VJLQy4rUxHLPgZrb00oY/mfdu9qzbgr5o+XJb34rT02zKpw3zdqp7amratqXXtPNmBj4yMHHQ1dXS0I3sWxjBHSr9vBmAKVHIz7g03O75XxtHB9/rUe0b0Rhz9EENsIghQEkfeHU/hV2SNM7jlm6cVUmlUhAhO8Ywc4x/jU0HnbD5jIQeTmsZRe7Iad7jblC8IZWwO3HWs8Q5ByBgjkii8uys/lyDaM8spqdQBGSCWHqK55JwVy1dI53VYxCS8Z2r3rGuYkcgqwJro9XBNuQqjGPWuQnZ4oSSCDuxiuqleSTRpKV4FXVoYbaN5JB8qqWJ+leAa5enUNVubntI5x9Ogr2P4kXkp0mOxtG/f3R259B3/ADrI8EfDW3ku4p9Wl8+McmFBhfxPevewcGo3Z87j6jnLkRzvhX4c6vr+kJfwQssLsQhYY3Ad/wCdFfS9siRwJHAuyJBtVVGAoHbFFdljz+U+Ob6MRXcir93ORXZ6Lcm502FtxLAbTnpkVzGrxhgkgHTg1c8KzkSywZOGG4D371zSXNC5tH3KjR0l3F828DIYc1XlXEa8Y4x9auEErjoBUd1hUGT09awizsi9LGaetB5FPkiOCVpvIHIIrRBYjP0NMYflUmCRmoz3FNCZGT2pAMdqGBH1q3p1nNqF7b2lqheedxGi+rGqM2dD8OPBN5401yO1hJis4sG4uCOEX0Hue1fW2l6XZ6FpcGm6fEIbS3TYiD+f196zfh/4XtfBnh6KxtcPK/z3Ex6yv3/D09q2JXfy8uRtPb0rohFI5Kk+Z2K0rM8bOcBQMknoMd/yzXhmp6p/amrXl424IW2RY5IUcCvS/iVrX9l+HJo4mKzXX7iMjsD94/l/OvJbBWaNUhJ3N/nFcGYT0UD18poXbqMvWMiIDIzFpDxW/pyJc/f6Ecj+tZlpp4jlTzgW3Y4HrXQ2ccNqjHZ84OBXjVWum57knZaFqOEWyA4PsQK1dNPluobLIeckYxWVBI1yxbDqV4UA8GtOO42gb9zRKMZHT8aUU7amE3obDPEFYhiAvUE1m3NwYpGEbBlHIppm3hmjIYHnk1VLNNOWU8L8pT3qFG12YRh3Kd/OSnzgHd071isGaUBVIHUbeK3b6VEfayHI7AdayIZh9pYMeM9D0FUpaG8dglvXVlVAc91B6Vl6hOSxBwH9DW0Il3MSB83TjP41j6nCqz7ygYgdc1MOVshNXG28uyIFyAAccioxErTeYcleoU1ViukV2QNgdQCKuNIHVTkEKM4WtpR5Q8yzNGgKydsYODWLqIjDj5yCDnIPWrElxjd85HHA6VnTENktjI5565rWjF31FsSWpkLY3HHqfSug0iBSzytjaRtGe9c7byF8EcEDoK6zTUK20a4JcjJxXo4anzT5ux5eYVHGNl1KdzpguA6opBGc4P5VWtbGVCwKkEcEGu002x3Fvl2huTmnX+nYKOpHXGAMV6VtTx3KxkabEFCjIOB0ro7WPChihyeTxVSws1DjfjA4zW3aIiK43A5POe3FUkZt3I1iYD5smPPY96nAHmFV6Ywcmmtn764PoM0FixZRgZHJz0qiUxwdVYkZfHTHarMYEcoKOMNjK461SClPvMMKe3OatM/7yPyRvAHbpQMi1pTKDgnpjOK4e/BhdlydoOK7/UMmEnpxXC6kv735cls9DSYFO3YKdsgOD69qdeALA7AjbjJPfFSzD91ngHt71heJr1o7JYM4duuDjionLli2a0abq1FBHLSFbi8nbk9lGKmlOyFIEbLHqKhQ/Z4fMXBJGas6La/aJfNl5LdK8Sq7+89j6qlFRikizbzz27DcWPoM8AVrvcTXdsrRBwB3Hemy23mlFVQW9Aa1tPtFigKAsB3HpXJKcVqdF1uU9P015OZNwA5/Gtr5oYwFKrjrk0RSKrsIiVPTJHB9qk8qaT5owDGzYYZzUKbm9SuZt6ly0v32kgAnocGniJpS0mDk9R61HbWTyLudSqdT2q9aqBLtJwBzirlZbGbaWqIFQrISVOwdc9Kia5lMhEeAAcY9a0JbcONqswQ9fWs6cC2VgDvK/nWcpKSCLUhJkL5Z1QsOMetMikWOExsZNp6A0/zEeJSXxJjv6Vk3QnRsRsCT2JrncebQrfQjnuhlkZsqOxrm9VlKllP3Sat3cBVyQxDEcgGsm6Z5JFHYdc13Yakr6GVaXKjMa1W91tZZFDGMbUHpXb6eqW1uqKBvPJ9a5zTra4eXzUhOScjIroILK6Z1JXY1e9BcqSPnKsuaTZrQXaGIdfeiqLW2xmEkuGz0BorW5nofPOo6czW7kA429q5/TpjbX0UnPDYI9q7wgEYPT/PFQLp9kkvnLbp5pOc46GuOnNKNmbVKbbTRaIZMdcHvmmSfOCCMqeDmgsRw5J/lSrgnptB4rH0NEUDayxk+UdyjnaetQx3UbOUfKMeMMK1GUlsht386hmiSUfNHnHQmrUrFJtbFUqpPAwaY8Q3nBq0DGgAxgjjpTmh3NlSNv1p8xSkUHtyVz1Ir3f4A+CBBH/wkmpxkPKu2yjdf4e8h/p+NcT8LPBkvi3XyJo2XSrTD3EnTf6ID6n+VfUSosMCRIFREAChOFAAwFA7CumlG6uzmrTWyI7qRUUEfMV7elVDKZOCCUI9Ofen3TKzbSpBI45rN1K9TSrG4vpDmKJC55IIIHA/Gt3ocyV9Dyj4hXz6v4oSzQk21ivlnJ43nlv6CpdJsUgbzMZJ5ArK02GS6MlzcsTNOxldj1Zicmuk0gZtwzOD2x618zi6znJ2PqsND2dJRRYjt8TIWbknoOn5VenClwznO0c56g1BcKAUZnIfHQelXLPTzIqynJJwMmueCvZs2k7K7GxxF1Uw5Yk4/StBrc/ZFMwIO05xx+lWbSH7PGVhh3legzjiobmZrmUoXIZecluGPetntoYOV3oFqIYII18wZ25BI/nUbqocspOBz6ZqtPDceY5jcBepUHkj2NU5JZIY0WZxuPPynisZp9BW7D7+fa4OD0xn1rHuSplZlQbeOPWrcheS5wWxCwyBnnNZGorIpbY5GKmnHWzNVoWEvdxYqR/s4NRO6y5ZsK3YGs+ykiVsMGBY4DdeatO4kfYikkAruFaumovQmWjM64jRJt+RluB7U+K4CghQuMYPOMUXcJUZyM46VmBwA5wC5OOvGa6Ix5kT0LVw/nSHaAMe+aoSHJKjPB5pSz7sY4p8Kbuc9K6KcbESlZGlpEAJj3Hvk12WmQNMy4OR7dq5DTiCM9FH+c16D4XtibdZiAVbgfT1r08PDlR4GMq88jetodiDbuzjGMVa+xiZSrrt7D2qazgcgkgED+91P0rQjh2BV4IPIBNdR5rZgSWohbYycY/Wo94Td0291P+NdJqdlviEgPzDsKwJ4AquDgAe/SmNMYroQfLByB3qLaScNlc/nQrcKY89OfU0qszsQ5wM+lAyHEkZB5Poc8ZrZiSS4tVkt1TJ4b/8AVVA4I/dr7c+taNhuitSi5Jzg49aAZSuFnSN1mAC4wPUVy2or5dwzlc9s11t4r4Z5TjjnNcrqYZ2IUgg8c0mNMyZ5cAswAUDtXJazvlczyLud+g7LXRatKIwsWRuJzXPahebFCpkupwPevMxdZuahE9vLaNk5swZGdpEj2Df347V0djmK3QKmHAxtqpptoxc3F0qgtyvqK1YXUzjcB0zzxivPrTvoj2IvoXrKGWNN+0M55960IbkxAIVy2eg7fWqKXhWX5FJX7uK19OidiSy5Zq43pqzTZaleCKa6uGJG1ScHnGa6XTYAMK6gkcelVkgKOGKAkdxVmK4+cAxnaP4h/gaV3JaEzk2XbyNWTYAflHYf1qhs8mIMA28HrVlpx5WYiSKptevnEiNjHpTSlYmKZdknDxrkbTjmqF/aiWLJwzdvU/jVlZwkSMRlenTNV3VnnPl7imM4B4rKV0wjo7ownEoYoACo6k9arXEjoMtjK1Z1GSSK4IAzjrn0rG1Gd5iMHaP4h61qk5G2rRFLMA2SueKjtYA8gYggdSMdagnByUBOD+ladsihV3EnsK9DCQ1PPxc7RZsWjRogwMfSrJtvPjYK7IScgjtVbS4d5yRgDt0roLGJVwCv6dK9pHgswY9Abb80hY+tFdrAiGMY5xx0oq7E3PlZiCeuOP7vSmSBQoIGT3NSDaQCSc/SopWzx0HfNeU+x6DGlsHgZ+tNbOcgkD0zSlSRwOPWkLEKADx9KaJEKjAIDZHWkZlI+Qke1LggBsnJ7UjqFbB/SmAwjCjAznvWn4e0e817VINPsIS88rbc9lHcn2AqDT7Wa+uY7eGJ3kYgKE5JJ6Ae9fT/AMOPBcHhXSV89A+oTLmZuy/7IP8AnmtaVPnd+hnUnyI1fDGh2nh3RbXTbFP3MQzJIOsr92P+emKuPLvbAIOOxNTXciqNoOGI5HvWeCMFSvzH9a7kjjHcQ/Mw3E+9cB8WNSEenW2nxsy/a3y3PVFOSPzrvLiYgeXg8DArwrxxqf2/xZMUOY7bECcenU/nWGJly02deCpOpVXkWdMZQFV1AXv/AIVs2kZ2BLYfx5IP8Irn7BZZJhtyq9z7+1ddpyJG2T1fnB45r5ieh9QlZFi0tjI+Hc7uxx1Fb9tGViRQTx1Hr7VmW5MsiqOec7vT2rXjQx4+8ccnODVUlfc56jI1uNjguq71JyR1P0rPulSS4Bx+8BDcnt71ZuInMknlZJYcDrg/0qjNHIJ1jA3leWyOa6LLoTGxLJdqsRXdkg4+Ujj8KxLufzmBcfdBIqZYish3ttyeGI5pr2u6XcXO0DGR3rnaszSNlqUIriMsQ5y45yRVe9lUBxuzjrzilvYVikIVznOC2f0rEvS8eR1HIB68VcKak7oHvcsW+JHD87R+RpJZ1jyRnGecGotPUraYYZPqajv1Kgt8vA4wetbWvKxLaIruUNHw7ZHQA9qrWsXmcnIOehprMCqEnBI5q3bOyg7eeMgVvsiJTSQjkLGBt5Py0FggSBMbmPzH0FVb65FtGpJ+cn5QRyam0CKQtI8/zOSCQa6qFJvVnmYqul7qNjTYyLhEQfeOOa9Z0CAfZolz9wYwBXnmjW6y3PmdCor0nwhGSkrkk8gDmvQjvc8eq9LHQQKI8qnGBkVPk7VIAz0ORUb4RfvZ96dGSvRhjFaHNcmUZySvbk5zisbU7IiUhADjlTWzG4zngHHbvRdRCa3yOX/lTBM48BRLmTKnJwKe0aopIILHv6VNqMbLNyBz39qpsMMCu72460FpiIcEheBn0rVs5DtYDOOwrJic+cQPmYVfgOQ2M4PUdhQDZHfS43I3B/PFcxqZAbHQ4JJrfu5BjKr8w964zxHdNFbzPvILYX86iTsmzSnDnko9zkNWunmuyI8t82MmkhsSzgyAMw5xTrZVaRnYE46ZqzNKIogWO0Hrt614NWo76H1VNcsVFBMq4AJOF7471CAznC5z13HvSoJbh1AJUE9K17e02kJn5u+PSudy5NzohpuGjWxYqZWwq+lddZmOUgIVOB2rEETQrhcH028k1r6bbTIPlwmeuR0Nc9R85VTXW5qxW6KyZk6HOM1LKYzmTI3gYGecUkMBYLvYEjn2NStCAAXxgHqOhqFojnuUFiWU4h6H7wNUtQSaOdVCjaB0I6itswoj7lxk8gDpVK/dc8nJHX2rWM7FqeuhBBK32cA4Unt6VTe7EckmF28ZBB4qC6lcFtzAY6H1qvdy5jQFQCR6VlKN3c0SIdSuXnjMgGMdR3rKnMbQHbjnrVy6CLEQz8sOcdq5ueZ1LiMhsGt6UHNWQ3tYuxEO5U8tj9KkVmMoVDxnGBVWxJKSOwwSas26lpU4xzmvXwsOVs8jGzvZHSWAAVcfia2rXeZNwJJGMfSsqxjyoBbkdx0Fb9iiLIu5gQwOK9FI8qTL8ClUw2Qc9hRVyKPKDBOPrRVkHyUcqBknimFSwz370+TAYZAbn1pWfnKkgjtjrXknpIhIIxlD+dJw+AAAfSnTN/E+7ae4HShgCMqwwaYmIOPl6k+lAjZpAoYgntimBTyBkkn0rtfh14c/tnVVS4VvJiw8+0ZJGeEHuaqEeZ2Jk7I9D+C3hBbGBddvEzKw/wBFUjt3f6+n517BbTFrd2kA2jJ57VQsraR0RHjSOBVAWMdQB0GKlkLSRtHEAA2Q3bNehBKKsjhlLmZUeQySZCZ3HqajdCeR2POKsBBFHhgPl6/N0qlu+U+UXGTjOKsRmeKL3+zNFu7yUg+XGSgz1J4H614bpdv5s4kcg5OSepJNd18WNXYpb6UrDduEz47f3f61ymkqUQD5Q2eOK8nMKn2Ue7ldFxhzvqdHaQYYNtGVHGa0FV2O+MBh2z2rNhuWjhJb74/CtrTm/dBtvXt1NeJZ3uz1XeKubGlIfNVEKr/FuAzmtGedIoWY5BY4yOOh9O9YrQhVDi4UZzlChyOOoNQNK3y8h4hwMnljmuqFPS5ytc7uasLBJnGct13EdjVPU5CrfL0J+96+2altwjKHZg3H3R3qtqgR95hHHHfIH09qm6iwS11Kc85bsW2jhumKpy3/APo+F++P7vSmXUrxqHzlj1FMyjMpCgNj5uOlZyXU1asiK7uonhCsVDn271zV5mRwAPkHUetblzaB2Zi2SDke9Zd8pjUlVAU/iBWtJpbE3SHwKoAABUdcVT1AcZHU9vWiG7VpETrxjrSXD7yNw4A4JraMWpXMZOzM12LIgYgEfpTGv/ssTsx+Vf1qO7mVXZmYKo5YntWMGfUb5duRAn3FbqT6n3r0KdPmOPEVlBaGrYRPeTNcXBOc8L6ewrrbGMfOn/LSQDJH8qxLeL7PHEANpHU+ldp4ctPNaO4wdueMDiuqKtoeROT3Zs6XYCJFibOdvUd/Su50KA2hSMjAdcgZrHs7JnnDjayoARn1rYhnSN1W6yir/Fg8VulY5Jyuzdk2YClQGPP0qM5WXKqNvQ5qRykkasDx2OKaMcsCSf71UZguWXkfN2NWIs9DjOarvJtJ6hSKVJgxCbiAOxFMCtqdqpYnv1HGRXOXORI25eQ3UcYrsZk82Iq3XtiuT1aDZzlgOQwx3oKTKkDBZyycEHOMVcLqMnsTzis+1AKkklT2z3qSaYKjdTgc4pFEF/I4VzwOMDFcB4pkG+3hBPJ3murvJZJXILEIo4Oc5rgtck8y/d85x8q1z4mVoWOzAQ5qt+w1JMgRrkc8mmygTOcg7AfwNV0dQCgOOcH61fDqiiJF3OR69K8Wd4s+jhuS6aqB2C5Cjr71t2QQzMN25s1nWlqzR/IQrk9c9K2EtGQAkIxx64xXJNps3ui7borTKinHPQ/0rpYFxbkDaWx0B4xXI2qziVfKQbc5wD/Wt+GZ1iKyBwSevXNQ6ZFVPQtfvVBd1ITHBBz+dSwM+SQPvD8KqpdMYv3gyc4x2FW4nVYcOR6jHpQ0RsiOOYkmPCjHUGs66UvMew9qmvrkR4OMEd/Ws7ULxPL3buR19QarkZpGJk6oHDqyNkHjFZ11HPBbhtzNuPPP3aW7vlkKOS2A2G4qW4mBjAViyyDH4CtHFxsmjezW5mmYyxEkEMDgjNZsS4aZCDyeCas3ZMd0Y4eVK5zmnDd5ca9z1NbU42ehjVly6hENlu/J54q5p3393LY4qkc79oJwB09a09KhbGCuSec169GNongYifNI37YnIxhgOfU10Wkx7lBz15Fc/aRsCCeR2HpXTaUxVACpI/lXVE5JM1kCAYZjn2oqYbSOG4oqjO58hhdx+b8u1JkxlgAGH1oJwQQQw7A0odS+NgGfSvJ6HqkchDjKgDPY8CmKOCHIGOwqeTdnB6dBzUlla+Yxd+IlPfuaaRLL+g6TcX15BFbRma5lYLFGp6k/y+tfTXhfw/B4f0a2tbdVaVeZpVXl3PU/T0+lcj8H/DK2Ng2taguJ5gVtk/uRngt9T29q9EibKfIGySfbFdtKnyq5yVZXegjFhIu3Oc9/SmtsQNtLgn19anRTGnB56nNVJ5Ng+UdevNdCMSsbhd5jfByM5NVbudYLd52+WFFLMc8ADr+lV7uXe3y/LzjGOlcx421BYtKFgHJmuvlK56KOpP8AKoqTUIuTKpwdSSiup5xcvLrus3OoSthZHLAdcL2H5YrZ/sxktwVlVWJzx6Vb0qwtoYgdufTHFaotoptnDAEgZr5ytiOeTZ9ZTj7OKiuhl2ltK5xndhe9bejwTb3V9w29MHkj1q2unjaGgzuX5ScUQWbhiy7uTglf60qaUgnPTQmKj5RIXPUfNwB+VRNEUmfLEqAMMBkD2x/WgyzCeRfLRghAJIxn3FPW+RyNoON3bt7V0NNLQwV0XitusAVI2RgOeQeaw5bhgSDkgHAyKvTSKys0cikL04rAvWnScFwfKYYHPSuOau9S4RuQ3pkCEqVPHzdzVS1ufKBL9TwR6/U0joxnX5s5ODz1qC/XajFBhe/PSnGzXKW+xOLkFXLMAMkYFY9xehg6OcMD26Upmk8jCKBn15rLuYS0wL5BbqK6KVFXMXoWIkDyGQnAPcVLdsiwnnCgZqGPMagYwv8AOq0Kvqd1sXJgQ84/iNddOm5SOPEVlBFCWzlvIt7KRADwD39zUlrZeS4JABx1ruLXSwLRi65G3IGetYGowkSsVHHT2r0FFJHjyqObuySGI3Ehxzkj8a9E8LWpRlhJIQDIB7GuX0O2ZYI5441yRyD2rvPCwVSzMNre/ergjCrLodFHH5YCoVU7cEepq1sJVfMwSo5xVSff5ihQfcHtWp5bYVhj5l5B7VqjmZLAxeJNqtuQY+anlj6Ec8fWq9uWglEYXcjDqDzVps4LKeo/OgAZh9n2gcDoe9QbhuG3nFSHCqNqHPUe4qAspl6YUnkUwLm994dD8uPyrL1tPOj3INoPXnrV+M8Kgzis/VMsX2MqyfoaARy43Qy4fGckBBUUrrI7bjtjA6g85p92dhO7Ab+JhzVBpoJseVJjb95W60iytfMi27+XwBzjOTXCT7pZ8qckk8V2OoyFLWViwI2kDArkyjRhiQORmuHFStoerly3ZXQLLcYGFQHqe5rXtxFGwAG5j7c1nafbedNubIQHg+/pWpEjRykt09TXk1pXdj3qaN21iG1QVC57EVauY2MYLDC4456Vl/2nHbQZkVnUDsMnNaEMwvIkeAEnH8XB+lcXLJMqzTuS2TyRH94mCx+UgdRW3CXdXDDJAyAeKy7ZixChB5ic4Y9KsG6QEuylMnHPPWt5RuiJXeo9wRJvPyqTz6VOu6RxnkR8gZ7VWJLRfIQ0eOeev0qNpiEaNn+hP8qIxb3HrIjvZFMmRklRg1j3j4Uqyhw3bpWjbKY7zbhmzzk1HqsWWJjVSM5JonLldjWL5XY5G7hcRs2QFJzyaS2dkZY5DnPHTpVrVQ6hucLxjArNhkBwG+9nrWspc0S29C+9usN6H3FlIwc9qGH7w5PbIqsJDNMQTnb1pLyfoucH+la4eDk0medianKrsRYm8zK5Lda3dPDBV5w+OcdqydPYSSIdxBWumtgjRnIGT3r2EjxJO5oWH7w9M9q6HTA0WAeVHXvWDpcAjzlxnPUV0VoqopORv44PStUZM0cK3K7sUUu9yAQAfpRQTY+RFUYyUG4dBTSMDkEegqYGNkXjD+uc0kab5Qq9e/FeYz1Li28TSuRt+UdT6V33w58LHX9ZRZQU022xJcMOmB0Ue5rlrW3GUhhUs7nGB1YmvpTwToUGjaBb2hjG8YeVgP8AWP3yfQdB9K3o07u7Ma0rI0okWR0CgJEgCxoBgACpVOZOOQc1WE63EkrJwp+5j0qdPvAEjcOxrsRySHygRgjO5Tz+FUL11BIXHA4I71Zmw2NoAK9TWXct8zs20nPAxzTJMu9dYkd5jtjRSzFuwrzCS6fU9UkvJuFJwgbso6Cuk+IuotbwJp0J/eXGGcDrs/8ArmuasIgir65yTivLzCs/gR7eV4da1X8jdtHIEfGdw6etblhBsChwQDnA64NZOlgSuUYEnHB6CurtoN0QJ7c8HvXjKN5HqVJcqHW7xxxrhQ5+nFE06tcfu1BwNrDotOumQq4CDcSOAOKyjO6yl1QcD7tdkYK2hgo82pYmkV58iNWBPO4/yqnPDG2zdhevy4qK7cqhf7vJwCcnnt0qBpZJJMS8hemOwokuVXNFEgvM28e2DhcnBxk1nGR5gA7Hk8k9q3JRujIUgHHU96y7pI4oleQK+D19Kx9opBe2xzV5I6XATeW5ByDUlzIHTAYEnrTdRi3ybkAPPABqisbEtuBBFa8ieopSuW4Dx5Z4we9V7tPMnUqR6CntJhRxjp0NVru4FmjXEhyMYUdye1b0oNs5atTl1M3X74W6paK37+UZz/dX1rrPCVgEtEZlAJwK82uYJZb5ryU5cnc3p9K9V8DyrLZsHIyoB5716dOPJoeLXqOpqdC0WItrDLY21yVzYtJNsClcHpXb+U0wAj+8TwQahutOEWHZCCRk47mtbXOVSsLoFuAY0UYCLjGOprbjszDPL9mBZCMsoPKmn+GLdQ4ZiuTwAeuamnZrXUwQSjZq0rGMndkzShtpLtnAyDx7Vo2k8qttJ3oPbmq7hHC52lj09cmpbNdqyfMW9ATyPamSbELBsMOM9x3pWBVeFYj+VULeTbcRgHcrYBHoa05Fdfmj5BPIPrTERIpMQYEc8kGopYzt3cEEcZ7VLMCuDkbx0AqOWQkBgnBOCe1MRVEwSMtvG/qOaqXl0szechGRgYPf1qW5RsMRjFZ0swVNmOcflQBk6va+SzSRgskmcYHQ+9Yi6d5kjzNOkDIudxHBrodSuZLTY8QEsTDAJOMetczqPn6lPnyZVgTvkDd9RUs0iUNVvY5rd44zGwyBlRjPvXPXJMrhF5AHNX9XTyWEUabcDpVC2wmA4LN715mLl7zZ7+X0rQTNCzJQKsK/XPrVieymlAYtsC+velsieRGVUHnPWr9oPMmUO+5B154ryOZqV2erF8pRs7Zyw+0OwfuBXYaXYKpDk/LjoBx9aovEqglI1x6d/atrRHlSEeZGM44K81NSfMuZE1ZNq6HyaasjkMvBHDKMEVn3dvIjEBlIOFy1dA0oC4cdeAVOc1RmljaYwyDqM5PSlCbM4SZjRn7M67yuM4IPTP1qS9XcquoBL/xDnBqxO0JJLcDocjI/+tVC6j8s/JJ5gxwp7VvfqbxdywoWG2Yl8s3bpWPdX6GNkT7w6iiaaQytliCRjBrK1EeWQSm49M56VztXlqXGKTuUL6V7kbNxKjtWfx5ncY9asWswaR4+AVNROhMjBiMevoa66e9iJysrEtg5iiJI5Y5NVLkyGZnx+FXbSIiM7ySBzj1pZYsgkAEH9K9KhT5Vc8XFVLy5ULpBYszFQAa6ezcKPVmHPPSsDTYcptcYOc4BrXt1ZJCE+7jua64nEzptJOSq4HA5rfjVY8fL+ArC0gjbjcFxzn1rcjYsMq/5VojJloFVGB/Oio9ytyc570UwPlJFGNoKn0FadtClug/ilbrjtVfT4EOZZFGScKPT3rRjt5mZVgwzMcAAck15qi2eg2dt8LNAXVdV+3TxlrWzIOfWTsPy5r2rU5/Js1ihYBpPu4/hXuTWH4R0eLw3o0NtOqGUp5krAdXbkj8On4VOzCV2ZiAPu4z0FdsI8qscsnzMtWKAHrgZq5IAASPvdcg1FbIu0l8k44pWZlPXg84FapGcmRSzYUiQDBqhcOiIzyNhB8xb0A5zV27WPZksc9wK4b4i6l/Z+hSW0T7ZbxvLUj+FerH8v51M5cquOnBzmoI8/wBRv/7T1q7vy3yM+EGfuqOg/L+dXdORpQApODzzWLp9mzsEX5UHK+9dhZQeRDuK7sgDgc14FWXM7n1tKCpwUV0J7eTydqkHOfvV0kV7tssRKVkAx8h/U5rJsLZpIy0kfB6HPNattbRyRMOOmOD0+tEOVK7IqWYjXUhSNZFdzgcgcZqq0cjTZU7O5w2PpTpiYsRuSpxkY74qlPqAjkwBlQPutzWq7oSXYt3RkZBuIAHXHX86y52eKYGFsoT1PJqI3cjExjIU8ipWicwplgz9yK55yaepXw7iTMx+ZTkDoT6VTuZDJHw2EJwQexqxJcbX8or8pH51kXTsco2c9QR2rBK70JbIbhiiFSBv6AisySQhiOdpFaN0CsZBbPOR7Vnyw5lUj6816FKKa1OWcrEDsuAWYKq/MTWVcNJqNxxjyl+6Pb1qTUZzPceRGcRj7xHc+laml2ijHAzgkk9gBXoUqaWrPJxNbm91GcIA8y24QMFX5uO9dj4J09xfQJGCVXhsjjHpXKWm436MnUtk4HUmvWvB1kYmRgCoKk59TW61ZxzdkdAluqKDt2lenGaZcWxkh5HAPP0rWWFlXOfmxgjHepRbERkkZzWtjkbMzTohB5YQAndnNGsjZexu6jDEjk57VPtCSIofbhqXVow1tGGAIDHkc/jTsK5FAAmHxjHI4zn8KmglAOBhQTnJ+nNUbOUxkJnditKWWN4wGHI7jvRYbJ7Q5lVjgMTkZ7CtgSjJ34z2OMA1h2QKzqGbKZz+Fbj+SW29D3B6YoENlCuVcKBxyetQSMQgCkYJ79qlXbEwA4HpUU6L2ztH3vpTEZt4GjHBznoBWDfSMi/MuSR1BrZ1Ihh+7fI7YrDmBkiKEgkc470hpXKaXPnFoZApC9ATjdWfdsYM8bUHTPNQtN5V22/NQarcFoQmT8xwPYd6ipLli2a04OUlFGBfMZJi3Bdz+lUJrdhLuD4A4PPU1edWB8xuT0AFVpw2AhzuJyMGvDlPmk2fWYeKirISKWeIAIxCH1rdsrxYgkeN0j9R0Bqta6aPLXzB2zk1oxWDKPmj2js1YScJaHV7tjYsxNIpMKLnPRj1rTsriaIOk6DPIB242mnaTA8aKJ9gOMjBq3c2yqzMA3qzL1Oahcuxyuab5RHKSRbXbDAc461myXAiYrIBkHaM9s9KJL5YHLHBRztORgiqd1i4gYqDvDZ3MOorSlTHGNtyxd3TJGgZ0252umB1rKv7xc4jycHJP9KsS26m1E6/N6Y6VlOjTxyJk9c5qZ2N4pWLU0uYw2AQBnOa57U5nfftPOaswzPE5R19uax9RlXe5Rx6Y9KyjF3HexTiieK7ZyyknrVsqzSYz8x7dsVXtTldz4LE4ra0u184vM33QdorvowcpWOLE1eVXEjAReSpz61HKGEgUcg9xV+SFlH3M8+lLBAHnTK4+teolZWPDbu7kltCU2/L0HSrduQpIZMgHB9asCEImT94UsJO87gBnmrRLZr6ePuYAA75rfb7mY04xjj+dYdky+XkEk91rdi+6pjZSCMYHarM2RNGQeClFWwFb044ooA+ZNmCDH8oPpW34OmEevQSS/OYcuFbpuA4/WsISZ4IJ9zWt4fRzfMVH3V657VwQ3R6DW57CnifzVjWWEFgMFs9felg8QQZ/eIQuevXmuNjJ+U859KdtYhiVPBzgDOK6+YxcUelWeq2tygMcqlj61sK0cqCVdpXGAB2rx6O4aNlQs0fbJFXYNduoHRfM+UdATVqRm6fY9BuxtYlTyeQR6V5B42vf7V8UzR7t9vZgQrjozdWP58fhXUzeMVWyuHniy6qdpU8E9q86tTvOWZlZjuY9yT1rkxlT3eVHoZbRvNzfQvxTLExBwHPAx/CK3NPWSeMDziqE/rVTS9HEx3yqxU8jPeurstPS3UEBcYxgdq8pyj0Pdcki9p1nthUFySw6f4VaA+zRkSAAnoAKlswlvEACR+OaZduGQs4yQCR71g6l3Y5nK7szLvsMcls5HHYiuev4k3KSzK7cE9c1cnuBK778qQOFJqiZ45PkfkA9+1bptG0dCOGJpYpMk5Toak+0gN5bYWQ9s9fpUZuYkRyhyD0I9aidIrgpdSLumjGFPcetZTk29RSfcqXkzEsAXBVsnHpWfNOx2FOc9efzq5KFldlHXuapR2+xyDk88VvTS3MpSVrEsbmQHI+XI6nNVNVuCo2x4EsgwOOgq1K4RWAG0Dris+3ja5uzIR8h7HsK76NO+p5eKq8qsiDSbAs25wSc859fWtS4nWFPs8fBK8nFWjGYecAA9AKzgrNLsddxLdRXY1Y8rfUu+HrAT3UbAck4/8Ar16t4TTe00MigNDjvjiuS8IWcTX8KIpBx0Iru/CVvuvtTlH3UYJzWkUY1JXN1IhgE8jpkVakAWL92ORTC3lKVOPm7Y4p+3fGMDHYgVoYmbdxcF8Lu7A96g1VGNo7KuEBGcdKuTqQ23JBHJPtSX6tJZsGJK4oA5kEiRWHPHTpV9JQAAueeKz5htYdDjvjqPSpojFJjaoxwD7Uhs2FMcSK2eCMHPWtSydJIz8xk75JrPnhVokkAxxg571HatJBLtcAL1AFMk2diiQgt15+lPcABgQTkdT3qqjhgCgznrzUrSDYCFJyfXj6UAYmppsQ4AIzkYPNYDEoZHBJCqSD3roL8KWIBAGfWuYlYRyEDJ3kgjtSKRgyqxudxxjPr1qjfSCS4JY4RRjitG9URK7YC4Pr0rm7iYNOiqxHPJ9a4MbUajyo9TLqPNPn7FieRUTcUJycCptOjVnDcFwc4IqGN95YYJVegxTEEqsrLlFB7c14m6sfRQjZWOljYBuSpPbjoauowJIcD3I7Vl2KtsZyDt7t3rW0GQ3UTie3dOTtIPLD1rOCXMRJ2NCHUUt2RJlDE9GAq3JdwujlWwMfh9KyWjidthUM5OOnBP19aabF0+dsFQcnB6CuqUY/Mz5Ve5DPbmZnSMK2Bk4PT86zrC5e0u3ABZj8uP8AEVsXMSv5YBVVGCH+7+B9axLgStqZbClEPykDANbqfJE1i77mpfZSyyNsbE5xXORyyiZ95YY6AdDW7fSCSIbecc1y2oTSJd+ZuOCPXGK8+L507lw1VirrN5+9EkYIxwa5yORvNLgEgnnPrWrfzJMGKsvTGB1FV9Ptw1uAwyfX3rrprlWpM5KKLVlbPO6rFy7nAHpXexaclrZRxKAdq549ayvCVltc3DR5CcDjqa6qZMjPGDzyK9TDwsrnhYurzy5UYk0ZbaFBOO1NtLVmckgAnjntWgYiBsB5zkAVq2FmuzDLz3rexx3MmS1cJkkY9KY0IDAZ3FfTtW/PZlVPUjGc1FNaI6ZU4YdTWltBXKlmdxGDnHGMc1t25GM4A6dKxYI3il+b7h4z61tWezcM84HPuaBFtcAcnmipEhOCQyYJz2ooA+XxI2QBjg/lXY+B9CvdTFzc20JaJMJvY7QT6DPWs3wfo41jWoYJAxhU+ZIQcEqO349K9xsoltoVigjEcKcKi8Ba5aNO/vM7qk7bHGxeGdSR8LEu7OPvBqd/YGph9ot2ZSOTwK9Bt8KMA4J71HdTcAKeowAT2rpsjBzdzgJPD+oTKVZAvfLdqZ/wjM6gGWRSOwTmu1lXepLEoM1ja9qkem2ZkGHfdiOM8bj/AIetTLlirsceaTtE868TWn2SYWyvvkzvcDsOwp2i2sQKsyh3/lULxSTzs8jl5JW3k+p749B2rc0+ExMGAVenyivGr1faPQ+kw1H2VPle5vWeVj2oiAAd6ng5lMjoxxx8vSqkxjITfIQRyAnGavQXqRoFKhfeuTlcVoVNNbCXVwsUnyE4757UguwYmLbWJ7Cq2oXEciFsL7e9YD3zRsUf5fQmj2fMiOW5bvEIud23Kt79KpX1ts+dRye4NOkuQ0fL7j+lV5ZbhQTkGMfpVq6eppqQQ4xwMAdeO9QC8aPepIA7VVmuGhdwRjcOAapCcy3HzL25960UHJ6kyZpJIq5BB57ilh+ZWZmwc4qMKqIoYnn9aATwFGc81rThdnJVlZXZHdRtPIVjBKjmp7JBkgngjBp8SlIiSDvxx9Kls08uPP8Az06CvVhHlVjwqtRzlcJeI8EZA6E0lhZ4lEsgxzx71etYDclVwMA4OKvm0MUixsp6cZ71olcxb0Oh8Iwbbti4IbYSPauq8IwhLK7kIJ8+UknPpxmsnR1WOzlnYAkREZHUcdBXQ6PG1rYwwEqfkG4Dsa1RzyZfky4G4qRnpSIcnqdwboe4oXqGI4x6c0/cq43KTnpTIKzbNznaNue5plxEogdUYn0HrTZlZZiSTgnv0qYJhQOT6GgDlrpA7lWOD3+lUlAimDISCDnBPatqaBftDDLHHJGP0rEuMNJhSc5OSfSpLWp1EjbrSPad3AORUk8KyyqwbBXGfc1g2OoCEJCXzg8966FCXClMcDPFMnYfZCSKTauGUnt2qS73LGQp+Y9qWMmKMOoy3Xniobwkhmzhj2zTEYN/LtQkjk9s1gXTjzdxAHPTPetC/LZYjJ54FYNy7F2AfCjr71L0Lir6FDXpQ5CKc55O3tWOiqDnAJ6Cp72QvMzgHk460kUeAGcAV4OMqOpM+mwVL2cBUjKplMk8YGetM3yGYkAKp4rStVQqckA9jT0gMkiFFBjY/M3pXLBanoRki/oKFkHmMXB529MVtTrJDCCpLR4Pyg4K/lVW1UWyZVd6fdGa1LZosMZF4PTHT60KPK+Y5pPUZYjYjmVTluQSO9SNudSCOfu/MP8AOakYRo4Xf8x+76GpPNjAORtA4JJ4rPmbfMyb9TG1UmOzIlUFmIxjgVmWzHD71UntjtUuvXnnysgbaB0wOM+1Y0cpAKhuR196upNyidEYvluyze3SkbYzwOCtctqzbpMFj+PetXU2JcHcFB6msG6ullkYDhk7mlQgUtEZVwWFwoAzk9Pauh0m2Z9iIOT2rF8szXCyBsgnj3ruPC1vt/eNnIGACO9enCnzNI4cVW5Ys6qyt/strHFGFIAAJ7k1PtByMEd8mo48sqg9RUxPIXOR6V6NrHhNtu7Ilty9wMDaBwTnFbNvCY1A7Z49ahtYgV+YE5H41dhVmYA9PTvVolkgjyvTKjvRLaJJCflIfGfrUkShjycjNaEcW+JlYEnGRVE3OSkUIzIRkDB560tvPG9wqLIsbY4B4z+ddBOLbcCYdxHVs4qGe1tZsb442UcDPNIpMr+TMPvq2fUDINFTKkEA2JK6r1AWRgP50UDPP/hboxs9Imv7lCsly3ycc+WO/wCJrszMD8iqSOwHU1TspA9uBtKoBjJ4/wAitGFfM45UD2pRjyxSR0SldtjokcEMwGeM+wpt4B5rSn5lXpt7CrsdoTEXQqW6KZCcVl6oXIK3DiMgZYAdh6H0pszuY2saokEbuzFkXk5NcLe3Eur37TsGVcbY1/uL6fXuTWh4gvV1ArDbnFmh5YD/AFh/wqvbOBGI4MBuh9hXkYyu5+5HY9vAYXlXtJLUjt9PLznkADr7VswWC7AEl5BGT0qOCNYF27WLH7x6k1et1VYsZIbqM9q40meo9NhXgCMAq8/3iciqN6hjBZpM9toq/u3B1fjI4xWHqSMkDFSWycj2pw3sxR8xLLz5X3SY29celM1KADc0hG08VV0uZ0n+8eeoNO1W6V1eNWBfGQKqV1LQiekjLS8EZdMjHYGpIL5jFkrjHr3rPmhlZc+Uc56DqTUSrInEgO49s9DWjgmJu6Jb+YSkAdRzgUy2UK25sA5x9arSHDMW9eGrStUSRFO4YH94VaVkZSdieZ4xFt4xnp3qaCPz5F2jCjrVa4hJlUqRgDJx3rUtovLtD1DnrXThqfU8rGVbR5URlWaFkUc9Fp0ylnEGSe2BUuCkRdTjj5fWp9Fh86RnkTIz36V27nl3NfS7NYVXaDux+da8lobhohtAkAyAfSizQvIuDtYDGD61rQWhMoZjl8gsa0SMZMtiAR6WyHaqsmAoHNblrEEtuwyaz5YlNu6qxIGO3vW1JEEISMZAHANWZESHCk4znsev50q4Ix82McZ55pfKJHGOD3NNSJlGMArnrmgRVl+W4AAxvPXHAqwV3KCOo9O9QXgy0LY2845PWra5QfNt47DvQJmNdqou3dTwB1/nWLeQh5iSwTArZuWUTKxB+bOfQGql9bxtGZTu3rweODQUjDlcRGMRpubgkk9a6eykLwRlGK5647VzF1hot4GCD+Yrd8NOJoCpYnChsdhzSKaujfcBbYAjBxWdNIPL2kcYqeeYSgZbC9+2Kzp7oxhfJj3r3bqBQQYGoyJhi6jK9wa5zVJTBbMBjL8D2zXQasimMNEBtLcHt9K4zXLnNx5MYZjg/gaxrz5Y3OvCUnUqJECQtKm4EjtnPSrtrEx+UEdOfWs21E7EIynD+1b1haypgK3y9+K+dqyabPqElFFcxSOeFGzOCR61pNbhEVgCG/h96vQWkYQjcSev0NTxQmeQLgBccnFRCsDknsZtlK0aEhisqHnaensatPdTHy12bZc5ODwR7etT3dm3zKgGCud2Oc1Vmilh2OdzqerA5x7muxSjNE7mlCGMSLuGxskHsp96bcKwjO/v0GeDVSKR1+RSvluM57e/40XF0nkbEGCeue1c1VcuwramJqgPlOAvA/iXkiucF15JIO7cBxk10N1JtiIXvnJrnbhQzrySW6ZqKeq1OmL0IJrozhsk7SOOehrH2j7UCM8Hn0rYuYQgZcAE+lU4bVvPLMe2cV00UuhnOSLlpa7pUYAhQM12ujbFULu/CuYgR0gBHrW3pcgJAzz+tepRhZXZ4WJqc8rdjpVKBsoPY81agQuV+YnHfFVLcszAJjgc+la1lb7V4H1IrpRxmhZoe4G4D86nDcscAcbtoPSmW6jb3bHHNWGjGScY/rVIlj4bfzFJBI4zk1p24A+XHzEfgarQICCMgjHarcAZRyMjPU0xFXUbTem5QPfiuduVMUoAwBnnb1/GuvUZ6kY9Ky9QgBk3eQ0hPIYDj8qBoxBECBv+ZvVaKtzS3ML7RA4GMjEdFIu5zzFoo0UnAxxn19K3bFwLdXXDAjOT0rOD79ryqodugPes6+8U2unboosXUi/wI3yg+7dB9BRKcYL3mbRhKo+WCudfcahbWVs007qkaDJdjgD3rzHxPrk+u3rJbq0OnkgZIw0nuR2HtWZqmsXmszZvH3BDlY1G2NPoO5+tLbMxcZbLt0BHSvJxWMc1yw2PaweWezfPU3LCxRRQnkM3bNQW+ftAVVjBJ5cnOKYxLz+ShJJ79qu2KrbMEn2nHIzXHBJK56yjyo24liER5Viwxjpmsx/LV2RsqrHgev41dWSKXAlTYg4DAZqveNDHERyx/hxUp20Mb20KhuBHmLecc4IPP41k3s0y7E8zJY9R6VryW4aJTnaxHOapTW6qvyspY9zTUlcjmsZs6rGpKOcjms22WSWciUOQx4atORXCsrISex6k1mRXEkbFVZTjqo4reLuhpts2IYuocHAOAfWq15aKdwJwQcggdRU0UkjpyMdOlXjxAFIUnpkjmsG3F3Jlcwv7OSSM89sgHtUcdr5EJZDuGcZzW2kbwNskjGw85XnPtVGVE8p9oO0tkYrWnNuVjnk7bkMLZ+fGWwOM1oqgcBpck8YBqhbAfaQpOGPati3Rinz5z0yK9enHlVjwa8uebZBduXaGFRgmTn6V0eh2/kjGD0xz6VlW8IedWKknPyjHaujsEZpAzDaO2K2ijmky1p0YEhIUqR365rpYUIjxgktWXpsALEqpDfTity3BWPfIdueFA6n3rRHPISbNvYuADngk/jV95JGJBBLdc1Q1PcbGY5wAnQVoEDC4bd8o6/55pkkZZl5YnaTyO9Ss6CPCklj+IAqPnkYGcUABlUhNvoaAI7kq5RVHOc59qfcM+M/eA644xUbjPl4zhjtY+n+TipoztQqScKME9aBGROcnhSFBzyaLknBbACjGRSynbcEBffIPX8KkliBjBZchh1zyDQM5+7jBDSDAXJyPSneFLoQz3EBOSV+Uk9s0l8CBIjbgG4rP0dsag6q23ehAJqXuaLY6bejxl12gE9CSeartdpFb/MP3jZBwO9VLW4L7Y3QsOc7TwDTby6eABVUtnsRyKoixj+Irz7PZFnJ3MeAOMGuMhUM7SucuT+NW/EV8LzUAkXzJHkemT61lecVfaPXHFeRjJucrI+iy7D8kObqzRiutjszIwUHArYsL0liDFtU9Kwo5QIHDMN/YAZpbITtMqrIGJ69sV5zo8y1PU5E1c7mGWFEBcqd/Ga0YAjPlZQTjGzPOK520haNUQKGwN3JrQgs42uxcqrecF27hx74IrJUUjBwRvGGPAJfPNZ16IjE8ZzlucAYBqSMgxAAFW9CeorN3LM8kUoI28Ag8mrjGwoxKDN5DFFz9cZ//AFVSv7iM7iRhyMge1WbhGEwYHCjggms3V4GCGWIsc9R6D2rW6lozaxl3E4Me4OcYxis8Df8AMH5HSqtzO6SeVKv/ANbNSqRGihTuPqKqVPlWg29CdctkNnHvU9rAZGKhRk9BUMLCUEZPfNbemwkfOCPatMNTbkcGJq8sWD2oMZC8FR2qG1zBJljyOQa1ZEwxzwpyDioZrHIDKdwP51654976s3dCYyEMoB44xXTwqVTGcE9gK5PQQ0E6BiVUccV10BbzfnqkZt2LduCUPy9uuatRoDt4qG1XawK8jp0q8ikkZ9etUSOjjAbC/KB17VZhBUDe2QD2pqjBOBx3p4ByCpyD2oAVgXwQxGDnGKY3IG0spHWlYZbJyRjsaVScnA60AgVXA4kJFFLsJ9aKBniWoXmoaoBvcWtsBgRJ1P1P9KypoY7WP926bscA0pvrqZ9igYHoKfb2bylnm2licDPUV4VTnlK9R3PtKFKFGNoqxQsle4kG9j97Ix2rdgt2hQkHLEYz61T+y/ZuVQKOhJPeiPUAAUOQegFZyi5bHRzdiy1wsbHefn6YC9KJLiKSP5SHkHO09fzqgpaWUEHPseuKtJaJBLkdCcD1pqKjuTJonjvizbCpjQ8EnpUVwTE4yxeMEFSOmKh1NiY1KgY6H3qgLuUxvEnAA/KkknqjNxuro3Hu1eMg8nvis75nuAF4j9aomcw2izZyCdpFaVgsd5AJMnkYAzS5VFXM3Hl1JWsJGJKkbTwBnn86xbiyEUzquFf1HP4ZrqI4SI2dJcsOp7Vg3kwe+IP3l4+WqpN6kxeo+2hZV2nBAGAanRGjy7SrnI75qobjcpVj8vTIpsjARFSdwbk4NS1djk9C9c3UbyKELk988CsbLrNJE+Nmdy47D0pH+dWijbj3PSkEBghK7mYkcFm5rsw9LWx5uLqckG0JbBnucsc59O1dDbwtJMoO5YyMY96yLCIFWJGd3Ga7DSoNtsCyndjOexr00jw5OxZtbZITvPKbAg78n0rUslKgkqN/ACkc9etV7OJWxGWUHOQSM49q19LjRrZJCh35yxz3HbFaxOeTuaFpFhWGQMKAO2fpVyMxDcJXG5QAAKgVVMzB1yu0EfWpB88hWNBj19KozEum32sqjAJQ/lVqBle3hZX4dR16dKqfNJbOAMHGDmnWEqmztgOfkA9uO1AFkM6kKvQHGTUeXLZbK44qUuWZQx28/dpZVB5yAx4OOc0CuRP5jRbSTjHbsanTO0Fvunk89arDGwtv6dR61MoOSqnggfhQJlF4zICSCeck56VMxzFEGGce2OfWm3ahGVyOBnOO4p8MpdWUHICjgDpQM5bV5RFdGOQbxnI/GspZks78b0LIATuHbIrW11Pn37cEdPasCUKZeGJ6c+lSzSJ0OmsksPnRnKuNuMdPrVDxHc/ZLSWdXO8DYgPqe9N0a4aBZ4hgk/MAe4rmPGuomaZbZCR5fUA9zWdWfLC5thqTqVVHoc6ko+ZgQX5yT1NRKrOTt4JPJqihwX3A+31rQ0mQO2xyTjsBXjzTTufV042RYUyqqo4RR2zW9o1mqAyD5iDnpRbWcZZXuWOxRk56VesvLLFIgfLJ+8TzWLnfRFuV1ZG5aRRs4k6Y447GtEKrEMckZx6VllxbwqcH5T+dWRceYm7fjPXFZNM52myK/dYJVXDBP7w7VW+0RNIOcv0ckdcVXvZ9lx87M4K4x2qtfOyou1cgdCBVvazLUbIluSobaAAp9ec1k6hMyjbnheOO9MFw5lZZAuwjge9U9QkVQOR0NZRi1IpqxiaqYlIBUlzzuqlbeYW+c4I54q1Ll2JJBGOhqG3QiVc8bu1d61iZzlY0tKiZ+pzuauutlEdv9wkZwDWJpMbKCGABznI9K3ML5aDe2ewx0ruoQ5UeHiqvPOwPnywXU47VPYws0gkHAx271EcvHiQkqPTvWvp0QC/IuOmD2rdI5m9C2LUyKhwEkx8pA6+xrbszvgUEEkfK2eq1StgQ5DEHHJz3+lbVqiFuACxGTjvV2sZtk8IdcZH0x3q2B8vP3j0pFdVVRt2g8etKF+YbeeKAHkkjjk+tPRjkEZ9CKhYELzjGcYHapA2U4JoACxyckkdMYpMkDrkk1NCcqecAHoaHVWb5gB3z60FEQdxwcE0U8rzw2BRQB4FZ+XcZkSVRg8n0qwJGj5B8zHcDFQrYxRqShZT3UdKph/KkOGJycfSvnmuZvU+8UU2X7n97GE3kjrx1rMuY385QoAU+vGa04gvDb8H3FNuxBMuQTuTsfWlGpZ2JtYhtGCzqXZTjjpitG6nCAMwHB6+lZttBG3LEsV7Z6Uag6tHmOU7hgFaJPmkRPcsR3CXA2wqDlec9/eqAizLcmAqgQBcN3NRWLMtzI8A28fMT/KmTXajSTLJgSyytt59OM01F81iLtaEUsRnUxLsLRgs3oK6HRLdYrCIzDy5XXuMbVrI8L28l02+Mry25yw6gdq0Ndu9127wvuSNDFHz1x1Jok7+6S3fQp6neNKVjtN0caMVVvWkttPkYGRmJYDgDqwqTStPcyQ3V0fMDcqg4A9zTr3UWvbt004GNE4eU+3YUax2Jb7FGVxbOEQAbic7j0qreSIIgATwevY0y3hd7mTaGnfJBJ9ajniC3Od6u+MYxwtXFO9zObexOk0gVWUbYwOpFXbVPtIVnYlerep9qpgFXDSsMJwQelaoJhtHG7cz4AAGO1dlB++jz8ZG1Js0fDtqtxcFto8tTkLmutSMGaNVGFXgjtWPoVoLOwjVRumlOSvcV0GnwGMSvNt29BjrmvSijwpjrW3imvwPmeIHJHTpWnZ7UDLGSCr5BPYGq2lARzOSpDHHSrwUKXIwTnvVmLJrcgTHLElQVNSyFgpGME/MQO9MslLIWbOD+QFTTulvC9w3KL0JP3jQSRI3L4JODtOfUdaZpysbJlLbVWRhj05pbYlLeJ2U7uuCepJ5qWFQsc4Y/dlJIX0OKYE0DB3C7skdOKnAQKzMvBPXvVJDlSUOPSrSONqDIwPWgTI5Aq5z8ycEHPSiJ9ykA+mCOpqR/lQDb8vc+tNyAgx9zpg0AQXnMbFugHANVtPk3FlD9B6Yq5cD5AQOe/wBKyLZw1y65xjPXvQG5U1vJnwx+UiuauFAJA/A5rqdYXCo5525GSa5m6PlDcp5J6HtUs0gVDeeRudXUNGpYP+mK5C/lLPvclnY5Pqa2dUlGzA6nlu1ctdSmSZlUng4JzXnYmd2o9j2svpbyJHjiIDdDnOBWnptvEreYSxbv2rn41ZZvvEkHPJ610OmGecMGQKorhqJpbntRWhryo08G2OQBfc02xhlXMYfao+bPel06Eo4wpb61teWvJO1Tgcms4tR0K+ETT0YgebOzEH86tzTI5G1gAeP/AK9Z88r22NqiQseKxJbuWK4JkJRW/hFU48+qM+TmZuiRZbgluGU/gKbc3CsWXOMVVS5xEBkZIxVK4uFGSSCfpiuaabZDWpS1aeONvlPzH0rIvbzCKNw989Kk1iVHZSvVeprMaPzVXYc+ua6aUVypyK2WpYt286RSowueeOtX7e0dr3dj5cdqhsIsR8ZGPSt6GPYmRgs36V2UYXk+x52KrcmwWiBWOcEHgjpmtGNi27GeOtU4j1O3PY8VYgUvIFRuO9egjx7mjaxHA3MCvXPpWxCSpUH5l7Ypmm2yCPG1Cep/+vW3bJEqjOzHrjpVRIbQkClSCvTsTW3aAKFBAB7n0qvbhAy4GVP5VfhC7iXI46VRBPtGNrHr1I70EA4G/Ix24zTCxZT8oAXv7UpVWA5HH+c0DQv8TB+c/pSow6A8U122tycjFKrAKDwccZpDJA43EgEA0pDHKuwwOaUBQQ2cj27UMVDDecg0DFUgjgcUUxplQ7VTIHcUUDPAJJlmVdkhX0X+tUZYnDFgcMOST0FVZpCI1KZLD0pI7l2X5xt55Jrwowtc+7UrG1DcAxje6bsYx61DcTqsJiPBIyT/APXrJku9hZtrYGRms+71EtJsDDd2zSjSbehDkbdtdGORQSC2O/8AWm3c6S75E+Vlx+NY9tfLHGxlI3Nwuf1qrc3O2Ikn5j79qp09TNyNe31EIszEjaT1/pWdqNyJpAiY2xLjHv1NU/MQRRhyduNzVTtpZJmYKuPMbJOK0jC2pnKVjsdI1GSw0AiN13yHAA6mpNTli2WttA+5uNzZ/M1zd7cOjpEpG4AAAf0rZ0m1KWM1/cP8icKCe4qZQXNcUdDf1jUF03S4reGQmWRcsx6qtY8bMkEccOFEqlif61jxStfztNdswhJzju3t7Cpprn5yIODjqe3sKc4hFaF9bxrUtHA4O/gkcZqxaQx7x8wzjnHXFZVm4EUgC7pmOFFa9km23EKJmb7zOPWk42Jdmyw0G8fIAEQ5zV+zjUNBv5EZzzxk81FE7OiRKcMO46E1IkofqBtDcgetOnJqSZhiIc1No6PTzIbeOX7zS8Lit5SYIEjJ4HPI6mqelRiRFYuI1A3ZxgKPQVfA+0SDnA9fSvajtc+XkmnYntEdXiLYJ6tkdvSte2tkwWc9+FHeq1uIUjHPHrVuC5jcmNBkgdPrVGbLCH5No2lAcVl6zIJpIrZT8pbOO1aCH94yD7oGTmqOmJ5+qTT7dyxjC+lISJZH8t2LAAItOsVf7OwkPzSbieM8/wCRVS/jf7RIHOCBtGO+atxq0UCPNu3EhcnuKYhF2MqnI+YZ47VNEUDqmTu9xVcLsXcBtw5yetPDEn5cE56sOtMTLcvChd557YqEMFbEhGCehocqAm89s4HemTx4bO7apH5mgB12T5UmwjJ4CgfrWHG5TUGxkkA8mtMzjcVYjOOM1iKxa7mOQTyePakCJtRkWSPJB2jqDXLakQsrJ8uBzz0ro7uZZbZtpGQMgdjXE6vcRmURIwYn5uOi1nUlyq5tRg6kuVGBrFyZHfnC52rn0qoltIVXy1B55NWriEy3IKjeB3xxWikXlQrvIA9a8erNvU+lpQ5I2OZltfKl+Zu/Kjmup0HywoOPlJ4yKzmgjkuvmDFc5+XvXQ2awLH8i7QDjkVhVd1ZnWnpqaULRmTaAAqjsKuyxJLHwFbI5FV4kC/OoBU9c1WmulS48tX4xkD39KxUW9gtzbFZ5fKeRJCNp5DHtisPVZUdgDjAOeO9ad2/mo6MQX/WsBo3lEi5ysZz61vBdWaJJaseLsHhGIwehqld3bZwVHuc0+5i8rDr361FNGMBycqV6U/duZuxm30+47VIOcc0/TkbLdy1Zt1E6y8jOW6Vs6KjPIFX6YFbqF1ZHPWmkjoNJtlyu7G3H51pPGUyqsN2alhtTDApUbscnimzqXBZSMjsK76VPkieDWqc8myILiQDv1rS023fdnAJPTFUYlMj7WPGentXQ6bbDyxycg5A9K1SMW7F+2Q4BYYboTjmtGzgwdx+ZewqCGMsfVMZPsa1LWJmwvbqK0Rm2WrWFSDjjH61dRVAYkDJ4BqOFMLgZBPcip9pwSMEigSEGWYEkgDPbg1IoAVsc/SlVeATx9aMZOSeO65pDRUnLEgAEjrxTlZgAMcD2qSSIkMFOB1B9KhyRncQSO570FE4+Ynpg+tSAqQEOOfbpUMGSpyo45wKlCh2GSNvX3zQgI225wMcUU37PE2TyvsDRQM+Y7S5DxEAqWHepZrgfZwcfNXMwXBQZ3YFWo7xpoxluF/WvFlFp3Ps3PQueYVUo2ADz+NUBDmUksSQM49ajmmLyBieB2qFrvYrEH5ycAetaK5jKoJO6x3OAflTv15pGdpcljn696qs6tknn+tVJroRuI1JLt6fwirSuZOoye9uHchE6dMitmzMVvAZpCMqvHvWLCVdlI6KKPtCzTBTjyweM96mWuwKV9Wa2l7ZpWurpmIzwAelXNR1OW8220IWK2TqoP8AOsmW98uAJFgEdMdvc1HbXBhiIZxzzkdSaXKDn0NlyuFw+Ao/CmRTeaxWNfl6bjWZC7XT/OzCP+7nmtuxVXkWGBFVSfmc84obsUm2a2g6f59yJWZliTgt6mtaW5jDOka4VeVC8ZPqarT3q28Mdta4JAwzD+dQTXKqgEZy5bnFZ3GjZsWCWkkrgHd3qKJ8SkYwjE/hVO6vI4IkhD5OMn6mmLKrKjDg59etRFNO4Ss0egaI5nt40ztjGA3+1iuss41d9wT92vT3NcR4TmVmZXXKhuPeu7spwQyRED69hXuUn7qPlKytNk4iRSTtVT3z601imN6YDKRz60ojJLhseWOSTT0TELAAFSc89a0MWJckiKV2YfN8oA9adpCLaadvdssWy2Ox7Cmq32i/RUGIrYbiD/E5qPU5AQUDEN1IA4FIRUSRrm8yOQpyK0p0IZN7Fj7jgVV0iFcB85HXOanvZH8yNM/ITg80AxVYzByFA+XqDwaWJmfCL2OCTSqql441XAC4FVpsxkkEADOCDzVEl9YUL53HpxTbtSVYgE7R69aWxl8xQmeg6kUy44kkG4Z449qBGNNMfMQooXb275rLlPlSGTzOSTuHqKuzHE55y689OgrI1a6i8jy948zqMdcVE5qEeZmtKDnLlRBeXQgUpAcS8++0Vyt2FiRS2JHJywPpVyeZyjCJ85+83WswBVcl23luOeteRWxDqPyPosNhI0V5mlbGExKcLhh1qncgFtruCvfnoKECxqd7sTjAA7VHCEnfbJxt/hrk63OuENbmlpkTSIwGNoPGeuKttEWKrgbQKrW0kcRCxodx65rR3Q+SzbwGbsKTTbNloZzXbicwFuAOcZp0jxlknAG9Dhh7etPit2dy7NiUA4+lZ90C8gUDBHUjrWiSRdl0JblRczZtwAfU96i8sWscihss3JyKfFJ9n3Z4PYVXkmWZyrDkjIIrFt3MpMo3ikxAHjuTWUsm1XUkNzV+8kJUg89ulZAxu2kgEGtaauiJTsrEcgzmRxyfWuv8L2RhRbh1wzdARWJo2nm/uwZc+SnzMccH2ru4lCuiDBAA2dsj0r0qFPqePi6+nIhZNvPfnGDVaXAUqr49cVadUWXhTzkZPaoxG0rYVRg8ZzXWcAaZBukBfPXiuktowAMEgjoc1TsLZRGAw9M44rbt4wOAM+ntQkQ2Ptx8pB6j9a1rONiMrwPeoLWEblPVcdO9bESgY7VZAqgBcNk+2KRn+bjt2xS8jryDUYxkZoGThQw5yc803OGPc/ShBzyfx9KejAcYyR3pDIW7tn8DVQnG4k/nVtpB9/HAPINVmyVbJGc8cdqBofET8uMfnU5UO55IbGetVVcD0PHerEbBiSU/3TSGOcEH72OPSilkbDdzx1FFMD4fW5wQD1PJFXUn+6QcZHSueMwMu/1IA+lTy3m2LAPJ9OtcDjc+g9tobRu1Cs3UVRlkYuHYYB6KKzFuiGBPVRwvYfU1DPqDux2HLHv2FChYl1W9jSnuvLAUY3noM9PrTLKPcWYtyerGs+Bdp8yZuTzk96sPcHZnlU7L3am0JTfUs3dzjEMBwDwzD09qmg2xx73wFUVnW6EsZJcYHJ/wFSu7SHfJ8qDoDScR876lmBy5LuepzU0lwN4ROPfPNZ7S7vucL/OliV1bcP1osg5jesp1RdoGO9aKXxACx8Dv71gQSNkZzz2FWoWOckD8ahwK9rY24rtzkZ5PerttcrCo3ZLY69qwkZh2GKlErHjAGO+elQ4WGqxrCYyTqTgjPNaUDl5hn9Olc8JhEmZHVRjvXQeHlaadJGP7vpzV0qblIxrYjlR23hON9pdV3HcSFz1/wrubA5cAs3IyQ3XNcn4cJg2sPuseMCuttlEd7uzuLdAc16UNjw6mrNoAleVJHpSXEv2a1diDkDCjGcmpYuUU8svrUDH7XqCRJgRQjcT7+lUZMdar9lsCXb97J87kjrWPNKZLnO4nPH0rU1Z18tSrA84FZVohkvkDgYJyaBxN2zjEMCBfvHr6VWvyWdMDPP61O0hkGAw2HgAcVXjclgjAhlY4J9PSmIlkli81NzYKYB7E0ssSfOQcqTmormPzY1cAbkHIIxTrBlnt2XJDL+GaBWEtMrIwDYHU+wovZFjnVm6uMVEWETP5p2jPFVtSuFktQ5P3GGSeMf8A1qBWu9DK1q8WxeUscPtIUf3veuJaZ7i43OR8/VjxUPi3XFu9TZISWjjAXPr6ke1VLRJLp0clli5xz1ryMZVcpWT0Posvw3s488t2aNzKiJ5aAc1mXTKiHaRvPFWbqFogZSwwvUZqpbWj3kxk5EfXB7VxpLc9FJLUVpPlQgHA+U+9aGm2LmQSFckjgZqzaWyeaqMgKj171puRaohJUEnCis3U1silK+iK728p2lTn17kVKYGVdwYBicEirdsVBLElc88d6GjWRnywIboDVKTQ23sQ3CGNB8uMDqDwaoeWG+faN2cYrYfA2o+CuOazbgrBMXfp0BxWfPcm+hkaq5DKB+NViVCrtI3Kc1bvE8xyxHOflNULiPaHKn65p7qxF9ChqU4XdyOaytOgkvbkLGMhjnFXrpfMU5XIJ5z6V0PhrTFtoPN8rMj+v8Ir0MNSucGIrckbmnp8KWVssSjbg8tjr71oQqrQgvuPOQai8sxEZ5X0PNTghlypAB7+hr0krHjt3dxGiQglTgdcE1Y0+LzJScY44x2psEaPtUcEHAJrUsoRG2T24xTRLZbgtznAU4HqKuxOM/KvI65p0QAAORx2zToYcyEgn8apEM0bQSbAZCAR6elXd2cYyM9KrW6sABkA91NTxtubHX3NMQ9sHB3e1NAKnA2kGnyLwMcEUirnGQM80hj1zkc8elL0B3cZ70xQQMY/WntjZ1OfegojbIOVIA6H3qCcN5g6Ee1Trhuep7gU2YnAAH6UWApOoGRk5PXHap43ZMAkmom5IBHftTxuOckcUhos78dQCaKhUptG7g/71FOwz4GDgHaOTSbsnnj6U3AHyx/iaeg2ggDLH1rkPXEILDA4X+dSRRpFyACf7x6CmEY5JyfegsCDkkn6UncnmsO3ruYn5396miRpD5k2AvfNV1lRP4CTQ12xJ2qBiizG5otvMzYWFTgdGI6/hUiwl1Bmb8DWd9rcEZGfxpTfv0CjFHK2HtEagUZ44A7mrEaZ4FYX2+fbhQoPrihbq8bA804pqDJdVHURRqCCeTUrTQwLmWREHqWxXK5uH4aSQ57ZwKlg0ya5kXCM3qW5xRyCdTsjbm1u1j/1beZjpgcVXbWbmYgWsWM9CakXQJmZV2n04rq9O8OJb243r94VUYIydQyvDei3F7fRy3sjPtOcdh+FenaXaBpEihXjdz9KzfD9k3mYRBgcA46fjXbaLpzQOPkDyNzkVtGPY55yubel2bRugAUKvtWrArNcKc5cHv6UW1s0UZBAJPJyasaagM4LY7jitUcr1Zp3twkFqAPvkYWorVGgtMSsoZvmd+/0qug+26krBf3MPfPep7v7zAHoOR6UElC+R5WTyiMKKrWI8m9jZsqGyM/hUkRYlmBYDpx3q8qKIDJKu7n5QaBgW2jGS3pmmzRO8fmxgrJ0OKrvKoOM85ABq/A5WVEJDBjzQKxHby+dYyI5O4kjHfPtVGxuNkrYIJH8Oec1pyRtbO7xKhRuSD1X1INefa74iEl7JHpjEIflabHJx1x6Cs6lVQV2aUaEq0uWJ0PiDXrWJsN80o48rvn3rhNf1y4v2ZZZAqE4WNeB/wDXrLvbzZu5yzH1zn3NMgEcvmTS8hFzz0Brzq2IlP0PcwmAhTab1ZW8gyy3Es2ecKo6Vo2kjpEMKAgGM5rPmk/dxhvkGdx9W+tWEucsFcDCjgAd64pe8elYv4eRikp/dj8zV2BCu1VQhe6+1Ztozswbac9qszyOwPmOyKDj5W5NTuLkbZdjuYy5EJyR2xTLprq6mACKwU5xt6VJFbJEqsj4yMgev1qVLlopC+FK9DjtS0TujSCtqix5hUqFUZxwO1OE3KySAjHGO9VpLjem4gg9Rtpok84bVHK9Se9TcdjQMqhnYN8oHQ1nXcgcOu374wCalWFsbt3ykcioJ8CHBwTWdrPQzkkkU1/eRBQTleBWbfPggE85xVtT5L4TvyazG3STyF/ug5Fbxjqc0nYl020F1cYb7obJrrE4wMcjris7RLcC3J6FuRWouOnAJ9e9e1RjyRPDrzc5g4bPQhfcURBWYDIHGBUk24xY5+tW9OgJcMw69M+tbGJPYWgPy/xZyDWrFasrr6D5ulJbgJt5UdsVdtzgAHg57HrTRnIdHD0Y8Z9atxLhgT2HQUqIGCkknipSqIQcdevNWSTgKCCBwfepYyuSpHXvRCvykbeD0zTzHswQe1AxsmwhR0YZ+hpQTgD8qQBRtzxz2oZcEfMeKkB4J3AA804jnB/Km7VPQc0rMWGOOPagojZRg+XgYqOU/KD1+lSkBRnPBpksbIvUDPIFAELHJOOGPQU3A684pXU7htJOOR7VCvVge5zSKJdkb8sGz/OipIiCgz2ooA+DBGFwFApTwatCDIyuTUqWJfkj6Vy3PVsZh+lMbI+6DW6ml5YEirMGi8528ZpoTSOXKORnBpfs8jDhTXcRaMuMFQT6Vct9EQnGzA9TVJGTaPP00+Z+iH8atwaFcSgcYr0W20qJOGA4OBVyOwGcFfkFUkRc8/tfDMjkA5OfTtWvaeFW3Y8vrxk13UVtGQBGpH4dav29i4UYUg+h5p2FzWOTtPDMEaEvGOO5Fa1vpsMAUCEBT1AFdLBp21CXAAJ7mrUenpkA4Hq3tTSIczlzYkSExRfhiry6dJcMqfdTqcdq6e105CQWAz3xzmtW1sU2/KvbjI6VSiZymZOl6asC7YUPPc11ekWgiA+XkHJb/ClWMIixRp855Zq04QsfGBjbjrWiVjGUhsiBmJUkAjniqiSuiyJFkyPx7D3q7MQAFBwPbvSQeWrs0nJxyfX2oJLcEYsrXAxkjLEnvWTdXO9sbiWPBOeKmurtpXEcRwrenJ+lQvCi8OPLGOc8tQCRasUBjEsvywxjgetUr+6+1uAgxg4UA4wKgmvZZikMSgRJ0APX3PvVvT9OZiskw256D2pAyC1tZHUMPXg1rWlskTCVzuPTJNWTFGqsx+UdyDVC8vVQMOBjqaYjlviZ4gFlbLp8Dnzrgbn5xtTPT8T/ACrztJmPQgcZz7etR+OdQNz4qvHY8RlUT2AFY0l4RE3JyRj8K8rESc5s9/BU1TpLuWZJ/MlbY2QD3q3I5a0igUAlm3Pz2rnrScb2BOR157VdSZ5NzBtpYE59AK55K56EZWRrySxKN7jJAwPoKWLfO6sEwGPA9B71n2jeYw3jgDIB7+1dHZACHcWALdT0x7Vk/dKv0J4GjiHzk44/OkaTCM8qEIWwvHJpufOYRxLuGetWZ4HlKJJxjtUxstWaWsPubzzLQxxjD4GMDmq7SOkK267snqfWtJYQoHyfdHJ9qoph5XZM5BHWiLVtC4NWJ7eVUUR4y3bNWoSfPG4AE/rVS62x5YrtYcAiq0U9zJcIe6nnAqGrobV0bExSNMKxzzlaoynsMEHn6VNIJJirq2AOtVpHKuokwRng4/SpirHNPRGfP8k24HIIxVOMh5wq92xirOpybXbaMKRkVW09lSdC5OFOTXbThzWOKrK0WzrI9qhURcFRt6danjdnGBjj15xVW1l81Q6ksvYjtVy3AYnA6+pxmvW20PDepNHC0nzFcAnt/OtqCPbEFbHBBziq9vDuRSQQB6mr9vG7AncpXt7irRDZJbxgHJOcnORV5EGEA+vIpsap5aq/znoCetWIoGXcy7ivSqJZYRcJlUGD69/wp0aLJIhyMKecCnrHvhOAQQcjmlgXyocN97OWoJLCZyQ5yO1AweMmo1LhuCcHnPWpsZUsCP8AGgaEUZXBHTpxQxLL83IFOHqwx6UzccEAj2pDHxj5ckY9MUc5GMH2NIHOwHPaomkfCjbn1oAkZRyeDjoKZKxccDjtxTgVccnGKZjng8Z4NBS2K8g2kKCQDzzUS5zg5xmp7pGVOWB5yR7VCOig7mHakBImNvJxRTWjLncFyKKBnxBbzNC3TIrZs7hGC7gMj0FYAbI+XkVJFJtPykg1yLQ9du52dukTdAPY1rW0SMhzjIGRgVxdlflGAk4HrW/Y6jt5/DPpWiZjJM6BYcBVCjHXIFSNBs+Y9D2xUNreB3AL8YzVyaSNmHzZU8DjvV3MnEasKuMKD7+1X7S0YBSybmPGB6UWUQIyAMEenSt+zjj+6+MgDB700iJOxDBZuifOijJ/hFXLe2Bk3KmfUH1rRhjRhtyWOMba0beyG7CKdxHHtVpGTkZVvY+YV3pknmtOGzQEiVCwHQDnJrVSHyYQABnoeaVYnZQSp3bs8VViHIo2wSNumDnGMVaC7sDb7mp3gOTtRuvX3ojh3NnOFHXHWmQyMqFlwF+Y1bAJHH3jjkjFMWPkjnJ5z7VODkBeeevy9KAISowB0H3cHtVS+lMeFXJNWrhvJQtk8n0qlCn2lw0nOTjk9qBWLNjCFi82QfM5AB9BUUmmzNI6QMvl9csSSK0GkIXyo/4ePxpsUpT5STz1NAhtnaRW7jYoLAYyf51eDYO3qc/xcZFNiVPLJHJ96ryv5aEnHHU9aBMbeyqo8tl6nrmuW1a6++oxtHBGavajMCjNk5xkc965a4YuSZD3znPJoGjzrxqSmuSvniQB1P4Y/pXPyXBKYWun8fgO0MiqAUyp+hrg3mKv9K8+rD3me1hal4I00cq5YY+70qzZ3HmxnI2g/KB+NY7sGjk5IbHatK0j5iXqAADWLidsJHQadku0jA47Cukso2d1LrhP7vrWLpSAqGPA6j2rpLMsx6cEda5ars7HRFNmnb+VBCdkahm/SoY8yTF2/XtTZZRDgOTk/wAqsW/lynLH5fauW3U1UWtSWaXZFhCen51jPHKrb8YJ/h9a2jbBzuTO0dOay5FYXZUkn1GadKSRcUraC2xM75ZfnHTNadtbdioBPQ1nZe3YbQSCMkdxWnHcp5KLJ8rDofWqqXesRTehTffHMUxwOnvUMsqsm09u9XLxAYvMXORzWNM2GBHcUU1c5qjuUdRwzRxk8Co0UkkgZB4p13h3XA6A5qe2h3MMfdXk16uHhrdnk4mpZcqNjQonFvgE4LZPtXT2UJjXcV3gjj2rO0G34y3IzniuntlBIzwMdK7kjzZMbboMELyOwNWrZTgdVx2p8dswkJAAGM5zViK3yeuMHIxVWMxyI2BgAZ9+lXIsxwfNnPt3qInYxUqMEZPvUgkAJ4JUDg0wJI9xQEMSCfyqfZ8hZhxUC4B3R8oRgVMilQpzle/tQxWIXl8pjkZU9CO1PimVuCfepGt/MRgOccms2ctAuCpOO/WkNGujKQRyRSEgLgDj3rKhuwo3YOO4/wAKuxXaspBXkUDJgpJ4yABTGmSPpk+tL5m5Plzj+VQohY5bg+woAmDrJgjAFODgNgrx61CkaJNxxu7E9anEeJMMefrQBFKOfbGMHvVRcspAznOMelXpB97H1xWfLvjcgDkH8qRQ9SR/fX2op8bsVyTz3ooA+EkYhhip155oorkPV7EiMWxnmrFvM8bgK3FFFBSN+1nkVFYMcmug0iZ55/LkOVJ/KiiriZTOu02FGQg54q6nNq5PYHFFFbI5ZF7TnbaHzyMGut0yZ5JPmxwM9KKK0RkzZlRcr8o5GTUSKHwT3oopmYx8sjDJGMDg+tSKcyImBtzjiiigAclV3AndzSIxJ3E80UUCKuouzSCMk7cdKfZoAV28bRkYoooAuSYEe3AwTzmoGGFfHHH9KKKBMVXbpk4xmmTORAw4oooYupz2ogYJ6nGawjgB+AfrRRUlo4fxnzFKDyK8yuTiY47Giiuapuehhdh0TsXOT/Ca6DTuXb2UUUVzzPRgddpyhVhQZwwya6OAbcKOBiiivPq/Ed1PYqXTNksWJIHFJKzRWqPGzKc9jRRRY6o7F57mVbcOrkMPSnWqCYeY5O4Hjmiisu4i7OiqAwHINZ2ocDeOpOaKKVLdGUtgM0nkld3BHSqdxwBjvRRW0NzlqFZRjJ79Ku2gCQsF7nmiivYo/CeFiPiZ2WmIEjj28ZXNbluxJBooroiccjRj5X078VdVFKqCOME0UVRIDiRY8fKaEiWOQKudoJwM0UUxknC5AHXvT4/lCkfxcGiipAkj4ZsE8iobpQUyR2oooAzioUkDpUiSsHzgdKKKYFi3cjcM8HqKsFQdgx1ODRRSGZl2zCReT8pwK1bSRnUbj0FFFAyRmJfHHSq7gHGQDmiikA5Yl56iiiigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph demonstrates a severe degree of livedo reticularis in a patient with cold agglutinin disease following exposure to cold. The patient's skin changes disappear completely without residua within several minutes following warming.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Dr. Jason Gotlib, Stanford University School of Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_55_10101=[""].join("\n");
var outline_f9_55_10101=null;
var title_f9_55_10102="Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia";
var content_f9_55_10102=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/55/10102/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/55/10102/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/55/10102/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/55/10102/contributors\">",
"     Claire Dearden, MD, BSc, FRCP, FRCPath",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/55/10102/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/55/10102/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/55/10102/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/55/10102/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/55/10102/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cell prolymphocytic leukemia (T-PLL) is a rare T cell neoplasm composed of lymphoid cells, typically with involvement of the peripheral blood, bone marrow, lymph nodes, and spleen. The name \"prolymphocyte\" is actually a misnomer, as the tumor cells in this disease are of post-thymic T cell origin. This class of neoplasms includes many cases previously classified as T cell chronic lymphocytic leukemia, a category no longer included in the current World Health Organization (WHO) classification.",
"   </p>",
"   <p>",
"    The epidemiology, clinical presentation, pathology, and diagnosis of T-PLL are discussed here. The treatment of T-PLL is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18680?source=see_link\">",
"     \"Treatment of T cell prolymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;T-PLL is an extremely rare disease, comprising approximately 2 percent of mature lymphocytic leukemias in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10102/abstract/1\">",
"     1",
"    </a>",
"    ]. Sporadic T-PLL mainly affects the elderly with a mean age at presentation of 65 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10102/abstract/2\">",
"     2",
"    </a>",
"    ]. It has not been reported in children or young adults. There is a slight male predominance with a male:female ratio of 1.33 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10102/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with ataxia telangiectasia have a greatly increased incidence of T-PLL with a different epidemiologic profile [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10102/abstract/4\">",
"     4",
"    </a>",
"    ]. In contrast to patients with sporadic T-PLL, the median age of onset of T-PLL in patients with ataxia telangiectasia is about 30 years of age, and some cases appear in adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10102/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link\">",
"     \"Ataxia-telangiectasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with T-PLL present with an elevated white blood count (typically",
"    <span class=\"nowrap\">",
"     &gt;100,000/microL),",
"    </span>",
"    hepatosplenomegaly (75 percent), and generalized lymphadenopathy (50 percent); anemia (36 percent) and thrombocytopenia (51 percent) can be seen, but are less common than in B cell prolymphocytic leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10102/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, skin infiltration and serous effusions (ie, pleural) occur in approximately 25 and 15 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10102/abstract/6\">",
"     6",
"    </a>",
"    ]. Involvement of the central nervous system is rare. Infrequently, asymptomatic patients are diagnosed as part of the evaluation of abnormal laboratory studies.",
"   </p>",
"   <p>",
"    Pertinent negatives in the laboratory work-up of patients include the absence of paraproteinemia or evidence of infection with HTLV (human T lymphotropic virus) types 1 or 2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Peripheral blood and bone marrow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the peripheral blood demonstrates a predominance of lymphoid cells (",
"    <a class=\"graphic graphic_picture graphicRef85962 graphicRef64572 \" href=\"UTD.htm?12/53/13144\">",
"     picture 1A-B",
"    </a>",
"    ). There are three morphologic variants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10102/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Typical (75 percent) &mdash; The tumor cells are medium-sized lymphoid cells with moderately condensed chromatin and a visible nucleolus [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10102/abstract/1,6\">",
"       1,6",
"      </a>",
"      ]. The nucleus can be round or oval. The cytoplasm is usually moderately abundant and slightly basophilic without granules. Cytoplasmic protrusions (blebs) are common.",
"     </li>",
"     <li>",
"      Small cell variant (20 percent) &mdash; The tumor cells are small with condensed chromatin and a small nucleolus visible only by electron microscopy.",
"     </li>",
"     <li>",
"      Cerebriform (Sezary cell-like) variant (5 percent) &mdash; The tumor cells have a very irregular nuclear outline resembling the cerebriform nucleus of Sezary cells seen in mycosis fungoides (",
"      <a class=\"graphic graphic_picture graphicRef75793 \" href=\"UTD.htm?10/56/11137\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The bone marrow is infiltrated in an interstitial pattern by cells with similar morphology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin infiltrations most commonly involve the face and are often clinically characterized by purpura and edema, often in a periorbital distribution (",
"    <a class=\"graphic graphic_picture graphicRef85961 \" href=\"UTD.htm?41/62/42982\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10102/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Skin biopsy of affected areas demonstrates perivascular or diffuse dermal infiltrates, sometimes with accompanying hemorrhage, but without epidermotropism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Other tissues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spleen demonstrates dense lymphoid infiltrates in the red pulp that often invade the splenic capsule. The white pulp is usually atrophied. Lymph node involvement is diffuse, often with prominent high-endothelial venules. Infiltration typically involves the paracortical areas and may spare the follicles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;T-PLL cells express CD52 (strongly) and pan-T cell markers (CD2, CD3, and CD7) (",
"    <a class=\"graphic graphic_figure graphicRef85963 \" href=\"UTD.htm?41/19/42293\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10102/abstract/1\">",
"     1",
"    </a>",
"    ]. Terminal deoxynucleotidyl transferase (TdT) is not expressed. There may be weak expression of CD3 on the membrane. Expression of CD4 and CD8 is variable: 60 percent of cases are",
"    <span class=\"nowrap\">",
"     CD4+/CD8-,",
"    </span>",
"    25 percent of cases are",
"    <span class=\"nowrap\">",
"     CD4+/CD8+,",
"    </span>",
"    and 15 percent of cases are",
"    <span class=\"nowrap\">",
"     CD4-/CD8+.",
"    </span>",
"    The coexpression of CD4 and CD8 is practically unique to T-PLL among post-thymic T cell malignancies. T-PLL cells overexpress the oncogene TCL1 as demonstrated by immunohistochemistry.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Genetic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cell receptor genes are clonally rearranged. Chromosomal abnormalities are common. Rearrangements involving TCL1 are common and relatively specific for T-PLL. These may take the form of either inv(14) or t(14;14)(q11;q32). Another abnormality, t(X;14)(q28;q11), involves a homolog of TCL1, MTCP1 (mature T cell proliferation 1 gene) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10102/abstract/1,4,9-11\">",
"     1,4,9-11",
"    </a>",
"    ]. Overall, approximately 90 percent of cases demonstrate chromosome abnormalities involving chromosome 14.",
"   </p>",
"   <p>",
"    Other chromosomal or genetic abnormalities include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormalities in chromosome 8 (70 to 80 percent of cases) including idic(8p11), t(8;8), and trisomy 8q [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10102/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Del(12p13), abnormalities in chromosome 6 (33 percent) and chromosome 17 (26 percent), deletion of p53 gene (17p13) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10102/abstract/4,12-14\">",
"       4,12-14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Deletions of or missense mutations at the ataxia telangiectasia mutated (ATM) locus 11q23, a tumor suppressor gene that is inactivated by inherited germ line mutations in patients with ataxia telangiectasia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10102/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of T-PLL is usually made by evaluation of the peripheral blood, bone marrow biopsy and bone marrow aspirate in the appropriate clinical setting. When evaluated with flow cytometry and immunostains, these samples demonstrate a T cell immunophenotype. There is expression of CD52 and pan-T cell markers (CD2, CD3, and CD7), as well as overexpression of TCL1. Expression of CD4 and CD8 vary. Serologic and PCR (polymerase chain reaction) testing for human T-lymphotropic viruses (HTLV), type I is negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of T-PLL includes other chronic lymphoid neoplasms or T cell neoplasms with a leukemic presentation (",
"    <a class=\"graphic graphic_table graphicRef56540 \" href=\"UTD.htm?11/8/11405\">",
"     table 1",
"    </a>",
"    ). They are described in more detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     B cell prolymphocytic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;B cell prolymphocytic leukemia (B-PLL) has a similar clinical presentation and morphologic appearance to T-PLL. Skin infiltration and lymphadenopathy, which are unusual in B-PLL, are much more common in T-PLL. These two entities differ in their immunophenotype. Unlike T-PLL, B-PLL expresses one or more B cell antigens (CD20, CD22, FMC7, CD79a). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20358?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of B cell prolymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mycosis fungoides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both T-PLL and mycosis fungoides (MF) are T cell neoplasms that can involve the blood and skin. The morphology of the \"cerebriform\" (Sezary cell-like) variant seen in 5 percent of patients with T-PLL resembles the Sezary cells seen in MF. MF is diagnosed using a diagnostic algorithm that incorporates clinical features, histology, immunophenotype, and molecular biology in a point-based system (",
"    <a class=\"graphic graphic_table graphicRef74457 \" href=\"UTD.htm?32/40/33420\">",
"     table 2",
"    </a>",
"    ). A diagnosis of MF is made when a total of four points or more is determined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Chronic lymphocytic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both T-PLL and chronic lymphocytic leukemia (CLL) can present with lymphocytosis and splenomegaly, and have circulating prolymphocytes in the blood.",
"   </p>",
"   <p>",
"    Typical CLL cells are small, mature appearing lymphocytes with a dense nucleus, partially aggregated chromatin, and without discernible nucleoli. There is a narrow border of clear to slightly basophilic cytoplasm (",
"    <a class=\"graphic graphic_picture graphicRef54469 \" href=\"UTD.htm?22/17/22803\">",
"     picture 4",
"    </a>",
"    ). Prolymphocytes usually comprise fewer than 10 percent of the circulating cells. Most importantly, CLL is a B cell neoplasm and demonstrates both expression of B cell associated antigens (CD19, CD20, and CD23) the T cell associated antigen CD5. T-PLL does not express B cell associated antigens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Adult T cell leukemia-lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult T cell leukemia-lymphoma (ATL) is a peripheral T cell neoplasm associated with infection by the human T-lymphotropic virus, type I (HTLV-I). Serologic and PCR (polymerase chain reaction) testing for HTLV-I is used to exclude this diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9945?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hairy cell leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cytoplasm of T-PLL can demonstrate cytoplasmic protrusions or blebs that may resemble the projections seen in the circulating tumor cells of hairy cell leukemia (HCL). Hairy cells strongly express pan-B cell antigens (CD19, CD20, CD22), and usually lack expression of CD5, CD10, CD21, and CD23. Hairy cells also characteristically express CD11c, CD25, CD103, CD123, cyclin D1, and annexin A1. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20841?source=see_link\">",
"     \"Clinical features and diagnosis of hairy cell leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     T cell large granular lymphocyte leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both T-PLL and T cell large granular lymphocyte (LGL) leukemia can present with a peripheral blood lymphocytosis. The tumor cells of LGL leukemia are characterized by their large size (15 to 18 microns), abundant cytoplasm containing typical azurophilic granules, a reniform or round nucleus, and a mature post-thymic immunophenotype. They express CD8 and CD57 with or without the expression of CD16 and the natural killer cell marker CD56 (",
"    <a class=\"graphic graphic_algorithm graphicRef80765 \" href=\"UTD.htm?20/42/21167\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2793?source=see_link\">",
"     \"Treatment of large granular lymphocyte leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;T-PLL is a highly aggressive T cell leukemia with a median survival less than one year [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10102/abstract/1\">",
"     1",
"    </a>",
"    ]. A minority of cases have a more chronic course [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10102/abstract/17\">",
"     17",
"    </a>",
"    ]. Such tumors typically express a memory T cell immunophenotype",
"    <span class=\"nowrap\">",
"     (CD45RO+/CD45RA-).",
"    </span>",
"    Increased expression of TCL1 and the resultant increased activity of the serine-threonine kinase AKT appear to correlate with a worse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10102/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T cell prolymphocytic leukemia (T-PLL) is a rare T cell neoplasm comprised of lymphoid cells, typically with involvement of the peripheral blood, bone marrow, and spleen. It is most common in the elderly. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients typically present with an elevated white blood count (usually",
"      <span class=\"nowrap\">",
"       &gt;100,000/microL),",
"      </span>",
"      hepatosplenomegaly, and generalized lymphadenopathy. Skin infiltration and serous effusions are not uncommon. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of T-PLL is most often made by examination of the peripheral blood and bone marrow coupled with flow cytometry. When evaluated with flow cytometry and immunostains, these samples demonstrate a T cell immunophenotype. Tumor cells express high levels of CD52 and also express pan-T cell markers (CD2, CD3, and CD7) and TCL1. Serologic and polymerase chain reaction testing for human T-lymphotropic viruses, type I is negative. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of T-PLL includes other lymphoid neoplasms with a leukemic presentation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Survival is usually less than one year despite therapy, but a more indolent variant may exist in a small subset of patients. Prognostic markers have been difficult to determine. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10102/abstract/2\">",
"      Melo JV, Catovsky D, Galton DA. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterization of an intermediate group. Br J Haematol 1986; 63:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10102/abstract/3\">",
"      Matutes E, Brito-Babapulle V, Swansbury J, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991; 78:3269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10102/abstract/4\">",
"      Brito-Babapulle V, Catovsky D. Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia. Cancer Genet Cytogenet 1991; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10102/abstract/5\">",
"      Taylor AM, Metcalfe JA, Thick J, Mak YF. Leukemia and lymphoma in ataxia telangiectasia. Blood 1996; 87:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10102/abstract/6\">",
"      Ravandi F, O'Brien S. Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc 2005; 80:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10102/abstract/7\">",
"      Magro CM, Morrison CD, Heerema N, et al. T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism. J Am Acad Dermatol 2006; 55:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10102/abstract/8\">",
"      Herling M, Valbuena JR, Jones D, Medeiros LJ. Skin involvement in T-cell prolymphocytic leukemia. J Am Acad Dermatol 2007; 57:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10102/abstract/9\">",
"      Maljaei SH, Brito-Babapulle V, Hiorns LR, Catovsky D. Abnormalities of chromosomes 8, 11, 14, and X in T-prolymphocytic leukemia studied by fluorescence in situ hybridization. Cancer Genet Cytogenet 1998; 103:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10102/abstract/10\">",
"      Pekarsky Y, Hallas C, Isobe M, et al. Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes. Proc Natl Acad Sci U S A 1999; 96:2949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10102/abstract/11\">",
"      Stern MH, Soulier J, Rosenzwajg M, et al. MTCP-1: a novel gene on the human chromosome Xq28 translocated to the T cell receptor alpha/delta locus in mature T cell proliferations. Oncogene 1993; 8:2475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10102/abstract/12\">",
"      Hetet G, Dastot H, Baens M, et al. Recurrent molecular deletion of the 12p13 region, centromeric to ETV6/TEL, in T-cell prolymphocytic leukemia. Hematol J 2000; 1:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10102/abstract/13\">",
"      Brito-Babapulle V, Hamoudi R, Matutes E, et al. p53 allele deletion and protein accumulation occurs in the absence of p53 gene mutation in T-prolymphocytic leukaemia and Sezary syndrome. Br J Haematol 2000; 110:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10102/abstract/14\">",
"      Costa D, Queralt R, Aymerich M, et al. High levels of chromosomal imbalances in typical and small-cell variants of T-cell prolymphocytic leukemia. Cancer Genet Cytogenet 2003; 147:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10102/abstract/15\">",
"      Stilgenbauer S, Schaffner C, Litterst A, et al. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med 1997; 3:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10102/abstract/16\">",
"      Vorechovsk&yacute; I, Luo L, Dyer MJ, et al. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. Nat Genet 1997; 17:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10102/abstract/17\">",
"      Garand R, Goasguen J, Brizard A, et al. Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Fran&ccedil;ais d'H&eacute;matologie Cellulaire. Br J Haematol 1998; 103:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10102/abstract/18\">",
"      Herling M, Patel KA, Teitell MA, et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood 2008; 111:328.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4745 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.69.132.100-0D12DA5E94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_55_10102=[""].join("\n");
var outline_f9_55_10102=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Peripheral blood and bone marrow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Skin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Other tissues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Genetic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      B cell prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Adult T cell leukemia-lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      T cell large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4745\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4745|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/42/21167\" title=\"algorithm 1\">",
"      Evaluation for LGL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4745|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/19/42293\" title=\"figure 1\">",
"      T-PLL flow cytometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4745|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/62/12260\" title=\"picture 1A\">",
"      T-PLL morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/33/1554\" title=\"picture 1B\">",
"      T PLL blood smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/56/11137\" title=\"picture 2\">",
"      Sezary cells mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/62/42982\" title=\"picture 3\">",
"      Clinical features T-PLL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/17/22803\" title=\"picture 4\">",
"      CLL smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4745|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/8/11405\" title=\"table 1\">",
"      DDx TPLL path",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/40/33420\" title=\"table 2\">",
"      Diagnosis early MF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20841?source=related_link\">",
"      Clinical features and diagnosis of hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20358?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of B cell prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9945?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=related_link\">",
"      Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18680?source=related_link\">",
"      Treatment of T cell prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2793?source=related_link\">",
"      Treatment of large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_55_10103="Inflammatory breast cancer: Pathology and molecular pathogenesis";
var content_f9_55_10103=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Inflammatory breast cancer: Pathology and molecular pathogenesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/55/10103/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/55/10103/contributors\">",
"     Sofia D Merajver, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/55/10103/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/55/10103/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/55/10103/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/55/10103/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/55/10103/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory breast cancer (IBC) is an aggressive form of locally advanced breast cancer. De novo IBC refers to primary disease. These patients typically present with pain and a tender, firm, and enlarged breast. The skin over the breast is reddened, warm, and thickened, with a \"peau d'orange\" (orange skin) appearance (",
"    <a class=\"graphic graphic_picture graphicRef70894 \" href=\"UTD.htm?13/8/13442\">",
"     picture 1",
"    </a>",
"    ). In comparison, the inflammatory recurrence of a noninflammatory breast cancer is called secondary disease. It usually develops on the chest wall at the site of previous mastectomy, but can also occur rarely as a distant cutaneous recurrence. The signs and symptoms of IBC arise rapidly compared to non IBC, typically within weeks to six months.",
"   </p>",
"   <p>",
"    Primary IBC is a relatively rare disorder accounting for approximately 1 to 5 percent of invasive breast cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, because of its aggressive nature, it accounts for a greater proportion of cases presenting with more advanced disease. In one report of 752 patients with stage III breast cancer, for example, 24 percent had IBC [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At presentation, almost all women with primary IBC have lymph node involvement and approximately one-third have distant metastases. The long-term prognosis is also relatively poor, which has led to the development of combined modality treatment regimens consisting of neoadjuvant chemotherapy to maximize clinical response, followed by locoregional treatment, and then consolidation chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31048?source=see_link\">",
"     \"Inflammatory breast cancer: Clinical features and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BASIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 American Joint Committee on Cancer and the International Union for Cancer Control (AJCC-UICC) TNM breast cancer staging system defines inflammatory breast cancer (IBC) as a clinical-pathologic entity characterized by diffuse erythema and edema (peau d'orange) involving a third or more of the skin of the breast (",
"    <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"     table 1",
"    </a>",
"    ). These \"inflammatory\" skin changes are not due to infiltration of inflammatory cells but rather to lymphedema caused by tumor emboli within the dermal lymphatics. However, the diagnosis is based upon the clinical presentation. Although dermal lymphatic involvement supports the diagnosis of inflammatory breast cancer, it is neither necessary nor sufficient in the absence of classical clinical findings.",
"   </p>",
"   <p>",
"    IBC is designated as primary tumor stage T4d. Tumor presentation with ulceration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ipsilateral satellite skin nodules",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    edema are T4b. Not all skin changes qualify as IBC or even locally advanced breast cancer (LABC). Invasion of the dermis alone, such as dimpling of the skin or nipple retraction does not qualify as T4 and may occur in T1, T2, or T3 without changing the classification.",
"   </p>",
"   <p>",
"    Of note, if a cancer is designated as inflammatory before therapy, the patient will be designated to have inflammatory breast cancer throughout, even if the patient has complete resolution of inflammatory findings.",
"   </p>",
"   <p>",
"    Primary IBC has several characteristic biologic features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It is rapidly progressive",
"     </li>",
"     <li>",
"      It is highly angiogenic and angioinvasive; these features account for the high metastatic potential",
"     </li>",
"     <li>",
"      The aggressive behavior and angiogenicity are intrinsic features of the tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The last characteristic was demonstrated in a unique human xenograft model, the scid (severe combined immune deficiency) mouse. Implantation of noninflammatory human tumors into the mammary fat pad in these mice resulted in the growth of isolated subcutaneous nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast, implantation of an IBC resulted in exclusive growth within lymphatic and blood vessels, with marked erythema of the overlying skin.",
"   </p>",
"   <p>",
"    Given these data, an international expert panel proposed the following consensus-based criteria for the diagnosis of IBC in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid onset of breast erythema, edema",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      peau d&rsquo;orange,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      warm breast, with or without an underlying palpable mass",
"     </li>",
"     <li>",
"      Duration of history no more than six months",
"     </li>",
"     <li>",
"      Erythema occupying at least one-third of the breast",
"     </li>",
"     <li>",
"      Pathologic confirmation of invasive carcinoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Primary IBC refers to a de novo IBC. Secondary IBC is the inflammatory recurrence of a noninflammatory primary breast carcinoma. Secondary IBC usually occurs on the chest wall at the site of previous mastectomy for a noninflammatory breast cancer, but occasionally may be found at a distant cutaneous recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic histologic finding in IBC on biopsy of affected skin is dermal lymphatic invasion by tumor cells; this change can also be seen in areas of skin that are clinically normal (",
"    <a class=\"graphic graphic_picture graphicRef60801 \" href=\"UTD.htm?12/6/12387\">",
"     picture 2",
"    </a>",
"    ). These malignant cells form tumor emboli, which are responsible for both the local signs and symptoms and for the development of metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Thus, the term \"inflammatory\" breast cancer is actually a misnomer since the clinical signs suggesting inflammation are not due to infiltration of inflammatory cells. Invasion of the dermis outside the lymphatics is uncommon in primary IBC but can be seen in secondary IBC.",
"   </p>",
"   <p>",
"    Several caveats need to be kept in mind when evaluating the skin biopsy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dermal lymphatic invasion is not always found in patients with primary IBC, primarily due to sampling error.",
"     </li>",
"     <li>",
"      Dermal lymphatic invasion can be an incidental finding in patients with breast cancer who do not have clinical evidence of IBC [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]; such tumors are not considered to be inflammatory cancers.",
"     </li>",
"     <li>",
"      Rarely, women with clinical features suggestive of IBC have other disorders; these include acute mastitis, diffuse infiltration by lymphoma or leukemia cells, and advanced noninflammatory breast cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Primary IBC is not a specific histologic subtype of breast cancer, but the tumor is often of the ductal type. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16040?source=see_link\">",
"     \"Pathology of breast cancer\"",
"    </a>",
"    .) These tumors generally have a high histologic grade, with pleomorphic tumor cells, highly atypical mitotic figures, and a high intratumoral microvessel density [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/9,13\">",
"     9,13",
"    </a>",
"    ]. It has been suggested that secondary IBC is more likely to be seen in recurrences of primary breast cancers with prominent apocrine features [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MOLECULAR GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the angioinvasive nature of primary IBC appears to be intrinsic to the tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/6,14\">",
"     6,14",
"    </a>",
"    ]. Experimental studies have begun to shed light on the pathogenetic factors that may be involved in the development and progression of this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/8\">",
"     8",
"    </a>",
"    ]. Among the factors that have been evaluated are hormone receptor status, the p53 tumor suppressor gene, other genetic determinants, and cytokines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hormonal receptors and other tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancers that do not express estrogen or progesterone receptors (ER and PgR) are generally associated with a shorter disease-free survival and a worse prognosis than receptor-positive tumors. The majority of IBCs are hormone receptor-negative [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/6,15-17\">",
"     6,15-17",
"    </a>",
"    ]. In one report of 60 patients with locally advanced breast cancer (LABC) of any type, both response to treatment and overall survival were significantly correlated with ER and PgR positivity as well as a lower mitotic index, histologic grade, and diploid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=see_link\">",
"     \"Measurement of prognostic factors in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IBCs are also characterized by a high proliferative rates [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Approximately 60 percent of IBCs overexpress the epidermal growth factor receptor (EGFR) and the type EGFR, also called HER2 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/19\">",
"     19",
"    </a>",
"    ]. Although not specific for IBC, these molecular markers may identify patients who have a worse prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Genetic changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of heterozygosity (LOH) is detected in approximately one-half of IBCs, and the most frequently lost alleles are at 3p, 6p, 8p, 11q, 13q, and 17q [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/20\">",
"     20",
"    </a>",
"    ]. Lack of expression of genes at some of these loci may have phenotypic and prognostic importance. As an example, in one series of 64 patients with IBC who were treated homogeneously at a single institution between 1988 and 1999, women who presented with extensive inflammation and who had a poor overall outcome had both a significantly higher overall frequency and a different pattern of intratumoral LOH compared to those who presented with localized inflammation and who had a better prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     p53 tumor suppressor gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the p53 tumor suppressor gene or accumulation of p53 protein have been reported in 20 to 50 percent of human breast cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. These abnormalities are more often seen in patients with",
"    <span class=\"nowrap\">",
"     familial/hereditary",
"    </span>",
"    breast cancer syndromes (such as the familial breast and ovarian cancer and Li-Fraumeni syndromes) than in those with sporadic breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=see_link\">",
"     \"Li-Fraumeni syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The p53 status in IBC was evaluated by immunohistochemistry in a series of 27 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/22\">",
"     22",
"    </a>",
"    ]. Three groups of almost equal size were identified: tumors with high levels of p53 in the nucleus, tumors with no detectable p53, and tumors with p53 in the cytoplasm. The last two groups had only wild-type p53, while the samples with intense nuclear staining had a variety of missense mutations. These findings suggest that two mechanisms, direct mutation and cytoplasmic sequestration of wild-type protein, can subvert the normal role of p53 in IBCs.",
"   </p>",
"   <p>",
"    A subsequent study by the same group evaluated 24 additional patients with IBC in an attempt to determine the prognostic significance of p53 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/24\">",
"     24",
"    </a>",
"    ]. Those patients with a p53 gene mutation and nuclear overexpression of p53 protein had an 8.6-fold higher risk of death compared with patients that had neither mutation nor protein overexpression. There was an important prognostic interaction with ER expression. The subset of patients who were both ER-negative and had nuclear p53 overexpression had a 17.9-fold higher risk of death, compared to 2.8-fold for women with tumors that had p53 nuclear overexpression alone.",
"   </p>",
"   <p>",
"    Similar findings were noted in a study of 39 LABCs, 32 of which were confirmed as IBCs by clinical and pathologic criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/25\">",
"     25",
"    </a>",
"    ]. p53 mutations were detected in 41 percent of the tumors analyzed, all but three of which had intense p53 nuclear staining. The presence of p53 mutations was significantly associated with large tumor size and disseminated disease at diagnosis. There was also a nonsignificant trend toward an association between p53 mutation, negative ER status and a lower rate of response to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     RhoC GTPase and WISP3",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an effort to identify new genes that may contribute to the rapidly growing and metastatic features of IBCs, we compared the genes expressed in two cells lines: an IBC cell line (SUM149) and two human mammary epithelial (HME) cell lines [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/26\">",
"     26",
"    </a>",
"    ]. Seventeen transcripts were identified as being differentially expressed, eight solely by the normal cell lines, and nine solely by the tumor cell line. This was followed by a blinded analysis of the seventeen transcripts in 20 archival IBCs and 30 stage-matched non-IBCs. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two genes, RhoC GTPase and a novel gene called WISP3 or LIBC (lost in inflammatory breast cancer), were concordantly altered in 91 percent of the IBC specimens compared to none of the controls.",
"     </li>",
"     <li>",
"      The putative RhoC GTPase oncogene was more often overexpressed (90 versus 38 percent) and WISP3 was commonly lost in the IBCs (80 versus 21 percent).",
"     </li>",
"     <li>",
"      Role of RhoC GTPase &mdash; RhoC GTPase is a member of the Ras superfamily of small GTP-binding proteins [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. It is involved in cytoskeletal reorganization, via regulation of the actin cytoskeleton [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/29\">",
"       29",
"      </a>",
"      ]. Transfection of the RhoC GTPase gene into human mammary epithelial cells leads to enhanced invasiveness, motility, and the release of angiogenic cytokines (eg, vascular endothelial growth factor), at least partially recapitulating the IBC phenotype (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Cytokines'",
"      </a>",
"      below) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. The additional observation that overexpression of RhoC GTPase correlates with tumor progression in aggressive ductal pancreatic cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/32\">",
"       32",
"      </a>",
"      ] is consistent with the hypothesis that RhoC GTPase is an important contributor to the IBC metastatic phenotype.",
"     </li>",
"     <li>",
"      Role of WISP3 &mdash; The product of the WISP3 gene is an insulin-like growth factor binding protein-related protein (IGFBP-rP) called IGFBPrP-9 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/33\">",
"       33",
"      </a>",
"      ]. It has been suggested that both the high-affinity IGF binding proteins (IGFBPs) and the IGFBPrPs modulate the availability of insulin-like growth factor to the cell surface IGF receptors [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/34\">",
"       34",
"      </a>",
"      ]. If so, they could potentiate IGF-mediated proliferative actions; they may also promote tumor cell growth by IGF-independent effects [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is suggestive evidence that at least some IGFBPrPs play a role in tumor progression. Downregulation or loss of IGFBPrP-1 expression has been associated with progression of breast cancer and prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], while transfection of WISP3 into breast cancer cells inhibits tumor cell growth, invasiveness, and angiogenic potential [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/38\">",
"     38",
"    </a>",
"    ]. Thus, the WISP3 gene appears to act as a tumor suppressor gene in breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the term inflammatory is a misnomer in IBC since the clinical signs suggesting inflammation are due to tumor cell invasion of dermal lymphatics, not infiltration of inflammatory cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, IBCs produce negligible levels of most inflammatory cytokines such as interferon-gamma, interleukin-1 (IL)-1, and IL-12.",
"   </p>",
"   <p>",
"    However, other cytokines may be important. As mentioned above, IBCs tend to be highly vascular tumors because of their angiogenic and angioinvasive potential [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/9\">",
"     9",
"    </a>",
"    ]. In preclinical models, IBC tumor cell lines and tumor specimens release increased amounts of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF, FGF-2), IL-6, and IL-8; increased release of these cytokines also occurs in human mammary epithelial cells that are transfected with and overexpress the RhoC GTPase gene, a gene specifically associated with IBC (see",
"    <a class=\"local\" href=\"#H8\">",
"     'RhoC GTPase and WISP3'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The VEGF receptor-3 (VEGFR-3) is expressed in the lymphatic endothelium, plays an important role in lymphatic development, and is activated after binding to VEGF-C and VEGF-D. The VEGFR-3 pathway also may play an important role in tumor lymphangiogenesis and subsequent metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. As an example, VEGF-C is overexpressed in some breast cancer cells, promoting both intratumoral lymphangiogenesis and metastases to the regional lymph nodes and lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/39\">",
"     39",
"    </a>",
"    ]. In contrast, VEGF ligands to VEGFR-2 do not stimulate lymphangiogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link\">",
"     \"Clinical manifestations and diagnosis of lymphedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These observations appear to be applicable to human disease. One study screened breast cancer cell lines for expression of members of the VEGF family [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10103/abstract/41\">",
"     41",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Expression of VEGF-A and VEGF-B, which play a role in tumor angiogenesis, was seen in both node-positive and node-negative tumors",
"     </li>",
"     <li>",
"      Expression of VEGF-C, a ligand for VEGFR-3, was detectable in some node-positive breast cancers but not in node-negative tumors",
"     </li>",
"     <li>",
"      Expression of VEGF-D, another ligand for VEGFR-3, was detected only in an inflammatory breast cancer cell line and in a tumor cell line that was developed from an inflammatory skin metastasis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, activation of VEGFR-3, particularly by VEGF-D in IBC, may be specifically involved in the lymphotactic process through the development of new lymphatic vessels near the tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/39/8818?source=see_link\">",
"       \"Patient information: Inflammatory breast cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542381308\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer, characterized by its inflammatory appearance with diffuse erythema and edema.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The classic histologic finding on biopsy of affected skin is dermal lymphatic invasion by tumor cells, which causes the inflammatory changes. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although dermal lymphatic involvement supports the diagnosis of inflammatory breast cancer, it is neither necessary nor sufficient in the absence of classical clinical findings. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Basic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Investigations into the molecular basis of IBC and its rapidly progressive and highly angiogenic and angioinvasive features have focused on hormone receptors, overexpression of the epidermal growth factor receptor and vascular endothelial growth factor, and the contributory role of the p53 tumor suppressor gene, RhoGTPase oncogene (a member of the Ras family of small GTP-binding proteins), and the WISP3 gene and its protein product, an insulin-like growth factor binding protein-related protein. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Molecular genetics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/1\">",
"      Berg JW, Hutter RV. Breast cancer. Cancer 1995; 75:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/2\">",
"      Chang S, Parker SL, Pham T, et al. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer 1998; 82:2366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/3\">",
"      Buzdar AU, Singletary SE, Booser DJ, et al. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am 1995; 4:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/4\">",
"      Merajver SD, Weber BL, Cody R, et al. Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience. J Clin Oncol 1997; 15:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/5\">",
"      Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992; 10:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/6\">",
"      Alpaugh ML, Tomlinson JS, Shao ZM, Barsky SH. A novel human xenograft model of inflammatory breast cancer. Cancer Res 1999; 59:5079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/7\">",
"      Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 2011; 22:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/8\">",
"      Kleer CG, van Golen KL, Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2000; 2:423.",
"     </a>",
"    </li>",
"    <li>",
"     Rosen PP. Rosen's Breast Pathology, Lippincott-Raven, Philadelphia 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/10\">",
"      Robbins GF, Shah J, Rosen P, et al. Inflammatory carcinoma of the breast. Surg Clin North Am 1974; 54:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/11\">",
"      Gruber G, Ciriolo M, Altermatt HJ, et al. Prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer. Int J Cancer 2004; 109:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/12\">",
"      L&ecirc; MG, Arriagada R, Contesso G, et al. Dermal lymphatic emboli in inflammatory and noninflammatory breast cancer: a French-Tunisian joint study in 337 patients. Clin Breast Cancer 2005; 6:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/13\">",
"      McCarthy NJ, Yang X, Linnoila IR, et al. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res 2002; 8:3857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/14\">",
"      Colpaert CG, Vermeulen PB, Benoy I, et al. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer 2003; 88:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/15\">",
"      Koh EH, Buzdar AU, Ames FC, et al. Inflammatory carcinoma of the breast: results of a combined-modality approach--M.D. Anderson Cancer Center experience. Cancer Chemother Pharmacol 1990; 27:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/16\">",
"      Paradiso A, Tommasi S, Brandi M, et al. Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer 1989; 64:1922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/17\">",
"      Nguyen DM, Sam K, Tsimelzon A, et al. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res 2006; 12:5047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/18\">",
"      Robertson JF, Ellis IO, Pearson D, et al. Biological factors of prognostic significance in locally advanced breast cancer. Breast Cancer Res Treat 1994; 29:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/19\">",
"      Gu&eacute;rin M, Sheng ZM, Andrieu N, Riou G. Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene 1990; 5:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/20\">",
"      Lerebours F, Bertheau P, Bieche I, et al. Evidence of chromosome regions and gene involvement in inflammatory breast cancer. Int J Cancer 2002; 102:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/21\">",
"      Lerebours F, Bertheau P, Bieche I, et al. Two prognostic groups of inflammatory breast cancer have distinct genotypes. Clin Cancer Res 2003; 9:4184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/22\">",
"      Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A 1992; 89:7262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/23\">",
"      Davidoff AM, Humphrey PA, Iglehart JD, Marks JR. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A 1991; 88:5006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/24\">",
"      Riou G, L&ecirc; MG, Travagli JP, et al. Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst 1993; 85:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/25\">",
"      Faille A, De Cremoux P, Extra JM, et al. p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer 1994; 69:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/26\">",
"      van Golen KL, Davies S, Wu ZF, et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 1999; 5:2511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/27\">",
"      Ridley AJ. The GTP-binding protein Rho. Int J Biochem Cell Biol 1997; 29:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/28\">",
"      Nobes CD, Hall A. Rho GTPases control polarity, protrusion, and adhesion during cell movement. J Cell Biol 1999; 144:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/29\">",
"      Hall A. Rho GTPases and the actin cytoskeleton. Science 1998; 279:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/30\">",
"      van Golen KL, Wu ZF, Qiao XT, et al. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000; 60:5832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/31\">",
"      van Golen KL, Wu ZF, Qiao XT, et al. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2000; 2:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/32\">",
"      Suwa H, Ohshio G, Imamura T, et al. Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 1998; 77:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/33\">",
"      Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 1999; 20:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/34\">",
"      Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 1998; 140:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/35\">",
"      Oh Y. IGF-independent regulation of breast cancer growth by IGF binding proteins. Breast Cancer Res Treat 1998; 47:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/36\">",
"      Burger AM, Zhang X, Li H, et al. Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas. Oncogene 1998; 16:2459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/37\">",
"      Sprenger CC, Damon SE, Hwa V, et al. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor suppressor protein for prostate cancer. Cancer Res 1999; 59:2370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/38\">",
"      Kleer CG, Zhang Y, Pan Q, et al. WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene 2002; 21:3172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/39\">",
"      Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/40\">",
"      Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001; 7:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10103/abstract/41\">",
"      Kurebayashi J, Otsuki T, Kunisue H, et al. Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res 1999; 90:977.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 742 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C801F8800B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_55_10103=[""].join("\n");
var outline_f9_55_10103=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H542381308\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BASIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MOLECULAR GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hormonal receptors and other tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Genetic changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - p53 tumor suppressor gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - RhoC GTPase and WISP3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cytokines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H542381308\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/742\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/742|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/8/13442\" title=\"picture 1\">",
"      Inflammatory breast cancer with peau d orange appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/6/12387\" title=\"picture 2\">",
"      Inflammatory breast ca Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/742|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/14/29920\" title=\"table 1\">",
"      TNM stage breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31048?source=related_link\">",
"      Inflammatory breast cancer: Clinical features and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=related_link\">",
"      Li-Fraumeni syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=related_link\">",
"      Measurement of prognostic factors in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16040?source=related_link\">",
"      Pathology of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/39/8818?source=related_link\">",
"      Patient information: Inflammatory breast cancer (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_55_10104="Treatment and prevention of vascular dementia";
var content_f9_55_10104=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of vascular dementia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/55/10104/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/55/10104/contributors\">",
"     Clinton B Wright, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/55/10104/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/55/10104/contributors\">",
"     Steven T DeKosky, MD, FAAN",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/55/10104/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/55/10104/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/55/10104/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/55/10104/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The entity of vascular dementia (VaD) is best understood as a heterogeneous syndrome rather than a distinct disorder, in which the underlying cause is cerebrovascular disease in some form, and its ultimate manifestation is dementia. There is considerable overlap between AD and VaD with regard to comorbidity as well as shared risk factors and even pathogenesis. The combination of pathologies may be more common than either in isolation, and it is not generally easy to identify the primary etiologic entity.",
"   </p>",
"   <p>",
"    Preventative agents and treatments for VaD have at least potential overlap. The same agent could both prevent the development of VaD in patients at risk and prevent cognitive decline in patients with VaD or in earlier stages of cognitive impairment.",
"   </p>",
"   <p>",
"    This topic will review the treatment, prevention, and prognosis of VaD. Other aspects of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37786?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of vascular dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTOR MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cognitive impairment and clinical or radiologic evidence of cerebrovascular pathology should be screened and treated for vascular risk factors, especially hypertension. Although these measures have been shown to be helpful in preventing rather than ameliorating dementia, there is a strong rationale for aggressive secondary stroke prevention measures in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/1\">",
"     1",
"    </a>",
"    ]. As an example, a cohort study of 99 cases followed after a first stroke found that those with recurrent stroke had greater cognitive decline [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, other studies have shown that poststroke dementia is associated with higher mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A few studies have examined the effects of programs that target all aspects of vascular risk factor reduction. One study compared a strategy of repeated systematic identification and treatment of vascular risk factors in a German population of patients &gt;54 years in age [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/4\">",
"     4",
"    </a>",
"    ]. After five years, there was a 10 percent reduction in the rate of long-term care dependence in the treated compared with a reference population (1240 cases observed, 1375 expected). The intervention was intended to target both stroke and dementia, but the specific incidence of either diagnosis over the study time period was not measured. A randomized study of patients with AD found that after two years, progression of white matter lesions on MRI was less in those who were assigned to vascular care (which included lifestyle interventions: physical exercise, smoking cessation, weight loss; daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ; antihypertensive treatment protocol, and statin treatment for hypercholesterolemia) compared to those who received standard care [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Antihypertensive drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;While blood pressure lowering is generally recommended for hypertensive individuals because of its compelling benefit for the reduction of mortality and cardiovascular events, randomized, controlled studies and meta-analyses have yielded conflicting data regarding the effect of antihypertensive therapy on incident dementia in general [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/6-15\">",
"     6-15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of hypertension in adults\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41369?source=see_link&amp;anchor=H12#H12\">",
"     \"Prevention of dementia\", section on 'Antihypertensive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Blood pressure lowering strategies have not been specifically tested for treatment or prevention of vascular dementia (VaD). Moreover, there is some concern that aggressive lowering of blood pressure could potentially compromise cerebral perfusion and actually may be deleterious in patients with established cerebrovascular disease. Studies have provided conflicting results regarding a possible association between hypotension and impaired cognition and incident dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Further studies are needed to define the optimal blood pressure targets in patients who have and who may be at risk for vascular dementia. The Systolic Blood Pressure Intervention Trial (SPRINT) (currently in progress) will compare rates of incident dementia (among other outcomes) among more than 9000 participants randomly assigned to either intensive blood pressure lowering",
"    <span class=\"nowrap\">",
"     (&lt;120/70",
"    </span>",
"    mm Hg) or standard of care",
"    <span class=\"nowrap\">",
"     (&lt;140/90",
"    </span>",
"    mm Hg).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diabetes management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies assessing treatment of diabetes mellitus in relation to cognitive function or dementia are limited. Mixed results from several small trials with methodological problems such as open-label design, subjective cognitive measures, and lack of baseline function suggest the need for larger trials [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/20-24\">",
"     20-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While unproven in the treatment or prevention of vascular dementia, tighter glucose control is generally recommended for the prevention of complications associated with diabetes. A randomized trial comparing two oral antidiabetic agents in 156 older patients with diabetes found that higher postprandial plasma glucose excursions (less tight diabetes control) were associated with greater declines in cognitive performance measures over one year of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/25\">",
"     25",
"    </a>",
"    ]. In another trial, even a one percent higher A1C value was significantly associated with poorer cognitive performance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statin drugs are of interest in the prevention of cerebrovascular disease both because of their lipid lowering effect and also their pleiotropic effects on vascular function, combining to inhibit atherosclerosis. A population-based nested case-control study revealed a substantively lowered risk of dementia among patients treated with statin therapies but did not distinguish between types of dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/27\">",
"     27",
"    </a>",
"    ]. In another nonrandomized cohort, patients on statins did not have a lower risk of VaD compared with patients not on statins [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized controlled clinical trials of cholesterol lowering have not shown a reduction in the incidence of cognitive decline or dementia in patients on statins, but they were probably underpowered to show this effect [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41369?source=see_link&amp;anchor=H16#H16\">",
"     \"Prevention of dementia\", section on 'Statins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Antiplatelet agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;While of established efficacy in secondary stroke prevention, there are no studies that examine the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or other antiplatelet therapy in the prevention or treatment of VaD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Homocysteine lowering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated homocysteine is an independent risk factor for vascular disease and may also be associated with risk of dementia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36202?source=see_link&amp;anchor=H417059#H417059\">",
"     \"Risk factors for dementia\", section on 'Homocysteine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A randomized, controlled clinical trial in 185 patients over 65 years with vascular disease studied cholesterol lowering with folate, vitamin B12, B6, and B2 supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/33\">",
"     33",
"    </a>",
"    ]. After one year, treatment lowered homocysteine levels but was not associated with improved cognition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Healthy lifestyle",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is mounting evidence that certain modifiable health behaviors, (smoking, alcohol use, physical activity, and diet) are associated with cognitive function later in life, underscoring the importance of promoting a healthy lifestyle at all ages [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41369?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention of dementia\", section on 'Diet'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41369?source=see_link&amp;anchor=H10#H10\">",
"     \"Prevention of dementia\", section on 'Lifestyle and activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In observational studies, participation in cognitive leisure activities has been associated with a reduced risk of vascular cognitive impairment and vascular and mixed dementias [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/1,35,36\">",
"     1,35,36",
"    </a>",
"    ]. The relationship between education and dementia risk is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36202?source=see_link&amp;anchor=H16#H16\">",
"     \"Risk factors for dementia\", section on 'Role of education and cognitive reserve'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another prospective study in Europe found that older patients who reported higher levels of physical activity were less likely to develop vascular dementia than those who were inactive, independent of age, education, and other risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/37\">",
"     37",
"    </a>",
"    ]. The impact of physical activity on dementia risk in general is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41369?source=see_link&amp;anchor=H10#H10\">",
"     \"Prevention of dementia\", section on 'Lifestyle and activity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DISEASE MODIFYING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acetylcholinesterase inhibitors and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=see_link\">",
"     memantine",
"    </a>",
"    have been studied in patients with vascular dementia (VaD), although the data are limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Acetylcholinesterase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholinergic dysfunction has been documented in VaD as well as Alzheimer disease (AD) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Three acetylcholinesterase inhibitors approved for use in AD,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"     donepezil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/27/6582?source=see_link\">",
"     galantamine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/26/6567?source=see_link\">",
"     rivastigmine",
"    </a>",
"    , have also been studied in VaD.",
"   </p>",
"   <p>",
"    Review of two trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"     donepezil",
"    </a>",
"    5 mg or 10 mg daily for 24 weeks in 1219 patients with VaD found that treatment significantly improved cognition, clinical assessment, and functional outcomes in the higher dose group [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/40\">",
"     40",
"    </a>",
"    ]. Side effects are low. However, longer studies are recommended before endorsement of donepezil for VaD.",
"   </p>",
"   <p>",
"    A double-blind, randomized controlled trial examined",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/27/6582?source=see_link\">",
"     galantamine",
"    </a>",
"    (24",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    versus placebo in 592 patients with mild to moderate VaD or mixed dementia and found a significant benefit of treatment after six months compared with placebo on measures of cognition, global assessment, and activities of daily living [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/41\">",
"     41",
"    </a>",
"    ]. In another trial of 788 patients, in whom VaD was more stringently defined, 26 weeks of galantamine treatment produced improved cognition and executive function but did not affect activities of daily living [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No randomized, double-blind, controlled trials have been performed using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/26/6567?source=see_link\">",
"     rivastigmine",
"    </a>",
"    in VaD. A post hoc \"on treatment\" analysis of a trial of rivastigmine (6 to 12",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in AD analyzed the subgroup in which Hachinski Ischemic Score (HIS) suggested a contribution of vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/43\">",
"     43",
"    </a>",
"    ]. This subgroup of patients did perform better on cognitive testing after two years of follow-up compared with controls. A small multicenter trial of rivastigmine in subcortical VaD showed a benefit compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of six trials of cholinesterase inhibitors (including an unpublished trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/26/6567?source=see_link\">",
"     rivastigmine",
"    </a>",
"    ) found an overall statistically significant benefit for each drug as measured by the ADAS-COG scale change from baseline, but no consistent benefit using measures of global change outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/45\">",
"     45",
"    </a>",
"    ]. The investigators concluded that the benefits were small and of uncertain clinical significance.",
"   </p>",
"   <p>",
"    While acetylcholinesterase inhibitors are not endorsed in patients with VaD, they are nonetheless often used in part because of the known co-association of AD and VaD and the absence of a biomarker or other criteria that reliably diagnose (or exclude) AD in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/38,46\">",
"     38,46",
"    </a>",
"    ]. There are no data that indicate that one agent is superior to another or that switching from one agent to another is helpful (",
"    <a class=\"graphic graphic_table graphicRef63284 \" href=\"UTD.htm?31/57/32667\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/47\">",
"     47",
"    </a>",
"    ]. In patients who can afford it, an acetylcholinesterase inhibitor is often used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=see_link\">",
"     memantine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     N-Methyl-D-aspartate receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;These agents putatively inhibit excitotoxicity and protect against neurologic injury from a variety of mechanisms.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=see_link\">",
"     Memantine",
"    </a>",
"    is approved for treatment of moderate to severe AD. Two studies have compared memantine 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    with placebo in patients with mild to moderate VaD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. These were of short duration, 28 weeks. Benefit was seen on cognitive scales but not on clinical global impression or activities of daily living [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/45,50\">",
"     45,50",
"    </a>",
"    ]. Memantine was safe and well tolerated.",
"   </p>",
"   <p>",
"    While the demonstrated efficacy is limited, and the duration of the trials was short, many clinicians are using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=see_link\">",
"     memantine",
"    </a>",
"    for patients with VaD because of a lack of other proven therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/45\">",
"     45",
"    </a>",
"    ]. In patients who can afford it, memantine is often used in combination with an acetylcholinesterase inhibitor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium channel blockers are of potential benefit in VaD because of their putative neuroprotective anti-ischemic effects, in addition to blood pressure lowering. A Cochrane review concluded that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/20/16710?source=see_link\">",
"     nimodipine",
"    </a>",
"    (90",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    appeared beneficial in VaD, with benefits on a variety of scales of cognition, but not on scales affecting daily living. Because of this and the relatively short duration of these trials (12 to 24 weeks), they concluded that trials with longer follow-up are needed to support chronic treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since that time, a safety and efficacy multicenter trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/20/16710?source=see_link\">",
"     nimodipine",
"    </a>",
"    with placebo for the treatment of subcortical VaD for 52 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/52\">",
"     52",
"    </a>",
"    ]. There was no benefit in cognitive outcome for the primary outcome measure, but there was a small benefit in 2 of 10 other",
"    <span class=\"nowrap\">",
"     scales/measures",
"    </span>",
"    used, one of which was a post hoc analysis. Blood pressure values did not differ between the two groups. Other agents with mixed but overall negative results in VaD trials include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    and cyclandelate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other agents that may be of some benefit in the prevention of cognitive decline in VaD or VCI include ergot alkaloids (hydergine, nicergoline) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/55-57\">",
"     55-57",
"    </a>",
"    ], ginkgo biloba [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/58\">",
"     58",
"    </a>",
"    ], xanthine derivatives (propentofylline, pentoxifylline, and denbufylline) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/59-61\">",
"     59-61",
"    </a>",
"    ], cytidinediphosphocholine [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/62\">",
"     62",
"    </a>",
"    ], and piracetam [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/63\">",
"     63",
"    </a>",
"    ]. None of these therapies are recommended at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;No studies address the duration of therapy in VaD, and the course of the disease is not predictable. The goal of treatment is primarily to delay cognitive decline. In any given patient, treatment benefit may not be evident to the patient, caregiver, or clinician. Clinical experience cautions halting therapy for apparent lack of efficacy, as anecdotal experience in AD teaches that stopping therapy may be associated with clinical decline that does not always reverse with resumption of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/64\">",
"     64",
"    </a>",
"    ]. In the absence of medication side effects, treatment duration is usually lifelong.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT OF BEHAVIORAL SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other categories of treatment include the treatment of behavioral and emotional problems related to vascular dementia (VaD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link\">",
"     \"Treatment of behavioral symptoms related to dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recovery of lost cognitive function beyond the initial recovery from a stroke is not likely. However, fluctuations in symptoms, with periods of improvement, may occur in some affected individuals. In one clinical trial the presence of hippocampal atrophy on MRI predicted the course of cognitive change; patients in the placebo group experienced overall cognitive decline in the presence of hippocampal atrophy, and cognitive stability when hippocampal atrophy was not present [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/65\">",
"     65",
"    </a>",
"    ]. Patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"     donepezil",
"    </a>",
"    in this study experienced cognitive stability in the presence of hippocampal atrophy and cognitive improvement when hippocampal atrophy was not present.",
"   </p>",
"   <p>",
"    Estimates of mortality vary depending on the diagnostic criteria used. Also, many studies are hospital or clinic based, resulting in referral bias [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/66\">",
"     66",
"    </a>",
"    ]. However, evidence from population-based studies suggests an increased mortality for vascular cognitive impairment (VCI), vascular dementia (VaD) and dementia after stroke:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Canadian Study of Health and Aging, mean survival for those with VCI was 41 months [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/67\">",
"       67",
"      </a>",
"      ]. Progression of cognitive deficits and time to institutionalization were similar in Alzheimer disease (AD) and VaD.",
"     </li>",
"     <li>",
"      A Finnish study with 14 years of follow-up found survival was only 1.7 percent for VaD compared with 2.4 percent for AD. Male sex, level of disability, and the presence of primitive reflexes were important predictors [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 451 consecutive patients with ischemic stroke, poststroke dementia was associated with a reduced survival compared with those who did not develop dementia (five versus nine years) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/3\">",
"       3",
"      </a>",
"      ]. The hazard ratio associated with the risk of death related to poststroke dementia was estimated as 2.3.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, survival has been estimated to be about five years for VaD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/20\">",
"     20",
"    </a>",
"    ] and is similar in patients with vascular cognitive impairment, no dementia (CIND), and dementia after stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10104/abstract/3,69\">",
"     3,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=see_link\">",
"       \"Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While considerable uncertainty continues to surround vascular dementia (VaD), the following summarizes current understanding and offers some pragmatic suggestions for prevention and treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with cognitive impairment and clinical or radiologic evidence of cerebrovascular pathology should be screened and treated for vascular risk factors, especially hypertension, although this has been shown to be helpful in preventing rather than ameliorating dementia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk factor management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evidence that specific treatments with acetylcholinesterase inhibitors",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=see_link\">",
"       memantine",
"      </a>",
"      are helpful in VaD is not conclusive. However, it is reasonable to use them in patients with suspected VaD because of the high prevalence of comorbid Alzheimer disease (AD) and the difficulty of reliably distinguishing between the primary etiologic entities. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Disease modifying therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A typical regimen aimed to slow disease progression in VaD might be",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"       donepezil",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=see_link\">",
"       memantine",
"      </a>",
"      20",
"      <span class=\"nowrap\">",
"       mg/day;",
"      </span>",
"      however, there are no data supporting the use of one acetylcholinesterase inhibitor over another.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/1\">",
"      Dichgans M, Zietemann V. Prevention of vascular cognitive impairment. Stroke 2012; 43:3137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/2\">",
"      Srikanth VK, Quinn SJ, Donnan GA, et al. Long-term cognitive transitions, rates of cognitive change, and predictors of incident dementia in a population-based first-ever stroke cohort. Stroke 2006; 37:2479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/3\">",
"      Melkas S, Oksala NK, Jokinen H, et al. Poststroke dementia predicts poor survival in long-term follow-up: influence of prestroke cognitive decline and previous stroke. J Neurol Neurosurg Psychiatry 2009; 80:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/4\">",
"      Bickel H, Ander KH, Br&ouml;nner M, et al. Reduction of Long-Term Care Dependence After an 8-Year Primary Care Prevention Program for Stroke and Dementia: The INVADE Trial. J Am Heart Assoc 2012; 1:e000786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/5\">",
"      Richard E, Gouw AA, Scheltens P, van Gool WA. Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI: the evaluation of vascular care in Alzheimer's disease (EVA) study. Stroke 2010; 41:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/6\">",
"      Rigaud AS, Seux ML, Staessen JA, et al. Cerebral complications of hypertension. J Hum Hypertens 2000; 14:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/7\">",
"      Birkenh&auml;ger WH, Forette F, Seux ML, et al. Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension. Arch Intern Med 2001; 161:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/8\">",
"      Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/9\">",
"      Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265:3255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/10\">",
"      Prince MJ, Bird AS, Blizard RA, Mann AH. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ 1996; 312:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/11\">",
"      Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/12\">",
"      Saxby BK, Harrington F, Wesnes KA, et al. Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. Neurology 2008; 70:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/13\">",
"      Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008; 7:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/14\">",
"      Anderson C, Teo K, Gao P, et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol 2011; 10:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/15\">",
"      McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev 2009; :CD004034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/16\">",
"      Rose KM, Eigenbrodt ML, Biga RL, et al. Orthostatic hypotension predicts mortality in middle-aged adults: the Atherosclerosis Risk In Communities (ARIC) Study. Circulation 2006; 114:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/17\">",
"      K&auml;h&ouml;nen-V&auml;re M, Brunni-Hakala S, Lindroos M, et al. Left ventricular hypertrophy and blood pressure as predictors of cognitive decline in old age. Aging Clin Exp Res 2004; 16:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/18\">",
"      Qiu C, von Strauss E, Fastbom J, et al. Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch Neurol 2003; 60:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/19\">",
"      Verghese J, Lipton RB, Hall CB, et al. Low blood pressure and the risk of dementia in very old individuals. Neurology 2003; 61:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/20\">",
"      H&eacute;bert R, Brayne C. Epidemiology of vascular dementia. Neuroepidemiology 1995; 14:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/21\">",
"      Ott A, Stolk RP, Hofman A, et al. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 1996; 39:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/22\">",
"      Rockwood K, Ebly E, Hachinski V, Hogan D. Presence and treatment of vascular risk factors in patients with vascular cognitive impairment. Arch Neurol 1997; 54:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/23\">",
"      MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 2002; 14:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/24\">",
"      Areosa SA, Grimley EV. Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev 2002; :CD003804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/25\">",
"      Abbatecola AM, Rizzo MR, Barbieri M, et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 2006; 67:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/26\">",
"      Cukierman-Yaffe T, Gerstein HC, Williamson JD, et al. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care 2009; 32:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/27\">",
"      Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000; 356:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/28\">",
"      Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 2004; 61:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/29\">",
"      Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/30\">",
"      Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/31\">",
"      Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/32\">",
"      Williams PS, Rands G, Orrel M, Spector A. Aspirin for vascular dementia. Cochrane Database Syst Rev 2000; :CD001296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/33\">",
"      Stott DJ, MacIntosh G, Lowe GD, et al. Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease. Am J Clin Nutr 2005; 82:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/34\">",
"      Sabia S, Nabi H, Kivimaki M, et al. Health behaviors from early to late midlife as predictors of cognitive function: The Whitehall II study. Am J Epidemiol 2009; 170:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/35\">",
"      Verghese J, Katz MJ, Sanders A, et al. Leisure activities and risk of vascular cognitive impairment in older adults. J Geriatr Psychiatry Neurol 2009; 22:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/36\">",
"      Coyle JT. Use it or lose it--do effortful mental activities protect against dementia? N Engl J Med 2003; 348:2489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/37\">",
"      Verdelho A, Madureira S, Ferro JM, et al. Physical activity prevents progression for cognitive impairment and vascular dementia: results from the LADIS (Leukoaraiosis and Disability) study. Stroke 2012; 43:3331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/38\">",
"      Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 1999; 13 Suppl 3:S115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/39\">",
"      B&auml;r KJ, Boettger MK, Seidler N, et al. Influence of galantamine on vasomotor reactivity in Alzheimer's disease and vascular dementia due to cerebral microangiopathy. Stroke 2007; 38:3186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/40\">",
"      Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev 2004; :CD004395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/41\">",
"      Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/42\">",
"      Auchus AP, Brashear HR, Salloway S, et al. Galantamine treatment of vascular dementia: a randomized trial. Neurology 2007; 69:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/43\">",
"      Craig D, Birks J. Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev 2005; :CD004744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/44\">",
"      Moretti R, Torre P, Antonello RM, et al. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am J Alzheimers Dis Other Demen 2003; 18:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/45\">",
"      Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007; 6:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/46\">",
"      Bonelli RM. Editorial comment--How to treat vascular dementia? Stroke 2003; 34:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/47\">",
"      Kester MI, Scheltens P. Dementia: the bare essentials. Pract Neurol 2009; 9:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/48\">",
"      Orgogozo JM, Rigaud AS, St&ouml;ffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/49\">",
"      Wilcock G, M&ouml;bius HJ, St&ouml;ffler A, MMM 500 group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002; 17:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/50\">",
"      McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; :CD003154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/51\">",
"      L&oacute;pez-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev 2002; :CD000147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/52\">",
"      Pantoni L, del Ser T, Soglian AG, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke 2005; 36:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/53\">",
"      [An experimental, randomized, double-blind, placebo-controlled clinical trial to infestigate the effect of nicardipine on cognitive function in patients with vascular dementia. Spanish group of nicardipine study in vascular dementia]. Rev Neurol 1999; 28:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/54\">",
"      Weyer G, Eul A, Milde K, et al. Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study. Pharmacopsychiatry 2000; 33:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/55\">",
"      Olin J, Schneider L, Novit A, Luczak S. Hydergine for dementia. Cochrane Database Syst Rev 2001; :CD000359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/56\">",
"      B&egrave;s A, Orgogozo JM, Poncet M, et al. A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. Eur J Neurol 1999; 6:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/57\">",
"      Herrmann WM, Stephan K, Gaede K, Apeceche M. A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia. Dement Geriatr Cogn Disord 1997; 8:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/58\">",
"      Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2002; :CD003120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/59\">",
"      Frampton M, Harvey RJ, Kirchner V. Propentofylline for dementia. Cochrane Database Syst Rev 2003; :CD002853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/60\">",
"      European Pentoxifylline Multi-Infarct Dementia Study. Eur Neurol 1996; 36:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/61\">",
"      Treves TA, Korczyn AD. Denbufylline in dementia: a double-blind controlled study. Dement Geriatr Cogn Disord 1999; 10:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/62\">",
"      Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev 2005; :CD000269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/63\">",
"      Flicker L, Grimley Evans G. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev 2001; :CD001011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/64\">",
"      Rainer M, Mucke HA, Kr&uuml;ger-Rainer C, et al. Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics. J Neural Transm 2001; 108:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/65\">",
"      Rom&aacute;n GC, Salloway S, Black SE, et al. Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. Stroke 2010; 41:1213.",
"     </a>",
"    </li>",
"    <li>",
"     Chui, H, Mack, W, Varpetian, A, Mungas, D. Evidence-based prognosis of vascular dementia: Survival and rate of cognitive decline. In: Vascular cognitive impairment, Hachinski, V (Ed), Oxford University Press, Oxford 2003. p.33.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/67\">",
"      Rockwood K, Wentzel C, Hachinski V, et al. Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Neurology 2000; 54:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/68\">",
"      M&ouml;ls&auml; PK, Marttila RJ, Rinne UK. Long-term survival and predictors of mortality in Alzheimer's disease and multi-infarct dementia. Acta Neurol Scand 1995; 91:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10104/abstract/69\">",
"      Wentzel C, Rockwood K, MacKnight C, et al. Progression of impairment in patients with vascular cognitive impairment without dementia. Neurology 2001; 57:714.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5086 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-09F22AFDA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_55_10104=[""].join("\n");
var outline_f9_55_10104=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTOR MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Antihypertensive drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diabetes management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Homocysteine lowering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Healthy lifestyle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DISEASE MODIFYING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Acetylcholinesterase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      N-Methyl-D-aspartate receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT OF BEHAVIORAL SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5086\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5086|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/57/32667\" title=\"table 1\">",
"      Cholinesterase inhibitors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37786?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of vascular dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41369?source=related_link\">",
"      Prevention of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36202?source=related_link\">",
"      Risk factors for dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=related_link\">",
"      Treatment of behavioral symptoms related to dementia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_55_10105="Medical therapy in hypertrophic cardiomyopathy";
var content_f9_55_10105=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical therapy in hypertrophic cardiomyopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/55/10105/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/55/10105/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/55/10105/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/55/10105/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/55/10105/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/55/10105/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/55/10105/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic cardiomyopathy (HCM) is a genetically determined heart muscle disease most often (60 to 70 percent) caused by mutations in one of several sarcomere genes which encode components of the contractile apparatus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link\">",
"     \"Genetics of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HCM is characterized by left ventricular hypertrophy of various morphologies, with a wide array clinical manifestations and hemodynamic abnormalities (",
"    <a class=\"graphic graphic_figure graphicRef58156 \" href=\"UTD.htm?11/9/11411\">",
"     figure 1",
"    </a>",
"    ). Depending in part upon the site and extent of cardiac hypertrophy, HCM patients can develop one or more of the following abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      LV outflow obstruction (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=see_link\">",
"       \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diastolic dysfunction",
"     </li>",
"     <li>",
"      Myocardial ischemia",
"     </li>",
"     <li>",
"      Mitral regurgitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These structural and functional abnormalities can produce a variety of symptoms, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Dyspnea",
"     </li>",
"     <li>",
"      Chest pain",
"     </li>",
"     <li>",
"      Palpitations",
"     </li>",
"     <li>",
"      Presyncope or syncope",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In broad terms, the symptoms related to HCM can be categorized as those related to heart failure (HF), chest pain, or arrhythmias. Patients with HCM have an increased incidence of both supraventricular and ventricular arrhythmias and are at an increased risk for sudden cardiac death (SCD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=see_link\">",
"     \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the majority of patients with HCM, LVH is not progressive, and the clinical course is relatively benign. A small subset of patients, however, will progress to an advanced form of the disease that is characterized by relative LV dilation and wall thinning and systolic dysfunction. Such patients are managed according to the standard approach to patients with HF due to systolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pharmacologic treatment of patients with HCM will be reviewed here. Other issues such as the clinical manifestations, natural history, management of arrhythmias, and nonpharmacologic treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link\">",
"     \"Natural history of hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=see_link\">",
"     \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=see_link\">",
"     \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no large randomized trials of pharmacologic therapies in HCM. As a result, treatment strategies are based upon observational data and clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/1\">",
"     1",
"    </a>",
"    ]. An empiric approach is usually required, since it is not possible to predict which drug will work best for a given patient (",
"    <a class=\"graphic graphic_algorithm graphicRef86793 \" href=\"UTD.htm?29/22/30048\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Because the impact of pharmacologic therapy on the natural history of HCM in asymptomatic patients is not known, routine prophylactic drug therapy is not recommended prior to the onset of symptoms. However, some experts suggest the use of beta blockers in patients with certain high-risk features (eg, severe hypertrophy or LV outflow obstruction) even if they are asymptomatic. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Asymptomatic patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms, including HF and chest pain, are probably due to the combination of diastolic dysfunction, LV outflow obstruction, and microvascular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/2\">",
"     2",
"    </a>",
"    ]. A detailed discussion of the pathophysiology of HCM is presented separately, but will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=see_link\">",
"     \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The two most important factors causing LV outflow obstruction are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inward movement and bulging of the hypertrophied interventricular septum during systole, which partially obstructs the outflow tract.",
"     </li>",
"     <li>",
"      Anterior displacement of the mitral valve during systole, which is referred to as systolic anterior motion (SAM). SAM is caused by high LV outflow tract blood velocities which pull the mitral valve leaflet toward the interventricular septum. SAM can also contribute to mitral regurgitation; thus, therapies that relieve SAM and outflow obstruction can also reduce mitral regurgitation (MR).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although outflow obstruction is the most prominently discussed feature of HCM, many symptomatic patients have little or no obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. As a result, symptoms are due to other factors, including diastolic dysfunction, MR, and microvascular dysfunction. Among these abnormalities, diastolic dysfunction appears to be the most important [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Negative inotropic agents, including beta blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    are the most widely used initial therapies. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Heart failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Possible mechanisms of benefit of these drugs include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta blockers and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      slow the heart rate and prolong diastole, allowing increased ventricular filling [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      All three agents are negative inotropes, which reduce outflow obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Beta blockers may reduce anginal symptoms by decreasing myocardial oxygen demand [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       Verapamil",
"      </a>",
"      may reduce anginal symptoms by improving microvascular function and, therefore, myocardial perfusion [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/9-11\">",
"       9-11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are little controlled data on the efficacy of any of these therapies. Either a beta blocker or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    is usually tried first, with the drug initiated at a low dose that is titrated until symptoms are relieved or side effects occur. If the first drug does not provide benefit, it is reasonable to switch to the other. Many experts favor beta blockers over verapamil in patients with evidence of outflow obstruction, due to the risks associated with the vasodilatory effects of verapamil [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/2,3,5,12\">",
"     2,3,5,12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Medications to be avoided or used with caution'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If neither",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    nor beta blockers provides relief,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    in combination with a beta blocker can be tried [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/12\">",
"     12",
"    </a>",
"    ]. If doses of 400 to 600 mg daily are tolerated, &gt;50 percent gradient reduction and symptomatic improvement can be anticipated. The anticholinergic side effects are dose-related and often limit use. Disopyramide is often better tolerated in children, adolescents, and young adults. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Disopyramide'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Persistent symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients have persistent HF symptoms despite maximal therapy with negative inotropes. The options in such patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cautious use of diuretics &ndash; Diuretics are relatively contraindicated due to the potential reduction in preload, which may exacerbate obstruction and cause hypotension. However, in patients with refractory HF symptoms who appear to be volume overloaded, diuretics may be used cautiously and are often effective in low-dose transiently or on an as-needed basis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Combination therapy &ndash; The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      and a beta blocker may be helpful in some patients. Patients treated with both verapamil and a beta blocker should be observed for bradyarrhythmias. As an alternative,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"       disopyramide",
"      </a>",
"      may be added to either a beta blocker or verapamil. There are little available data regarding the efficacy of such an approach, but it may be valuable in some patients prior to the consideration of more invasive therapies [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nonpharmacologic therapies &ndash; Nonpharmacologic therapies include surgical myectomy and alcohol septal ablation. These therapies are only appropriate for patients with both symptoms and severe resting or provocable outflow tract obstruction (eg, LV outflow tract gradient &ge;50 mmHg). Exercise echo may be required to unmask important",
"      <span class=\"nowrap\">",
"       exertion/stress-related",
"      </span>",
"      obstruction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mitral regurgitation, which should be considered in patients with refractory symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=see_link\">",
"       \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Rate and rhythm control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with symptomatic HCM can be intolerant of tachyarrhythmias. Both rapid heart rates and the loss of \"atrial kick\" impair left ventricular filling, which has an even greater clinical impact in patients with diastolic dysfunction. Thus, aggressive rate control and, if necessary, rhythm control is particularly important in these patients. The management of arrhythmias in HCM, including the role of anticoagulation, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=see_link\">",
"     \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Medications to be avoided or used with caution",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with significant LV outflow obstruction, hemodynamics can be compromised by the following medications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vasodilators &ndash; Vasodilators, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      , angiotensin converting enzyme inhibitors, and angiotensin II receptor blockers, can produce a fall in peripheral resistance, with an increase in outflow obstruction and filling pressures, thereby resulting in hypotension",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      worsening heart failure symptoms.",
"     </li>",
"     <li>",
"      Diuretics &ndash; By reducing preload, diuretics can result in less LV filling, a smaller LV chamber, and therefore greater outflow obstruction. However, as noted above, cautious use of diuretics may be attempted in patients with persistent heart failure and volume overload.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      &ndash; Early reports suggested adverse hemodynamic consequences because of the potential positive inotropic effect of digitalis glycosides [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Competitive and recreational athletics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HCM are at risk for a variety of complications related to exertion, the most concerning being sustained ventricular arrhythmias and sudden cardiac death. A detailed discussion of activity limitations in patients with HCM and other cardiac disorders is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link&amp;anchor=H13#H13\">",
"     \"Risk of sudden cardiac death in athletes\", section on 'Hypertrophic cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Endocarditis prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HCM and either a resting or provocable outflow gradient are considered to be at increased risk for developing endocarditis. Revisions to guidelines for endocarditis prophylaxis, however, state that patients with HCM are among those who are no longer considered to require routine prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link&amp;anchor=H10#H10\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\", section on 'No longer indicated'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22696?source=see_link\">",
"     \"Overview of hypertrophic cardiomyopathy management including treatment of special problems\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Family screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic cardiomyopathy is an autosomal dominant disorder, and most forms have a high degree of penetrance. As a result, first-degree family members of an affected individual should be evaluated for possible inheritance of the disease. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link&amp;anchor=H31#H31\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'Screening of first-degree relatives'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HEART FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of heart failure are among the most common clinical manifestations of HCM. Most HCM patients have normal systolic function, and HF is due to one or more of the following; diastolic dysfunction, outflow obstruction, and MR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers were among the first drugs used for the treatment of symptomatic HCM and a number of predominantly uncontrolled studies have noted beneficial effects [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/7,8,15-18\">",
"     7,8,15-18",
"    </a>",
"    ]. In patients with advanced heart failure and LVOT obstruction, society guidelines have advocated for the use of beta blockers as first-line therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/12,19\">",
"     12,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential benefits of beta blockers were first described in hemodynamic and observational studies in the 1960s [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Since then, little clinical data have been reported. One small randomized, crossover trial compared the beta blocker",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and placebo in 18 patients with mild or moderately symptomatic HCM [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/18\">",
"     18",
"    </a>",
"    ]. After four weeks of treatment, neither drug improved measured exercise capacity compared to placebo. However, 13 patients reported fewer symptoms with drug treatment (8 with verapamil and 5 with nadolol). Because the patients were only mildly or moderately symptomatic at baseline, the lack of improvement in exercise capacity cannot be extrapolated to patients with more severe disease.",
"   </p>",
"   <p>",
"    Beta blockers may play an important role in the treatment of LVOT obstruction induced by exercise. In a cohort study of 27 patients without resting LVOT obstruction but an exercise-provoked LVOT gradient of 30 mmHg or greater, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    for one year resulted in significantly lower post-exercise LVOT gradients (36 mmHg versus 87 mmHg at baseline) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/20\">",
"     20",
"    </a>",
"    ]. While the findings of a reduction in LVOT obstruction are encouraging, additional studies are needed to confirm these results and investigate whether this reduction in provocable LVOT obstruction results in improved outcomes.",
"   </p>",
"   <p>",
"    In the absence of large randomized trials, the use of beta blockers is based upon an understanding of the pathophysiology of HCM, the characteristics of these drugs, and extensive clinical experience. Potential mechanisms of benefit include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced heart rates at rest and exercise, permitting improved LV filling, which reduces outflow obstruction.",
"     </li>",
"     <li>",
"      Negative inotropy, which can also alleviate outflow obstruction.",
"     </li>",
"     <li>",
"      Reduced myocardial oxygen consumption, which may improve chest pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, beta blockers do not have the potential risks associated with vasodilators, which may be harmful in patients with significant outflow obstruction. Thus, many experts prefer beta blockers over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    in HCM patients with obstruction. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Medications to be avoided or used with caution'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Treatment of symptomatic HCM patients is usually initiated at a low dose (eg, 25 to 50 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    or an equivalent drug per day), which is then titrated to achieve symptom control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Verapamil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nondihydropyridine calcium channel blockers, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , are also used for the treatment of symptomatic HCM. As with beta blockers, most of the data supporting their use come from uncontrolled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/9,21,22\">",
"     9,21,22",
"    </a>",
"    ]. The potential mechanisms of benefit are similar to beta blockers, with some differences:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced heart rates at rest and exercise, permitting improved LV filling, which reduces outflow obstruction.",
"     </li>",
"     <li>",
"      Negative inotropy, which can also alleviate outflow obstruction.",
"     </li>",
"     <li>",
"      Improved cardiac microvascular function, which may alleviate chest pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to beta blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    has more significant vasodilatory properties, which may cause hypotension in HCM patients with outflow obstruction. For this reason, many experts reserve the use of verapamil to symptomatic patients without significant obstruction. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Medications to be avoided or used with caution'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The potential benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 15 HCM patients with severe symptoms despite beta blockade, intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      reduced the resting LV outflow tract gradient in six (40 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/21\">",
"       21",
"      </a>",
"      ]. Chronic oral verapamil was given to 11 of these patients for six months, nine of whom experienced an improvement in symptoms. Despite symptomatic improvement, only five had a reduction in the LV outflow gradient, supporting the possible significance of additional pathophysiologic mechanisms, such as diastolic dysfunction or ischemia.",
"     </li>",
"     <li>",
"      Among 55 patients treated with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      (360 to 640",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for one to four weeks, 35 (64 percent) reported an improvement in symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/9\">",
"       9",
"      </a>",
"      ]. Symptomatic improvement correlated with improvements in diastolic filling. This benefit persisted for one to two years and was reversed when therapy was discontinued.",
"     </li>",
"     <li>",
"      In a series of 227 patients, 59 percent remained on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      at two years because their perceived quality of life was improved compared to their previous therapy (usually a beta blocker) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    is tolerated well in most patients. However, it may be associated with a variety of side effects including sinus arrest and atrioventricular block, pulmonary edema in patients with markedly elevated pulmonary venous pressures, and perhaps a few cases of SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experience with other calcium channel blockers in obstructive HCM is limited.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     Diltiazem",
"    </a>",
"    may improve LV diastolic function, although the benefit may be less than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/22,24\">",
"     22,24",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     Nifedipine",
"    </a>",
"    should be",
"    <strong>",
"     avoided",
"    </strong>",
"    in patients with resting or provocable LV outflow obstruction because of its potent peripheral vasodilator properties. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Medications to be avoided or used with caution'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Disopyramide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     Disopyramide",
"    </a>",
"    , an antiarrhythmic drug with negative inotropic properties, has been used to treat symptomatic obstructive HCM [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. The potential efficacy of disopyramide was illustrated in randomized, double-blind crossover study of ten patients with obstructive HCM that compared the effects of disopyramide (150 mg four times daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    (40 mg four times daily), and placebo, each given for a period of four days [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/26\">",
"     26",
"    </a>",
"    ]. The subaortic pressure gradient was decreased from 61 mmHg with placebo to 5 mmHg with disopyramide and 30 mmHg with propranolol. Disopyramide also increased the exercise duration, while propranolol produced no significant change.",
"   </p>",
"   <p>",
"    A larger multicenter report evaluated the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    (mean dose 432",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in 118 patients with obstructive HCM (mean age 47 years); almost all were also treated with a beta blocker and the mortality results were compared to 373 patients with obstructive HCM not treated with disopyramide [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/27\">",
"     27",
"    </a>",
"    ]. The following findings were noted at a mean of 3.1 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seventy-eight patients (66 percent) were maintained on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"       disopyramide",
"      </a>",
"      without the need for major nonpharmacologic interventions (surgical myectomy, alcohol ablation, or pacing). The mean outflow gradient at rest fell from 75 to 40 mmHg and New York Heart Association functional class significantly improved from 2.3 to 1.7 (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The remaining 40 patients required invasive intervention because they could not be adequately managed with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"       disopyramide",
"      </a>",
"      due to inadequate gradient and symptom control in most patients and to vagolytic side effects in eight.",
"     </li>",
"     <li>",
"      When the patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"       disopyramide",
"      </a>",
"      were compared to those not treated with this agent, there was a trend toward lower rates of mortality (1.4 versus 2.6 percent per year) and sudden death (1.0 versus 1.8 percent per year) even though they had a significantly higher outflow gradient at baseline (74 versus 62 mmHg).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations seem to allay concerns about proarrhythmia in patients with HCM, although patients receiving diuretics or other antiarrhythmics may be at risk [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/28\">",
"     28",
"    </a>",
"    ]. No patient required cessation of therapy for QT interval prolongation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it appears to be a more potent negative inotrope than either beta blockers of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , there are important limitations to the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    , which preclude its use as a first-line treatment in symptomatic HCM patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"       Disopyramide",
"      </a>",
"      can accelerate AV nodal conduction, resulting in an increased ventricular rate if atrial fibrillation or flutter develops. Thus, patients treated with disopyramide should also be treated with a beta blocker [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"       disopyramide",
"      </a>",
"      may subside over time [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Like other class IA antiarrhythmic drugs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"       disopyramide",
"      </a>",
"      can prolong the QT interval, possibly leading to torsades de pointes. Patients treated with disopyramide should have a baseline 12 lead ECG and periodic ECGs during follow-up (eg, every 6 to 12 months). Disopyramide should not be used if the baseline QTc is prolonged and it should be discontinued if the QTc prolongs by 25 percent or more. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37018?source=see_link\">",
"       \"Major side effects of class I antiarrhythmic drugs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"       Disopyramide",
"      </a>",
"      should not be given to patients concurrently treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      , or other class I antiarrhythmic drugs because of concern about proarrhythmia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/12,27\">",
"       12,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"       Disopyramide",
"      </a>",
"      can have significant anticholinergic side effects, and should not be given to patients with symptoms of prostatic hypertrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/12,27\">",
"       12,27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    may be limited to patients with outflow obstruction at rest. Patients who have evidence of obstruction only during exercise or provocative maneuvers (eg Valsalva) appear to benefit from beta blockers, but not disopyramide [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/14,29\">",
"     14,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative class IA agent, cibenzoline, is devoid of anticholinergic side effects and has reported to be effective in HCM [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/30\">",
"     30",
"    </a>",
"    ]. This drug is not available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8794539\">",
"    <span class=\"h2\">",
"     Investigational therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac energy deficiency may contribute to exercise limitation in HCM [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Preliminary evidence of a beneficial effect of metabolic modulation was provided in a trial in which 46 patients with HCM were randomly assigned to perhexiline 100 mg or placebo and followed for a mean of 4.6 months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/34\">",
"     34",
"    </a>",
"    ]. Perhexiline is postulated to improve cardiac energetics by shifting substrate use to more efficient carbohydrate metabolism. Treatment with perhexiline improved myocardial energetics (myocardial ratios of phosphocreatine to adenosine triphosphate measured by",
"    <sup>",
"     31",
"    </sup>",
"    P magnetic resonance spectroscopy) and normalized impairment in dynamic myocardial relaxation in response to exercise. Perhexiline also improved exercise capacity (peak VO",
"    <sub>",
"     2",
"    </sub>",
"    ) and New York Heart Association functional class.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OTHER CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manifestations of HF are the most common indication for pharmacologic therapy in patients with HCM. However, there are several other circumstances that should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Chest pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest discomfort is a common symptom, which can be due to several causes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chest fullness and pressure is often associated with HF and increased filling pressures.",
"     </li>",
"     <li>",
"      Angina may be due to increased myocardial oxygen demand or impaired microvascular function.",
"     </li>",
"     <li>",
"      Patients may have coincident coronary artery disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most patients, the pharmacologic management of chest discomfort is similar to that of HF, as described above. Beta blockers and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    are the first-line agents. In patients without outflow tract obstruction in whom chest discomfort is the most prominent symptom, some experts prefer verapamil. Isolated refractory chest pain is uncommon, but may be troublesome and requires aggressive use of high dose verapamil or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and occasionally nitrates.",
"   </p>",
"   <p>",
"    For patients with significant obstruction and persistent chest pain despite medical therapy, nonpharmacologic therapies may be beneficial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=see_link\">",
"     \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with angina or coronary disease risk factors, coronary artery disease should be excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of symptoms may be associated with supraventricular and ventricular arrhythmias, including palpitation, lightheadedness, syncope, and exacerbations of HF and chest pain. The management of arrhythmias in patients with HCM is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=see_link\">",
"     \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     End-stage disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 5 percent of patients with HCM will progress to an end-stage phase of the disease that is characterized by LV dilation and thinning and systolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link&amp;anchor=H5#H5\">",
"     \"Natural history of hypertrophic cardiomyopathy\", section on 'End-stage HCM'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence regarding the optimal approach to such patients is limited, but most experts recommend treating these patients according to the standard approach to patients with HF due to systolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/12,36\">",
"     12,36",
"    </a>",
"    ]. In addition, many of these patients become candidates for heart transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/5,12,36,37\">",
"     5,12,36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ASYMPTOMATIC PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of pharmacologic therapy in HCM have largely been limited to symptomatic patients. In these populations, such treatment has not altered the natural history of HCM. As a result, routine pharmacologic therapy is not recommended in asymptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, some asymptomatic patients have clinical or morphologic features that put them at an increased risk for the future development of HF or SCD (eg, massive hypertrophy with LV wall thickness &ge;35 mm, or severe LV outflow obstruction, with a gradient &ge;75 mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. Some experts recommend treating such patients with beta blockers, even if they are not symptomatic. Furthermore, some asymptomatic patients will be candidates for an implantable cardioverter-defibrillator (ICD). The issue of ICD use for the prevention of SCD is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=see_link\">",
"       \"Patient information: Hypertrophic cardiomyopathy in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=see_link\">",
"       \"Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations apply to the pharmacologic management of patients with HCM. They are in broad agreement with a 2011 consensus statement from the American College of Cardiology and the American Heart Association (",
"    <a class=\"graphic graphic_algorithm graphicRef86793 \" href=\"UTD.htm?29/22/30048\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10105/abstract/12\">",
"     12",
"    </a>",
"    ]. Pharmacologic therapy is primarily intended to alleviate the symptoms associated with HCM, since no drug has been shown to alter the natural history of the disease in either symptomatic or asymptomatic patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     HCM with preserved systolic function",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 90 percent of HCM patients have normal indices of radial systolic function. In these patients, symptoms are due to one or more of the following; diastolic dysfunction, outflow obstruction, MR, ischemia, and arrhythmias.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In HCM patients with preserved systolic function and symptoms of HF, we suggest initiating therapy with a negative inotropic agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Heart failure'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Selection of a drug and dose is empiric. Patients who do not respond to one drug may be tried on another. Available data do not support choosing one agent over the other, but we suggest the following approach:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Initial therapy with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      or a beta blocker, with dosing titrated to symptom relief. If the first drug does not relieve symptoms, it is reasonable to switch to the other. Due to the potential risks associated with the vasodilatory properties of verapamil, beta blockers are preferred in patients with resting or provocable LV outflow tract obstruction. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Medications to be avoided or used with caution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with resting or provocable obstruction, if symptoms are not relieved with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      or a beta blocker,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"       disopyramide",
"      </a>",
"      in combination with a beta blocker may be tried. Because disopyramide can accelerate AV conduction, leading to a rapid ventricular response if an atrial arrhythmia develops, a non-selective beta blocker should be given to all HCM patients treated with disopyramide. In patients with refractory symptoms and hyperdynamic systolic function in the absence of obstruction, the addition of disopyramide may also be helpful. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Disopyramide'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In HCM patients with persistent symptoms of HF after trials of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      , beta blocker, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"       disopyramide",
"      </a>",
"      , we suggest the cautious addition of a diuretic (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In HCM patients with significant LV outflow obstruction who have persistent HF symptoms despite pharmacologic therapy, nonpharmacologic interventions are often necessary (eg, surgical myectomy or alcohol septal ablation). These issues are discussed in detail separately. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Persistent symptoms'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=see_link\">",
"       \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The management of HCM patients with supraventricular and ventricular arrhythmias is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=see_link\">",
"     \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Patients with systolic dysfunction and end-stage HCM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5 percent of HCM patients will progress to an end-stage phase of the disease, characterized by LV dilation, wall thinning, and systolic dysfunction. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'End-stage disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with end-stage HCM, characterized by LV dilation and systolic dysfunction, we recommend standard medical therapy for HF due to systolic dysfunction (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). These patients may also be candidates for cardiac transplantation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"       \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with HCM remain free of symptoms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In asymptomatic HCM patients, we suggest that routine pharmacologic therapy",
"      <strong>",
"       not",
"      </strong>",
"      be given (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Beta blockers, however, should be considered in selected cases, such as young patients with severe left ventricular hypertrophy or obstruction and in those at risk of developing supraventricular arrhythmia. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Asymptomatic patients'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link&amp;anchor=H13#H13\">",
"       \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\", section on 'High-risk clinical features'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/1\">",
"      Fifer MA, Vlahakes GJ. Management of symptoms in hypertrophic cardiomyopathy. Circulation 2008; 117:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/2\">",
"      Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/3\">",
"      Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 1995; 92:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/4\">",
"      Briguori C, Betocchi S, Romano M, et al. Exercise capacity in hypertrophic cardiomyopathy depends on left ventricular diastolic function. Am J Cardiol 1999; 84:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/5\">",
"      Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/6\">",
"      Sherrid MV, Pearle G, Gunsburg DZ. Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. Circulation 1998; 97:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/7\">",
"      HARRISON DC, BRAUNWALD E, GLICK G, et al. EFFECTS OF BETA ADRENERGIC BLOCKADE ON THE CIRCULATION WITH PARTICULAR REFERENCE TO OBSERVATIONS IN PATIENTS WITH HYPERTROPHIC SUBAORTIC STENOSIS. Circulation 1964; 29:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/8\">",
"      Cohen LS, Braunwald E. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation 1967; 35:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/9\">",
"      Bonow RO, Dilsizian V, Rosing DR, et al. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation 1985; 72:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/10\">",
"      Udelson JE, Bonow RO, O'Gara PT, et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1989; 79:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/11\">",
"      Gistri R, Cecchi F, Choudhury L, et al. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy. Am J Cardiol 1994; 74:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/12\">",
"      Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/13\">",
"      Maron BJ, Bonow RO, Cannon RO 3rd, et al. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med 1987; 316:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/14\">",
"      BRAUNWALD E, LAMBREW CT, ROCKOFF SD, et al. IDIOPATHIC HYPERTROPHIC SUBAORTIC STENOSIS. I. A DESCRIPTION OF THE DISEASE BASED UPON AN ANALYSIS OF 64 PATIENTS. Circulation 1964; 30:SUPPL 4:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/15\">",
"      Fananapazir L, Chang AC, Epstein SE, McAreavey D. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation 1992; 86:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/16\">",
"      Stenson RE, Flamm MD Jr, Harrison DC, Hancock EW. Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy. Am J Cardiol 1973; 31:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/17\">",
"      Thompson DS, Naqvi N, Juul SM, et al. Effects of propranolol on myocardial oxygen consumption, substrate extraction, and haemodynamics in hypertrophic obstructive cardiomyopathy. Br Heart J 1980; 44:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/18\">",
"      Gilligan DM, Chan WL, Joshi J, et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol 1993; 21:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/19\">",
"      Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003; 42:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/20\">",
"      Nistri S, Olivotto I, Maron MS, et al. &beta; Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Am J Cardiol 2012; 110:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/21\">",
"      Anderson DM, Raff GL, Ports TA, et al. Hypertrophic obstructive cardiomyopathy. Effects of acute and chronic verapamil treatment on left ventricular systolic and diastolic function. Br Heart J 1984; 51:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/22\">",
"      Rosing DR, Id&auml;np&auml;&auml;n-Heikkil&auml; U, Maron BJ, et al. Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy. Am J Cardiol 1985; 55:185B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/23\">",
"      Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation 1981; 64:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/24\">",
"      Nagao M, Omote S, Takizawa A, Yasue H. Effect of diltiazem on left ventricular isovolumic relaxation time in patients with hypertrophic cardiomyopathy. Jpn Circ J 1983; 47:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/25\">",
"      Pollick C. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl J Med 1982; 307:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/26\">",
"      Pollick C. Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration. Am J Cardiol 1988; 62:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/27\">",
"      Sherrid MV, Barac I, McKenna WJ, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 45:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/28\">",
"      Miyajima S, Aizawa Y, Matsuoka A, et al. Danger of use of disopyramide in patients with hypertrophic obstructive cardiomyopathy. An electrophysiologic study. Jpn Heart J 1988; 29:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/29\">",
"      Millaire A, Goullard L, Decoulx E, et al. Efficiency of disopyramide in hypertrophic cardiomyopathy during stress states. Am J Cardiol 1992; 69:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/30\">",
"      Hamada M, Shigematsu Y, Ikeda S, et al. Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1997; 96:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/31\">",
"      Jung WI, Sieverding L, Breuer J, et al. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1998; 97:2536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/32\">",
"      Crilley JG, Boehm EA, Blair E, et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 2003; 41:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/33\">",
"      Lele SS, Thomson HL, Seo H, et al. Exercise capacity in hypertrophic cardiomyopathy. Role of stroke volume limitation, heart rate, and diastolic filling characteristics. Circulation 1995; 92:2886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/34\">",
"      Abozguia K, Elliott P, McKenna W, et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 2010; 122:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/35\">",
"      Sorajja P, Ommen SR, Nishimura RA, et al. Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. Circulation 2003; 108:2342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/36\">",
"      Spirito P, Autore C. Management of hypertrophic cardiomyopathy. BMJ 2006; 332:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10105/abstract/37\">",
"      Shirani J, Maron BJ, Cannon RO 3rd, et al. Clinicopathologic features of hypertrophic cardiomyopathy managed by cardiac transplantation. Am J Cardiol 1993; 72:434.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4950 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.208-7855FF150B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_55_10105=[""].join("\n");
var outline_f9_55_10105=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Persistent symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Rate and rhythm control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Medications to be avoided or used with caution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Competitive and recreational athletics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Endocarditis prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Family screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HEART FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Verapamil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Disopyramide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8794539\">",
"      Investigational therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OTHER CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      End-stage disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ASYMPTOMATIC PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      HCM with preserved systolic function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Patients with systolic dysfunction and end-stage HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4950\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4950|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?29/22/30048\" title=\"algorithm 1\">",
"      HCM treatment algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4950|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/9/11411\" title=\"figure 1\">",
"      Morphologic variants HCM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4950|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=related_link\">",
"      Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=related_link\">",
"      Genetics of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37018?source=related_link\">",
"      Major side effects of class I antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=related_link\">",
"      Natural history of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=related_link\">",
"      Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22696?source=related_link\">",
"      Overview of hypertrophic cardiomyopathy management including treatment of special problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=related_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=related_link\">",
"      Types and pathophysiology of obstructive hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_55_10106="Total hip arthroplasty";
var content_f9_55_10106=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Total hip arthroplasty",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/55/10106/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/55/10106/contributors\">",
"     Greg A Erens, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/55/10106/contributors\">",
"     Thomas S Thornhill, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/55/10106/contributors\">",
"     Jeffrey N Katz, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/55/10106/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/55/10106/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/55/10106/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/55/10106/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/55/10106/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total hip arthroplasty (THA) is one of the most successful orthopedic procedures performed today. For patients with hip pain due to a variety of conditions, THA can relieve pain, can restore function, and can improve quality of life. Sir John Charnley, a British orthopedic surgeon, developed the fundamental principles of the artificial hip and is credited as the father of THA. He designed a hip prosthesis in the mid to late 1960s that still sees use today. It is estimated that over 300,000 total hip arthroplasties are performed each year in the United States alone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The normal hip functions as a &ldquo;ball-and-socket&rdquo; joint. The femoral head (ball) articulates with the acetabulum (socket), allowing smooth range of motion in multiple planes. Any condition that affects either of these structures can lead to deterioration of the joint. This, in turn, can lead to deformity, pain, and loss of function. The most common condition affecting the hip in this way is osteoarthritis. Other conditions that may affect the hip adversely include inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, spondyloarthropathies, etc), developmental dysplasia, childhood hip disorders (Legg-Calve-Perthes disease, slipped capital femoral epiphysis, etc), trauma, neoplasms, and osteonecrosis. (See appropriate topic reviews.)",
"   </p>",
"   <p>",
"    THA is a procedure whereby the diseased articular surfaces are replaced with synthetic materials, thus relieving pain and improving joint kinematics and function. Preoperative and operative issues related to THA are discussed in this topic review. Intraoperative and postoperative complications of THA are listed briefly below (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Complications'",
"    </a>",
"    below) and are presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1658?source=see_link\">",
"     \"Complications of total hip arthroplasty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    THA is an elective procedure and should be considered as an option among other alternatives. The decision to proceed with THA is made with an understanding of the potential risks and benefits. A thorough understanding of both the procedure and the anticipated outcome is an important part of the decision-making process. For the appropriate candidate, THA can be a life-altering procedure that relieves pain, that improves function, and that enhances quality of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Published results of THA demonstrate excellent clinical, functional, and radiographic results. These results vary depending upon the implant, the surgical technique, the type of fixation, the biomaterials, the patient&rsquo;s age, and a myriad of other factors. THA may be performed successfully in patients ranging from the very young [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/2-4\">",
"     2-4",
"    </a>",
"    ] to older adults (over 80 years of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/5\">",
"     5",
"    </a>",
"    ]. However, young and active patients must be made aware that premature failure of the replaced joint may occur if activity levels are not reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Impact activities, manual labor, heavy lifting, and high-intensity sports should be avoided.",
"   </p>",
"   <p>",
"    In general, over 90 percent of THAs are working successfully, are pain-free, and are without complication 10 to 15 years postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/6\">",
"     6",
"    </a>",
"    ]. Some patients continue with their original implant even after 25 years of use. The rate of revision of THA is approximately 1 percent per year (that is, 1 percent of persons entering into a given year with a total hip replacement will have revision that year) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/7\">",
"     7",
"    </a>",
"    ]. It is hoped that this service-life can be extended even further using contemporary surgical techniques and implants. In addition, patient satisfaction following the procedure is extremely high [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many complications that can occur during and following THA.",
"   </p>",
"   <p>",
"    Intraoperative problems that may arise that are relatively specific to this type of surgery are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fracture",
"     </li>",
"     <li>",
"      Nerve injury",
"     </li>",
"     <li>",
"      Vascular injury",
"     </li>",
"     <li>",
"      Cement-related hypotension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Postoperative complications include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infection",
"     </li>",
"     <li>",
"      Dislocation",
"     </li>",
"     <li>",
"      Osteolysis and wear",
"     </li>",
"     <li>",
"      Aseptic loosening",
"     </li>",
"     <li>",
"      Periprosthetic fracture",
"     </li>",
"     <li>",
"      Implant failure or fracture",
"     </li>",
"     <li>",
"      Leg length discrepancy",
"     </li>",
"     <li>",
"      Heterotopic ossification",
"     </li>",
"     <li>",
"      Thromboembolic disease",
"     </li>",
"     <li>",
"      Medical complications (eg, myocardial infarction, pneumonia, and urinary tract infection)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These potential complications are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1658?source=see_link\">",
"     \"Complications of total hip arthroplasty\"",
"    </a>",
"    .) Other complications that may occur with any major surgery, such as those related to anesthesia, to blood loss, or to transfusion reactions, may also develop during or after joint arthroplasty and should be considered and discussed with the patient preoperatively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective study of patients undergoing arthroplasty between 1995 and 2000 included 6703 who had THA in Veterans&rsquo; Administration hospitals in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/9\">",
"     9",
"    </a>",
"    ]. The 30-day mortality was 0.7 percent. Reductions in mortality rates between 1991 and 2008 were shown in an analysis of over 1.4 million Medicare beneficiaries in the United States who underwent elective primary total hip arthroplasty during this period [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/10\">",
"     10",
"    </a>",
"    ]. In these patients, the 30-day mortality decreased during this interval from 0.7 to 0.4 percent, despite a mean increase of one year in age and despite a mean increase from one to two in the number of comorbid medical conditions. Mortality rates are higher in patients who have THA in the setting of hip fracture management when compared with those who have elective surgery for other indications [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;THA is indicated in patients who have failed conservative or previous surgical treatment options for a deteriorated hip joint and who continue to have persistent, debilitating pain and a significant decrease in the activities of daily living. THA may also be indicated even in the absence of severe pain. Patients with significant deformity and limitation of motion may be candidates if the disability that results is considerable. Age itself is not a contraindication to proceeding with replacement. THA is indicated for patients of all ages (except the skeletally immature). Because the joint replacement can fail with time, the revision rate is lower if surgery is delayed as long as possible. On the other hand, patients who elect surgery at a better level of functional status have better functional outcomes. Surgeons and patients need to weigh carefully the relative advantages and drawbacks of earlier versus later THA for each patient [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;THA should",
"    <strong>",
"     not",
"    </strong>",
"    be undertaken in a number of clinical settings, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Active infection (local or systemic)",
"     </li>",
"     <li>",
"      Preexisting significant medical problems (eg, recent myocardial infarction, unstable angina, heart failure, or severe anemia)",
"     </li>",
"     <li>",
"      Skeletal immaturity",
"     </li>",
"     <li>",
"      Paraplegia or quadriplegia",
"     </li>",
"     <li>",
"      Permanent or irreversible muscle weakness in the absence of pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Active infection is perhaps the most significant of these contraindications to THA. An infected THA can be a devastating and costly complication.",
"   </p>",
"   <p>",
"    Relative contraindications include a neuropathic (Charcot) joint [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/13\">",
"     13",
"    </a>",
"    ], inability to ambulate that is not related to the hip disorder per se, absence of hip abductor muscle mass, progressive neurologic loss, and morbid obesity. However, the effects of obesity on outcome remain uncertain. Most studies do show an increased risk of infection, particularly in the highly obese [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/14\">",
"     14",
"    </a>",
"    ]. This must be weighed against the fact that some morbidly obese patients can have significant improvement postoperatively. A 2011 study from Canada noted that patients with morbid obesity can experience substantial benefit, despite a very small but statistically significant increase in the need for revision due to septic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/15\">",
"     15",
"    </a>",
"    ]. Other studies have emphasized the increased risk of both superficial and deep infections and have described an increased risk of dislocation in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Infection and other complications are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1658?source=see_link&amp;anchor=H19#H19\">",
"     \"Complications of total hip arthroplasty\", section on 'Infection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1658?source=see_link&amp;anchor=H20#H20\">",
"     \"Complications of total hip arthroplasty\", section on 'Dislocation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful preoperative evaluation is essential to help diagnose hip pathology, to identify appropriate surgical candidates, to assist with surgical planning, and to minimize perioperative and postoperative complications. General issues in preoperative medical consultation and management are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=see_link\">",
"     \"Evaluation of preoperative pulmonary risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Key elements of the preoperative evaluation include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History",
"     </li>",
"     <li>",
"      Physical examination",
"     </li>",
"     <li>",
"      Laboratory testing",
"     </li>",
"     <li>",
"      Imaging studies",
"     </li>",
"     <li>",
"      Review of treatment alternatives",
"     </li>",
"     <li>",
"      Consideration of autologous blood donation",
"     </li>",
"     <li>",
"      Consideration of alternatives to THA",
"     </li>",
"     <li>",
"      Selection of prosthetic components",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with deterioration of the hip joint present with pain. This is typically localized to the anterior hip or groin. Occasionally, posterior buttock pain may also be present. Pain typically occurs with hip motion but can be present at rest. The pain is often exacerbated by weightbearing and can radiate (commonly towards the knee). Patients frequently describe &ldquo;stiffness&rdquo; or &ldquo;tightness&rdquo; of the hip, and loss of motion is often noted. It is important to elicit any history of back pain, since hip pain may be the indirect result of radicular pathology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22088?source=see_link\">",
"     \"Evaluation of the adult with hip pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Disruption of sleep and difficulty walking, climbing stairs, or getting into and out of a car are common complaints. These patients may also need an assistive device (eg, cane); difficulty putting on socks and shoes may also be a problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Comorbid medical problems and review of systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific attention should be paid to signs, symptoms, and previous history of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiovascular disease &mdash; Myocardial infarction, angina, hypertension, heart failure, arrhythmia, or valvular heart disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"       \"Estimation of cardiac risk prior to noncardiac surgery\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pulmonary disease &mdash; Chronic obstructive pulmonary disease, restrictive lung disease, respiratory infection, pulmonary embolus, sleep apnea, or asthma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=see_link\">",
"       \"Evaluation of preoperative pulmonary risk\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cerebrovascular disease &mdash; Stroke, transient ischemic attacks, or carotid stenosis",
"     </li>",
"     <li>",
"      Hematologic disorders &mdash; Anemia, coagulopathies, or blood dyscrasias",
"     </li>",
"     <li>",
"      Endocrine disorders &mdash; Diabetes, hyperthyroidism, hypothyroidism, lipid disorders, or glucocorticoid use that could result in adrenal insufficiency",
"     </li>",
"     <li>",
"      Urologic disorders &mdash; Benign prostatic hypertrophy, obstructive uropathy, prostate cancer, or urinary tract infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The classic symptoms of dysuria, urgency, and frequency seen with urinary tract infections may be absent in older adults. In general, it is appropriate to perform urinalysis prior to hip arthroplasty if a urinary catheter is expected to be in place postoperatively, and an abnormal urinalysis should prompt urine culture. The approach to treatment of asymptomatic bacteriuria in such patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/19/42295?source=see_link&amp;anchor=H2424798#H2424798\">",
"     \"Approach to the adult with asymptomatic bacteriuria\", section on 'Patients undergoing joint arthroplasty'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the preoperative evaluation reveals symptoms related to urinary obstruction, surgery should be postponed until the obstruction has been diagnosed and treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Irritative symptoms in combination with bacteriuria should also serve as an indication to postpone surgery. To diminish the risk of postoperative urinary tract infection, a bladder catheter should be inserted immediately preoperatively and should be removed within 24 hours of surgery. This decreases the risk of urinary retention, which has been shown to increase the likelihood of a postoperative urinary tract infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=see_link\">",
"     \"Urinary tract infection associated with urethral catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vascular disease &mdash; Peripheral vascular",
"      <span class=\"nowrap\">",
"       disease/claudication,",
"      </span>",
"      renal artery stenosis, aortic stenosis, peripheral edema, or deep vein thrombosis",
"     </li>",
"     <li>",
"      Musculoskeletal disorders &mdash; Degenerative spine disease, developmental hip dysplasia, or history of childhood hip disorders (Legg-Calve-Perthes disease, slipped capital femoral epiphysis, etc)",
"     </li>",
"     <li>",
"      Infectious diseases &mdash; Human immunodeficiency viral infection (HIV), hepatitis, or history of osteomyelitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is essential to obtain a complete and accurate list of current medications. Specific attention to the following medications should be made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      and nonsteroidal antiinflammatory drugs (NSAIDs) &mdash; NSAIDs should be discontinued at least one week prior to surgery. Continuation of NSAIDs prior to arthroplasty surgery has been shown to increase perioperative bleeding up to twofold [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Selective cyclooxygenase-2 (COX-2) inhibitors &mdash; There is controversy as to whether or not selective COX-2 inhibitors significantly affect the coagulation system. No consensus exists regarding continuation of COX-2 inhibitors in the immediate preoperative or perioperative period; however, they are often used as part of a multimodal pain regimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The literature provides conflicting evidence. In one prospective study, 100 patients undergoing total knee arthroplasty were randomly assigned to receive rofecoxib or placebo. There was no significant difference in the incidence of perioperative bleeding or in the international normalized ratio (INR). Rofecoxib was withdrawn from the market in 2004 because of an increase in myocardial infarctions (heart attacks) and strokes in patients. It is not known if this is an effect that is shared by all COX-2 inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link&amp;anchor=H2#H2\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\", section on 'Ischemic cardiovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other studies demonstrate an interaction between COX-2 inhibitors (predominantly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Interaction with warfarin appeared to be less of a problem with rofecoxib [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/25\">",
"     25",
"    </a>",
"    ], but this agent is no longer available. The risk of bleeding in systemically anticoagulated patients (as in most postoperative THA patients) appears to be lower with very or somewhat selective COX-2 inhibitors than with nonselective NSAIDs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    .) Ultimately, whether or not to discontinue COX-2 inhibitors preoperatively is left to the discretion of the surgeon.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      &mdash; Warfarin should be discontinued a minimum of three to five days prior to surgery. Preoperatively, the prothrombin time (PT) and corresponding international normalized ratio (INR) should be normalized. For certain high-risk patients (eg, those with mechanical heart valves),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      may be required to minimize the amount of time spent off anticoagulation. The heparin should be stopped approximately six hours preoperatively, and normalized partial thromboplastin time (PTT) should be achieved before the operation begins. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link\">",
"       \"Management of anticoagulation before and after elective surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antibiotics &mdash; As noted earlier, active infection is a contraindication to THA. Patients who have received treatment for an infection recently should be off the antibiotic for at least 48 hours preoperatively and should have no evidence of residual infection prior to proceeding with surgery.",
"     </li>",
"     <li>",
"      Insulin and oral hypoglycemics &mdash; Most oral hypoglycemics should be held the day of surgery. Insulin dose should be reduced or held depending upon the patient&rsquo;s typical dose and upon the scheduled time for surgery (am or pm). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29688?source=see_link\">",
"       \"Perioperative management of diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cholesterol-lowering drugs &mdash; A retrospective cohort study of more than 780,000 patients who underwent major noncardiac surgery found a reduced risk of mortality in those receiving statins [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/26\">",
"       26",
"      </a>",
"      ]. Based upon this and other evidence, it is recommended that statin therapy be continued up to and including the day of surgery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40666?source=see_link&amp;anchor=H10#H10\">",
"       \"Perioperative medication management\", section on 'Statins'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glucocorticoids &mdash; Prior to surgery, glucocorticoids should be tapered to the lowest dose tolerated in order to minimize immunosuppression and to optimize wound healing. Perioperatively, &ldquo;stress-dose&rdquo; glucocorticoids are often given to avoid the possible effects of adrenal insufficiency. The utility of this practice has been debated, but it continues to be practiced by many orthopedic surgeons and anesthesiologists. Typically, 100 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      is given intravenously within one hour before surgery and then every eight hours postoperatively. Half this dose is given the first postoperative day, and, subsequently, the regular oral dose of glucocorticoid is resumed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of adrenal insufficiency in adults\", section on 'Choice of glucocorticoid'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      &mdash; There are conflicting data whether to discontinue methotrexate (MTX) during the perioperative period [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/27-29\">",
"       27-29",
"      </a>",
"      ]. In a prospective trial, 388 patients with rheumatoid arthritis (RA) were randomly assigned to discontinue or continue taking methotrexate [",
"      <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/29\">",
"       29",
"      </a>",
"      ]. Postoperative infections",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      surgical complications were not significantly different in the two groups. The authors recommended that MTX treatment should not be stopped in patients whose disease is controlled by the drug before elective orthopedic surgery.",
"     </li>",
"     <li>",
"      Anticytokines &mdash; The use of anti-tumor necrosis factor (TNF)-alpha therapies (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      ) have been associated with an increase in infections, most notably in those patients with a history of recurring infections or with underlying conditions which may predispose patients to infections (such as rheumatoid arthritis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      poorly controlled diabetes). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link\">",
"       \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many arthroplasty surgeons prefer to avoid anti-TNF agents in the perioperative period. There are no data on the safety of the recombinant human interleukin-1 receptor antagonist (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    ) in the setting of total joint arthroplasty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough musculoskeletal examination should be performed in every candidate for THA. A more detailed description of hip anatomy, pain patterns, differential diagnosis, and physical examination of the hip, including special maneuvers, is available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22088?source=see_link\">",
"     \"Evaluation of the adult with hip pain\"",
"    </a>",
"    .) Prior to surgery, the following evaluations are essential:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inspection &mdash; Gait, previous incisions, abnormal swelling of hip or limb, abrasions, discolorations, and cutaneous infections should be evaluated by inspection. Gait assessment should include an evaluation of any limp, use of assistive devices,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      limb length discrepancy. The presence or absence of a Trendelenburg gait should be noted. Any evidence of a &ldquo;minor&rdquo; infection (eg, infected ingrown toenail) should prompt a delay in surgery until the infection has completely resolved.",
"     </li>",
"     <li>",
"      Palpation &mdash; Anterior superior iliac spines, iliac crest, greater trochanter, posterior superior iliac spines, ischial tuberosity, and sacroiliac joint should be evaluated by palpation. Palpation can help rule out nonarticular causes of &ldquo;hip pain.&rdquo; For example, lateral hip pain localized over the greater trochanter is usually not an indicator of hip joint pathology but rather an inflammation of the greater trochanteric bursa.",
"     </li>",
"     <li>",
"      Range of motion &mdash; Hip",
"      <span class=\"nowrap\">",
"       flexion/extension,",
"      </span>",
"      <span class=\"nowrap\">",
"       abduction/adduction,",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       internal/external",
"      </span>",
"      rotation should be recorded. Contractures should be noted. Limitation of motion often develops as hip pathology progresses. Joint surface incongruity, muscle spasms, soft tissue contracture,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mechanical block (eg, osteophytes or loose bodies) may all contribute to decreased motion.",
"     </li>",
"     <li>",
"      Muscle testing &mdash; Motor strength and tone should be evaluated for hip flexors, extensors, abductors, and adductors. In addition, distal motor strength and tone of the limb should be tested.",
"     </li>",
"     <li>",
"      Nerve and vascular status &mdash; Preoperatively, it is imperative to evaluate and document nerve and vascular status. Sciatic and peroneal nerve function testing, assessment of arterial pulses, and a thorough sensory examination should be performed and documented for both limbs. In addition, venous insufficiency should be noted. Severe vascular disease should be evaluated by a vascular surgeon prior to proceeding with surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Special tests",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leg length &mdash; As part of preoperative planning, leg lengths must be evaluated. There are two types of leg length discrepancy. &ldquo;Apparent&rdquo; leg length discrepancy is the result of compensation in response to pathology or contracture rather than an actual difference in leg lengths (eg, presence of scoliosis or pelvic obliquity). True leg length discrepancy is the result of an anatomic or structural change in the lower limb (eg, tibia fracture). To measure true leg length, have the patient lie supine and place the lower limbs in comparable positions with the legs slightly apart and parallel. Next, use a tape measure to record the length between the anterior superior iliac spine (ASIS) and the medial malleolus for each limb. Another useful method of determining true leg length discrepancy is by using blocks of varying height. The patient is asked to stand, and blocks of varying height are placed under the short limb. When the iliac crests are at the same level, the block height represents a good approximation of the true leg length discrepancy. Typically, a deteriorated hip joint will cause a decrease in true leg length.",
"     </li>",
"     <li>",
"      Trendelenburg&rsquo;s sign &mdash; This test assesses the strength and function of the hip abductors. The sign is elicited by asking the patient to stand on the involved leg. Normally, the pelvis on the opposite side rises. However, if the pelvis on the opposite side drops, this test is positive. A positive test indicates that the hip abductors of the involved limb are weak or are relatively inhibited.",
"     </li>",
"     <li>",
"      Straight leg raise &mdash; When this test is performed against resistance, groin pain is typically elicited if significant hip pathology is present. In addition, when this test is performed passively by the examiner, radiating pain from the back or posterior hip into the lower leg suggests a radicular pathology.",
"     </li>",
"     <li>",
"      Related areas &mdash; Particular attention to the spine, pelvis, and knees is essential to rule out radicular pathology as well as other concomitant diseases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Baseline laboratory tests should include a complete blood count, protime (PT), INR, activated partial thromboplastin time (aPTT), and basic chemistries. An electrocardiogram (EKG) and urinalysis with culture should also be performed. Urinary tract infection should be identified and treated with antibiotics prior to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/30\">",
"     30",
"    </a>",
"    ]. Other laboratory tests can be ordered to assess pathologies found during the preoperative examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs of the hip and pelvis are essential for diagnosis and evaluation of hip disease, as well as preoperative planning for THA. Preoperative films should include a weightbearing anteroposterior (AP) pelvis, as well as AP and lateral views of the affected hip. Care should be taken to ensure that the entire proximal femur is visualized so that any deformity can be identified. In addition to plain radiographs, magnetic resonance imaging (MRI) may be necessary to evaluate certain hip disorders such as osteonecrosis. A discussion of imaging techniques and modalities for evaluation of hip pain is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22088?source=see_link\">",
"     \"Evaluation of the adult with hip pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CONSERVATIVE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before proceeding to THA, a more conservative approach should be tried. For patients with osteoarthritis, this usually includes nonoperative treatment measures, such as weight reduction, physical therapy, medications,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    use of an assistive device (eg, a cane). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=see_link\">",
"     \"Nonpharmacologic therapy of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=see_link\">",
"     \"Pharmacologic therapy of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with hip involvement due to inflammatory arthritis (eg, rheumatoid arthritis or spondyloarthropathy), THA is offered to address the symptoms of advanced structural disease and not those of the underlying inflammatory disorder, which is treated medically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37861?source=see_link\">",
"     \"Evaluation and medical management of end-stage rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=see_link\">",
"     \"Assessment and treatment of ankylosing spondylitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ALTERNATIVES TO TOTAL HIP ARTHROPLASTY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon the etiology of the hip deterioration, other surgical treatment options may be considered, including the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Core decompression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Core decompression is used in patients with early femoral head osteonecrosis. The femoral head is drilled to remove necrotic debris and to potentially decrease pressure within the head. This procedure may be useful in early osteonecrosis but is not useful in the later stages (once collapse has occurred) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=see_link\">",
"     \"Osteonecrosis (avascular necrosis of bone)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Intertrochanteric osteotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intertrochanteric osteotomy may be useful in patients with deformity or disease of the proximal femur. Indications may include early or post-collapse osteonecrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/31\">",
"     31",
"    </a>",
"    ], femoral dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/13\">",
"     13",
"    </a>",
"    ], fracture malunion or non-union, and congenital deformities such as coxa vara or coxa valga. The goal of this procedure is to correct the deformity, to eliminate impingement, and to restore a functional range of motion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Periacetabular osteotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periacetabular osteotomy has been shown to be an effective intervention in patients with acetabular dysplasia. By rotating the acetabulum, the hip biomechanics can be improved to provide a better bearing surface for the femoral head. This has been shown to delay or prevent the development of arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Surgical dislocation and debridement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative evaluation and treatment of a variety of intracapsular hip disorders, including rheumatoid synovitis, synovial chondromatosis, pigmented villonodular synovitis, labral tears, chondral injury, impingement, previous trauma, and loose bodies, may be accomplished with surgical dislocation and debridement [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Resection arthroplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resection arthroplasty, also called a Girdlestone procedure, consists of surgical removal of the femoral head and creation of a fibrous articulation between the proximal femur and the iliac bone. This is typically considered a salvage procedure. It is reserved for patients who have a chronic infection of the hip, certain bone tumors, or severe hip disease not amenable to other options. It can be a useful and important procedure to control infection, to relieve pain, and to restore hip motion. Leg length discrepancy, limp, hip instability, and early fatigue should be anticipated. Persistent infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pain may be complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Hip arthroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An arthroscopic approach may be useful in patients with labral tears, chondral injuries, synovial chondromatosis, and loose bodies affecting the hip.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Hip arthrodesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hip arthrodesis, also known as hip fusion, is performed infrequently today. However, this procedure may be indicated for severe unilateral arthritis after traumatic injury or infection in a young but otherwise healthy individual [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. This can be particularly useful in a heavy male patient that desires to return to high-impact or heavy-loading physical activity, such as manual labor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Total hip resurfacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total hip resurfacing is the only good surgical alternative to THA in patients with end-stage arthritis. Total hip resurfacing involves resurfacing, rather than replacing, the damaged femoral head. Implants for this procedure were approved by the United States Food and Drug Administration (FDA) in 2006. These are metal-on-metal devices with a polished acetabular component and a mated metal head ball which caps the prepared femoral head.",
"   </p>",
"   <p>",
"    The proposed advantages of this device include minimal bone resection, more normal femoral loading, restoration of natural anatomy, a large head size with reduced risk of dislocation, and the ability to revise to a standard total hip replacement should failure occur. The principal complication leading to failure of the device is femoral neck fracture, reasons for which are a subject of debate.",
"   </p>",
"   <p>",
"    Although results from early studies appeared promising, concern has arisen over the long-term benefits and risks of metal-on-metal devices [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. An analysis of long-term data from several national registries found greater rates of re-revision following resurfacing compared with total hip arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/38\">",
"     38",
"    </a>",
"    ]. For example, the five-year cumulative revision rate in Australia was significantly greater following resurfacing (3.7 versus 2.7 percent). (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Bearing surface'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patient selection and surgical technique seem to be the most important factors for success; young, active males under age 55 with osteoarthritis and minimal underlying hip deformity appear to be the best candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. The best results in females were in women with a femoral head component diameter of 50 mm or greater [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14257847\">",
"    <span class=\"h2\">",
"     Hemiarthroplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemiarthroplasties, a form of &ldquo;partial&rdquo; hip replacement, can be either unipolar (single head) or bipolar (head within a head). A bipolar hemiarthroplasty consists of a femoral stem and head ball (with no acetabular component). Hemiarthroplasties (such as a bipolar) are most often used in the setting of a femoral neck fracture in an older patient, but they are rarely used for degenerative hip disease. Historically, some surgeons used the procedure for the treatment of osteonecrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     AUTOLOGOUS BLOOD DONATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total hip arthroplasty may involve substantial intraoperative and perioperative blood loss (typically over 200 mL). This places some patients at increased risk for myocardial infarction, angina, claudication, transient ischemic attack, stroke, and seizure (especially in patients with significant systemic illness). Therefore, to maintain acceptable red cell indices, transfusions are often utilized. During the 1980s, concerns over allogeneic blood infectivity prompted the establishment of autologous blood donation programs. Autologous blood donation helps to alleviate patient concerns about blood infectivity while also avoiding risks associated with allogeneic transfusion, decreasing the incidence of allogeneic transfusion, and stimulating erythropoiesis.",
"   </p>",
"   <p>",
"    Orthopedic surgeons at many institutions utilize preoperative autologous blood donation routinely for all patients undergoing joint replacement. However, some question this practice. In one retrospective study that assessed risk factors for allogeneic transfusion, the authors concluded that patients with an initial hemoglobin level &gt;15",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    or patients with an initial hemoglobin level between 13 and 15",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and an age &lt;65 were at minimal risk of needing a transfusion during or after a primary total joint replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autologous blood donation, however, has its own set of risks and drawbacks. Issues of patient inconvenience, phlebotomy-induced anemia, possible exacerbation of medical conditions, waste of donated blood, and cost suggest that autologous blood donation may not be beneficial in all patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=see_link\">",
"     \"Preoperative autologous blood donation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Erythropoietin, approved by the FDA for use in patients with a hemoglobin level between 10 and 13",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    may benefit anemic patients who are unable to donate autologous blood. Erythropoietin has been shown to decrease the allogeneic transfusion rate while increasing mean postoperative hemoglobin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/41\">",
"     41",
"    </a>",
"    ]. The cost effectiveness of erythropoietin has not been carefully evaluated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31605?source=see_link\">",
"     \"Controversial areas in preoperative autologous blood donation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PREVENTION OF PROSTHETIC JOINT INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of prophylactic antibiotics in patients undergoing total joint replacement surgery is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28198?source=see_link&amp;anchor=H2#H2\">",
"     \"Prevention of prosthetic joint infections\", section on 'Before and after joint replacement surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     CHOICE OF PROSTHESIS AND FIXATION TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;All total hip arthroplasties consist of a femoral component, an acetabular component, and a bearing surface. Most systems are modular with a separate femoral stem, femoral head, acetabular liner, and acetabular shell. This modularity gives the operating surgeon tremendous flexibility in dealing with any intraoperative situation or anatomical variation. There is a staggering number of femoral and acetabular implants available for use in THA. The multitude of choices reflects different philosophies regarding the type of fixation, design features, and materials.",
"   </p>",
"   <p>",
"    Fixation of the prosthetic components to host bone can be achieved with one of two techniques. The first involves the use of cement, which serves as a grout between the implant and the host bone. The second technique achieves fixation without the use of cement and relies on bony ingrowth into or onto the porous implant surface which has been either &ldquo;press-fit&rdquo; or &ldquo;interference-fit&rdquo; into the surrounding bone. The uncemented approach was introduced in the 1980s and has proven to be a useful technique, providing secure and long-lasting fixation for THA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Implants",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Acetabular implant",
"    </span>",
"    &nbsp;&mdash;&nbsp;While there are many options for acetabular components in primary THA, the large majority of acetabular components inserted today are cementless, porous, and modular. Typically, a hemispherical porous metal shell is inserted into the acetabulum, and a modular liner is then placed within the shell. The acetabular liner, typically made of high-density polyethylene, is designed to articulate with a highly polished femoral head (ball). The porous surface of the implant varies from manufacturer to manufacturer and may have a surface coating (such as hydroxyapatite) that promotes bony ingrowth or overgrowth. Many designs allow for the insertion of screws for supplementary fixation of the shell.",
"   </p>",
"   <p>",
"    The alternative to a cementless acetabular component is an acetabular component fixed to the acetabulum with cement. This type of acetabular implant has fallen out of favor due to studies showing a higher overall loosening rate than with uncemented implants. However, some surgeons advocate the use of an all-polyethylene cemented acetabular implant for older patients with poor bone stock [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Bearing surface",
"    </span>",
"    &nbsp;&mdash;&nbsp;For years, the standard bearing surface has been a metallic femoral head, which articulated with a smooth, high-density polyethylene acetabular liner. Due to concerns about wear and resultant particle debris, alternate bearing surfaces have been developed. The most widely used of these is made of highly crosslinked polyethylene. Laboratory results using highly crosslinked polyethylene show a reduction in wear rates and particle debris when compared with ordinary high-density polyethylene [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Clinical results also appear promising, but longer-term results are not available.",
"   </p>",
"   <p>",
"    Other bearing surfaces developed and used in the hip are ceramic-on-polyethylene, ceramic-on-ceramic, and metal-on-metal. Concerns regarding ceramic fracture or failure (in ceramic-on-ceramic bearing surfaces) have not been fully evaluated, especially in the long term. Again, short-term clinical results on these bearing surfaces appear promising, but longer-term results are necessary to compare with metal-on-polyethylene.",
"   </p>",
"   <p>",
"    Complications from metal-on-metal devices have been a subject of increasing concern with greater experience [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/37,45,46\">",
"     37,45,46",
"    </a>",
"    ]. Problems have included osteolysis; local soft tissue reactions, such as pseudotumors; tissue and bone necrosis around the arthroplasties; and effects of metal ions on other organs. It was thought that metal-on-metal bearing surfaces might offer advantages over other materials, including a reduced need for revision. However, a systematic review of clinical trials and observational studies, involving 3139 patients and 3404 hips, and of five national registries and the US Medicare database, including over 887,000 surgeries, found no advantage for metal-on-metal or ceramic-on-ceramic implants compared with use of metal-on-polyethylene or ceramic-on-polyethylene bearing surfaces [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/47\">",
"     47",
"    </a>",
"    ]. Functional outcomes did not differ between patients receiving different bearing surfaces. In the national registries, the rate of revision was higher in patients who received metal&ndash;on-metal implants compared with those who received metal&ndash;on&ndash;polyethylene.",
"   </p>",
"   <p>",
"    A randomized trial of 195 patients demonstrated no advantage in clinical outcomes at 10 years of follow-up for cemented metal-on-metal total hip arthroplasties compared with metal-on-polyethylene, but the patients with metal-on-metal devices had twice the serum levels of cobalt and chromium [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/48\">",
"     48",
"    </a>",
"    ]. The clinical importance of the elevated cobalt and chromium levels is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Femoral implant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Femoral components can be classified as either cementless or cemented. Cemented femoral components were the gold standard until the late 1980s and early 1990s when published results of cementless implants demonstrated excellent results and durability.",
"   </p>",
"   <p>",
"    A cementless femoral component is the implant of choice for the young patient and for any patient with good bone stock (particularly those with thick femoral cortices and with smaller diameter femoral canals). However, it is sometimes difficult to get good initial stability with a cementless implant in patients with large femoral canal geometry. In addition, a larger (and necessarily stiffer) implant would be required. Therefore, a cemented implant is an appropriate choice in the older, low-demand patient with poor bone stock (thin cortices and larger canal diameter).",
"   </p>",
"   <p>",
"    Cementless implants are typically porous-coated to increase surface area for bone ingrowth. In addition, the roughened surface helps to achieve initial stability of the implant, which is critical for long-term success of the implant. The porous coating may be limited to the proximal portion of the femoral implant or may extend over the entire length of the implant. This varies depending upon the philosophy of the design. Proximally porous coated implants rely on the metaphysis or metadiaphyseal junction for fixation and stability. Extensively porous-coated implants rely more on diaphyseal fixation. Cementless implant designs utilize a circumferential porous coating, which has been shown to help prevent access of wear particles from the articulating surface down along the implant-bone interface.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Femoral head",
"    </span>",
"    &nbsp;&mdash;&nbsp;The femoral head in any THA must match the acetabular bearing surface. As mentioned above, different materials may be utilized for the bearing surface. However, most total hip arthroplasties performed today in the United States utilize a highly polished cobalt chrome femoral head. Different diameters are available ranging from 22 mm up to 38 mm (or greater). The key considerations regarding head size are range of motion, stability, and propensity for wear. In general, increasing head size is correlated with increased range of motion and decreased dislocation rate but also with increased volumetric wear and generation of particle debris. Therefore, a compromise must be made. The introductions of more durable acetabular liners (eg, highly crosslinked polyethylene) and alternative bearing surfaces are leading some surgeons to use a larger head size than the prior standard of 28 mm typically used in primary THA; the goal with the larger prosthetic head is to improve range of motion and to decrease the risk of dislocation. Long-term studies to evaluate this trend are not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical procedure for THA has undergone an evolution since it was initially introduced, and a variety of surgical approaches to the hip have been described. Most are performed through a posterolateral, direct lateral, or anterior approach. &ldquo;Minimally invasive&rdquo; techniques have been developed and publicized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Posterolateral versus direct lateral versus anterior approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The posterolateral approach, also called the Kocher-Langenbeck approach, gains exposure to the hip by splitting the gluteus maximus muscle and dissecting off the short external rotators on the posterior aspect of the hip. The joint is entered posteriorly through the capsule. The hip abductor muscles (gluteus medius and minimus) are left intact.",
"   </p>",
"   <p>",
"    The direct lateral approach, also called the Hardinge or modified Hardinge approach, gains exposure to the hip by splitting the anterior portion of the abductors. This provides access to the hip through the anterior hip capsule. Typically, these approaches are performed with the patient in the lateral position. However, the direct lateral approach may be performed with the patient supine or semi-lateral.",
"   </p>",
"   <p>",
"    The anterior approach, also called the Smith-Petersen approach, gains exposure to the hip without detachment of the surrounding muscles. An interval is created between the tensor fascia and the sartorius. Access to the hip is provided through the anterior hip capsule. This approach is performed with the patient supine and often with the assistance of fluoroscopy.",
"   </p>",
"   <p>",
"    These surgical approaches provide excellent exposure of the hip joint and allow access to the acetabulum and femur for THA. The posterolateral approach disrupts the posterior soft tissue of the hip and historically has shown a higher rate of dislocation than the direct lateral approach. However, the direct lateral approach has demonstrated a higher risk of postoperative limp and heterotopic ossification secondary to disruption of the abductors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The anterior approach is thought to have an even lower dislocation rate because the muscles around the hip are not detached during the procedure. Many surgeons who use the anterior approach tell their patients that dislocation precautions are not required for this approach, which requires a special operating table and surgical instruments. Potential complications include intraoperative femoral and ankle fractures and damage to the lateral femoral cutaneous nerve.",
"   </p>",
"   <p>",
"    These factors should be taken into consideration when choosing a surgical approach for a patient, but they do not preclude the use of the approach with which the surgeon is most comfortable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Minimally invasive versus standard techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minimally invasive THA has been of increased interest to both patients and surgeons. Using the standard surgical approaches described above, the incision for THA has traditionally been about 15 to 30 cm (6 to 12 inches) in length. This varies depending upon the patient&rsquo;s weight, height, morphology, and particular hip anatomy.",
"   </p>",
"   <p>",
"    Using minimally invasive techniques, the standard incision for THA may be reduced to 10 cm (4 inches) or less [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. A two-incision approach using even smaller incisions has also been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/55\">",
"     55",
"    </a>",
"    ]. This two-incision technique is a novel approach to THA and requires the use of fluoroscopy and special training of the surgeon. It should be noted that regardless of which approach is used (standard, single-incision mini, or two-incision mini), the total hip joint implants inserted are the same.",
"   </p>",
"   <p>",
"    The proposed advantages of using a smaller incision (or two minimal incisions) are the potential for decreased blood loss, decreased surgical time, less surgical trauma, quicker rehabilitation, shorter hospital stay, and reduced costs. Initial reports confirmed these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/51-55\">",
"     51-55",
"    </a>",
"    ], with complications comparable to those encountered via a standard incision. However, a subsequent comparison of 42 primary procedures through a standard incision with 42 primary total hip arthroplasties performed though a single mini-incision did not demonstrate any significant differences in blood loss or length of hospital stay, nor did the comparison demonstrate any difference in complications [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/56\">",
"     56",
"    </a>",
"    ]. The conclusion was that the only difference was cosmetic.",
"   </p>",
"   <p>",
"    Potential disadvantages of operating through one or two minimal incisions include limited visualization, component malposition, increased skin trauma, and difficulty determining leg lengths. There are no long-term studies to critically evaluate the minimally invasive procedure, and long-term durability remains to be seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Surgical navigation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical navigation in THA is also being developed. Navigation involves real-time tracking of bones and surgical instruments during surgery. The potential benefits of navigation in THA are improved accuracy of implant position (particularly the acetabular component) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/55/10106/abstract/57\">",
"     57",
"    </a>",
"    ] and smaller incisions because direct visualization is not necessary. The disadvantages of navigation systems are increased operative time, the need for image acquisition preoperatively or intraoperatively, and increased expense. Again, long-term studies are not available to compare results of THA with and without surgical navigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H446375011\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical hospital length of stay following total hip arthroplasty is one to three days. Mobilization and physical therapy are initiated as soon as possible to facilitate recovery of function and to help prevent deep vein thrombosis (DVT). Appropriate attention to medical comorbidities such as diabetes is critical. Medical consultation may be needed for medically complex patients. Multimodal pain management is employed and usually includes an opioid for the treatment of pain. Pain medications are weaned as soon as pain allows but may be needed for a number of weeks postoperatively. DVT prophylaxis is also utilized and includes chemical prophylaxis (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ), as well as mechanical prophylaxis (eg, sequential compression boots). Many patients can be discharged to home after the brief hospitalization, but some may require an inpatient rehabilitation or nursing facility. Time to full recovery varies widely, but patients are typically doing quite well with minimal pain by three months postoperatively. There may be further improvement noted even up to one year following surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/34/23075?source=see_link\">",
"       \"Patient information: Hip replacement (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/30/21987?source=see_link\">",
"       \"Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H392071945\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Total hip arthroplasty (THA) is a highly effective elective procedure for patients with hip pain due to joint deterioration from a variety of conditions; it can relieve pain, can restore function, and can improve quality of life by replacement of the diseased articular surfaces with synthetic material. The 30-day mortality rate of THA is less than 1 percent, although a variety of complications may occur during and following the procedure. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Outcomes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Complications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1658?source=see_link\">",
"       \"Complications of total hip arthroplasty\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      THA is indicated in patients who have failed conservative or previous surgical treatment options for a deteriorated hip joint and who continue to have persistent, debilitating pain and a significant decrease in the activities of daily living. Some patients with significant disability, deformity, and limited motion may also benefit, even in the absence of severe pain. Contraindications to THA include active infection (local or systemic), preexisting significant medical problems, skeletal immaturity, paraplegia, quadriplegia; and permanent or irreversible muscle weakness in the absence of pain. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A careful preoperative evaluation is essential to help diagnose hip pathology, to identify appropriate surgical candidates, to assist with surgical planning, and to minimize perioperative and postoperative complications. Key elements of the preoperative evaluation include history, physical examination, laboratory testing, imaging studies, review of treatment alternatives, consideration of autologous blood donation, consideration of alternatives to THA, and selection of prosthetic components. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Before proceeding to THA, a more conservative approach should be tried, which, depending upon the underlying condition, may include nonoperative treatment measures, such as weight reduction, physical therapy, and medications or medication adjustments. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Conservative treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential surgical alternatives to THA depend upon the etiology of the hip deterioration; they include core decompression, intertrochanteric osteotomy, periacetabular osteotomy, surgical dislocation and debridement, resection arthroplasty, hip arthroscopy, hip arthrodesis, and total hip resurfacing. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Alternatives to total hip arthroplasty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      THA may involve substantial intraoperative and perioperative blood loss (typically over 200 mL), which may increase risk of cardiovascular and cerebrovascular ischemic events. Thus, blood obtained through autologous or allogeneic blood donation for transfusion or erythropoietin may be employed in patients with significant anemia; each of these approaches has its own set of benefits, risks, and drawbacks. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Autologous blood donation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Total hip arthroplasties consist of a femoral component, an acetabular component, and a bearing surface. Most systems are modular, providing flexibility in dealing with any intraoperative situation or anatomical variation. Numerous different femoral and acetabular implants are available, reflecting different philosophies regarding the type of fixation, design features, and materials. Fixation of the prosthetic components to host bone is achieved either by the use of cement or by an uncemented approach. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Choice of prosthesis and fixation technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of surgical approaches to the hip have been described. Most are performed through a posterolateral, a direct lateral, or an anterior approach. Minimally invasive THA has been of increased interest to both patients and surgeons, but whether these approaches offer greater benefit overall remains uncertain. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     HCPUnet, Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality. file://hcupnet.ahrq.gov (Accessed on December 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/2\">",
"      Crowther JD, Lachiewicz PF. Survival and polyethylene wear of porous-coated acetabular components in patients less than fifty years old: results at nine to fourteen years. J Bone Joint Surg Am 2002; 84-A:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/3\">",
"      Duffy GP, Berry DJ, Rowland C, Cabanela ME. Primary uncemented total hip arthroplasty in patients &lt;40 years old: 10- to 14-year results using first-generation proximally porous-coated implants. J Arthroplasty 2001; 16:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/4\">",
"      McLaughlin JR, Lee KR. Total hip arthroplasty in young patients. 8- to 13-year results using an uncemented stem. Clin Orthop Relat Res 2000; :153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/5\">",
"      Keisu KS, Orozco F, Sharkey PF, et al. Primary cementless total hip arthroplasty in octogenarians. Two to eleven-year follow-up. J Bone Joint Surg Am 2001; 83-A:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/6\">",
"      Beswick AD, Wylde V, Gooberman-Hill R, et al. What proportion of patients report long-term pain after total hip or knee replacement for osteoarthritis? A systematic review of prospective studies in unselected patients. BMJ Open 2012; 2:e000435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/7\">",
"      Katz JN, Wright EA, Wright J, et al. Twelve-year risk of revision after primary total hip replacement in the U.S. Medicare population. J Bone Joint Surg Am 2012; 94:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/8\">",
"      Mancuso CA, Salvati EA. Patients' satisfaction with the process of total hip arthroplasty. J Healthc Qual 2003; 25:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/9\">",
"      Ibrahim SA, Stone RA, Han X, et al. Racial/ethnic differences in surgical outcomes in veterans following knee or hip arthroplasty. Arthritis Rheum 2005; 52:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/10\">",
"      Cram P, Lu X, Kaboli PJ, et al. Clinical characteristics and outcomes of Medicare patients undergoing total hip arthroplasty, 1991-2008. JAMA 2011; 305:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/11\">",
"      Cleves MA, Golden WE. Assessment of HCFA's 1992 Medicare hospital information report of mortality following admission for hip arthroplasty. Health Serv Res 1996; 31:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/12\">",
"      Fortin PR, Penrod JR, Clarke AE, et al. Timing of total joint replacement affects clinical outcomes among patients with osteoarthritis of the hip or knee. Arthritis Rheum 2002; 46:3327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/13\">",
"      Sprenger TR, Foley CJ. Hip replacement in a Charcot joint: a case report and historical review. Clin Orthop Relat Res 1982; :191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/14\">",
"      Namba RS, Paxton L, Fithian DC, Stone ML. Obesity and perioperative morbidity in total hip and total knee arthroplasty patients. J Arthroplasty 2005; 20:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/15\">",
"      McCalden RW, Charron KD, MacDonald SJ, et al. Does morbid obesity affect the outcome of total hip replacement?: an analysis of 3290 THRs. J Bone Joint Surg Br 2011; 93:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/16\">",
"      Dowsey MM, Choong PF. Obesity is a major risk factor for prosthetic infection after primary hip arthroplasty. Clin Orthop Relat Res 2008; 466:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/17\">",
"      Dowsey MM, Choong PF. Early outcomes and complications following joint arthroplasty in obese patients: a review of the published reports. ANZ J Surg 2008; 78:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/18\">",
"      Chee YH, Teoh KH, Sabnis BM, et al. Total hip replacement in morbidly obese patients with osteoarthritis: results of a prospectively matched study. J Bone Joint Surg Br 2010; 92:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/19\">",
"      David TS, Vrahas MS. Perioperative lower urinary tract infections and deep sepsis in patients undergoing total joint arthroplasty. J Am Acad Orthop Surg 2000; 8:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/20\">",
"      Robinson CM, Christie J, Malcolm-Smith N. Nonsteroidal antiinflammatory drugs, perioperative blood loss, and transfusion requirements in elective hip arthroplasty. J Arthroplasty 1993; 8:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/21\">",
"      Connelly CS, Panush RS. Should nonsteroidal anti-inflammatory drugs be stopped before elective surgery? Arch Intern Med 1991; 151:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/22\">",
"      Stoner SC, Lea JW, Dubisar BM, Farrar C. Possible international normalized ratio elevation associated with celecoxib and warfarin in an elderly psychiatric patient. J Am Geriatr Soc 2003; 51:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/23\">",
"      Stading JA, Skrabal MZ, Faulkner MA. Seven cases of interaction between warfarin and cyclooxygenase-2 inhibitors. Am J Health Syst Pharm 2001; 58:2076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/24\">",
"      Mersfelder TL, Stewart LR. Warfarin and celecoxib interaction. Ann Pharmacother 2000; 34:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/25\">",
"      Schwartz JI, Bugianesi KJ, Ebel DL, et al. The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin. Clin Pharmacol Ther 2000; 68:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/26\">",
"      Lindenauer PK, Pekow P, Wang K, et al. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 2004; 291:2092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/27\">",
"      Perhala RS, Wilke WS, Clough JD, Segal AM. Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. Arthritis Rheum 1991; 34:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/28\">",
"      Carpenter MT, West SG, Vogelgesang SA, Casey Jones DE. Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy. Orthopedics 1996; 19:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/29\">",
"      Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 2001; 60:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/30\">",
"      Sanders DP, McKinney FW, Harris WH. Clinical evaluation and cost effectiveness of preoperative laboratory assessment on patients undergoing total hip arthroplasty. Orthopedics 1989; 12:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/31\">",
"      Simank HG, Brocai DR, Brill C, Lukoschek M. Comparison of results of core decompression and intertrochanteric osteotomy for nontraumatic osteonecrosis of the femoral head using Cox regression and survivorship analysis. J Arthroplasty 2001; 16:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/32\">",
"      Millis MB, Murphy SB, Poss R. Osteotomies about the hip for the prevention and treatment of osteoarthrosis. Instr Course Lect 1996; 45:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/33\">",
"      Ganz R, Gill TJ, Gautier E, et al. Surgical dislocation of the adult hip a technique with full access to the femoral head and acetabulum without the risk of avascular necrosis. J Bone Joint Surg Br 2001; 83:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/34\">",
"      McCarthy JC. Hip Arthroscopy: Applications and Technique. J Am Acad Orthop Surg 1995; 3:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/35\">",
"      Callaghan JJ, Brand RA, Pedersen DR. Hip arthrodesis. A long-term follow-up. J Bone Joint Surg Am 1985; 67:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/36\">",
"      Sponseller PD, McBeath AA, Perpich M. Hip arthrodesis in young patients. A long-term follow-up study. J Bone Joint Surg Am 1984; 66:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/37\">",
"      Crawford R, Ranawat CS, Rothman RH. Metal on metal: is it worth the risk? J Arthroplasty 2010; 25:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/38\">",
"      Corten K, MacDonald SJ. Hip resurfacing data from national joint registries: what do they tell us? What do they not tell us? Clin Orthop Relat Res 2010; 468:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/39\">",
"      Shimmin A, Beaul&eacute; PE, Campbell P. Metal-on-metal hip resurfacing arthroplasty. J Bone Joint Surg Am 2008; 90:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/40\">",
"      Hatzidakis AM, Mendlick RM, McKillip T, et al. Preoperative autologous donation for total joint arthroplasty. An analysis of risk factors for allogenic transfusion. J Bone Joint Surg Am 2000; 82:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/41\">",
"      Stowell CP, Chandler H, Jov&eacute; M, et al. An open-label, randomized study to compare the safety and efficacy of perioperative epoetin alfa with preoperative autologous blood donation in total joint arthroplasty. Orthopedics 1999; 22:s105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/42\">",
"      Ranawat CS, Peters LE, Umlas ME. Fixation of the acetabular component. The case for cement. Clin Orthop Relat Res 1997; :207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/43\">",
"      McKellop H, Shen FW, DiMaio W, Lancaster JG. Wear of gamma-crosslinked polyethylene acetabular cups against roughened femoral balls. Clin Orthop Relat Res 1999; :73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/44\">",
"      McKellop H, Shen FW, Lu B, et al. Development of an extremely wear-resistant ultra high molecular weight polyethylene for total hip replacements. J Orthop Res 1999; 17:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/45\">",
"      Rizzetti MC, Catalani S, Apostoli P, Padovani A. Cobalt toxicity after total hip replacement: a neglected adverse effect? Muscle Nerve 2011; 43:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/46\">",
"      Mabilleau G, Kwon YM, Pandit H, et al. Metal-on-metal hip resurfacing arthroplasty: a review of periprosthetic biological reactions. Acta Orthop 2008; 79:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/47\">",
"      Sedrakyan A, Normand SL, Dabic S, et al. Comparative assessment of implantable hip devices with different bearing surfaces: systematic appraisal of evidence. BMJ 2011; 343:d7434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/48\">",
"      Zijlstra WP, Van Raay JJ, Bulstra SK, Deutman R. No Superiority of Cemented Metal-on-Metal Over Metal-on-Polyethylene THA in a Randomized Controlled Trial at 10-Year Follow-up. Orthopedics 2010; :154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/49\">",
"      Foster DE, Hunter JR. The direct lateral approach to the hip for arthroplasty. Advantages and complications. Orthopedics 1987; 10:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/50\">",
"      Callaghan JJ, Dysart SH, Savory CG. The uncemented porous-coated anatomic total hip prosthesis. Two-year results of a prospective consecutive series. J Bone Joint Surg Am 1988; 70:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/51\">",
"      Sherry E, Egan M, Henderson A, Warnke PH. Minimally invasive techniques for total hip arthroplasty. J Bone Joint Surg Am 2002; 84-A:1481; author reply 1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/52\">",
"      Wenz JF, Gurkan I, Jibodh SR. Mini-incision total hip arthroplasty: a comparative assessment of perioperative outcomes. Orthopedics 2002; 25:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/53\">",
"      Waldman BJ. Minimally invasive total hip replacement and perioperative management: early experience. J South Orthop Assoc 2002; 11:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/54\">",
"      Wright JM, Crockett HC, Sculco TP. Mini-incision for total hip arthroplasty. Orthopedic Special Edition 2001; 7:18.",
"     </a>",
"    </li>",
"    <li>",
"     Berger RA. Two-Incision Micromini Total Hip Replacement: When and When Not Indicated. Advances in Minimally Invasive Surgery of the Hip Symposium. Presented at: American Academy of Orthopaedic Surgeons 70th Annual Meeting. New Orleans; February 5, 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/56\">",
"      Wright JM, Crockett HC, Delgado S, et al. Mini-incision for total hip arthroplasty: a prospective, controlled investigation with 5-year follow-up evaluation. J Arthroplasty 2004; 19:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/55/10106/abstract/57\">",
"      Murphy SB, Gobezie R. Image-guided surgical navigation: Basic principles and applications to reconstructive surgery. Orthopaedic Journal at Harvard Medical School 2002; 4:68.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7972 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-219.243.220.100-C5CC09C3EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_55_10106=[""].join("\n");
var outline_f9_55_10106=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H392071945\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Comorbid medical problems and review of systems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Special tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CONSERVATIVE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ALTERNATIVES TO TOTAL HIP ARTHROPLASTY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Core decompression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Intertrochanteric osteotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Periacetabular osteotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Surgical dislocation and debridement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Resection arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Hip arthroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Hip arthrodesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Total hip resurfacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14257847\">",
"      Hemiarthroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      AUTOLOGOUS BLOOD DONATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PREVENTION OF PROSTHETIC JOINT INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      CHOICE OF PROSTHESIS AND FIXATION TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Implants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Acetabular implant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Bearing surface",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Femoral implant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Femoral head",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Posterolateral versus direct lateral versus anterior approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Minimally invasive versus standard techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Surgical navigation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H446375011\">",
"      POSTOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H392071945\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/19/42295?source=related_link\">",
"      Approach to the adult with asymptomatic bacteriuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=related_link\">",
"      Assessment and treatment of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1658?source=related_link\">",
"      Complications of total hip arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31605?source=related_link\">",
"      Controversial areas in preoperative autologous blood donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37861?source=related_link\">",
"      Evaluation and medical management of end-stage rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=related_link\">",
"      Evaluation of preoperative pulmonary risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22088?source=related_link\">",
"      Evaluation of the adult with hip pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=related_link\">",
"      Nonpharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=related_link\">",
"      Osteonecrosis (avascular necrosis of bone)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/34/23075?source=related_link\">",
"      Patient information: Hip replacement (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/30/21987?source=related_link\">",
"      Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29688?source=related_link\">",
"      Perioperative management of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40666?source=related_link\">",
"      Perioperative medication management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=related_link\">",
"      Pharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=related_link\">",
"      Preoperative autologous blood donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28198?source=related_link\">",
"      Prevention of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=related_link\">",
"      Urinary tract infection associated with urethral catheters",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_55_10107="Adjustments for missed appointments";
var content_f9_55_10107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F59180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F59180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adjustments in subcutaneous immunotherapy dosing for gaps in treatment",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Build-up phase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Up to 7 days late",
"       </td>",
"       <td>",
"        Continue build-up as scheduled",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8 to 13 days late",
"       </td>",
"       <td>",
"        Repeat previous dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14 to 21 days late",
"       </td>",
"       <td>",
"        Reduce dose 25 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        21 to 28 days late",
"       </td>",
"       <td>",
"        Reduce dose 50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Maintenance phase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2 to 4 weeks late",
"       </td>",
"       <td>",
"        Reduce dose 75 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;4 weeks late",
"       </td>",
"       <td>",
"        Reduce by&nbsp;one or more dilutions depending on length of time and patient sensitivity",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_55_10107=[""].join("\n");
var outline_f9_55_10107=null;
var title_f9_55_10108="Reversible cause incontinence B";
var content_f9_55_10108=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Identification and management of reversible conditions that cause or contribute to urinary incontinence: part B",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Condition",
"      </td>",
"      <td class=\"subtitle1\">",
"       Management",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Increased urine production",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Metabolic (hyperglycemia, hypercalcemia)",
"      </td>",
"      <td>",
"       Improved control of diabetes mellitus or treatment of hypercalcemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Excess fluid intake",
"      </td>",
"      <td>",
"       Reduction in intake of excess fluids, especially diuretic fluids (eg, caffeinated beverages, including soda, alcohol)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"2\" rowspan=\"1\">",
"       Volume overload:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Venous insufficiency with edema",
"      </td>",
"      <td class=\"sublist_other\">",
"       Support stockings; leg elevation; sodium restriction; diuretic therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Heart failure",
"      </td>",
"      <td class=\"sublist_other\">",
"       Medical therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Impaired ability or willingness to reach a toilet",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Delirium",
"      </td>",
"      <td>",
"       Diagnosis and treatment of underlying causes of acute confusional state",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Chronic illness, injury or restraint that interferes with mobility",
"      </td>",
"      <td>",
"       Address cause of impaired mobility, remove restrains if possible. Regular toileting; use of toilet substitutes and environmental alterations (eg, bedside commode, urinal)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Psychological",
"      </td>",
"      <td>",
"       Appropriate pharmacologic and/or nonpharmacologic treatment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Nocturia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Nocturnal polyuria",
"      </td>",
"      <td>",
"       Assess evening fluid intake, assess for volume overload, consider sleep apnea if other symptoms, signs, or risk factors present",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sleep disturbance",
"      </td>",
"      <td>",
"       Sleep hygiene; assess for pain, depression, and environmental causes; consider sleep apnea if other symptoms, signs, or risk factors present",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_55_10108=[""].join("\n");
var outline_f9_55_10108=null;
var title_f9_55_10109="LV structure and function in chronic heart failure";
var content_f9_55_10109=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Left ventricular structure and function in chronic heart failure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Systolic heart failure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diastolic heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        LV remodeling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        End-diastolic volume",
"       </td>",
"       <td class=\"centered\">",
"        &uarr;",
"       </td>",
"       <td class=\"centered\">",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        End-systolic volume",
"       </td>",
"       <td class=\"centered\">",
"        &uarr;",
"       </td>",
"       <td class=\"centered\">",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mass",
"       </td>",
"       <td class=\"centered\">",
"        &uarr;",
"       </td>",
"       <td class=\"centered\">",
"        &uarr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Geometry",
"       </td>",
"       <td class=\"centered\">",
"        Eccentric",
"       </td>",
"       <td class=\"centered\">",
"        Concentric",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cardiomyocyte",
"       </td>",
"       <td class=\"centered\">",
"        &uarr; Length",
"       </td>",
"       <td class=\"centered\">",
"        &uarr; Diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extracellular matrix",
"       </td>",
"       <td class=\"centered\">",
"        &darr; Collagen",
"       </td>",
"       <td class=\"centered\">",
"        &uarr; Collagen",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        LV systolic properties",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        Performance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Stroke volume",
"       </td>",
"       <td class=\"centered\">",
"        &darr; (or normal)",
"       </td>",
"       <td class=\"centered\">",
"        Normal (or &darr;)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Stroke work",
"       </td>",
"       <td class=\"centered\">",
"        &darr;",
"       </td>",
"       <td class=\"centered\">",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        Function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Preload recruitable stroke work",
"       </td>",
"       <td class=\"centered\">",
"        &darr;",
"       </td>",
"       <td class=\"centered\">",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Ejection fraction",
"       </td>",
"       <td class=\"centered\">",
"        &darr;",
"       </td>",
"       <td class=\"centered\">",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        Contractility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        (+)dP/dt",
"       </td>",
"       <td class=\"centered\">",
"        &darr;",
"       </td>",
"       <td class=\"centered\">",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        End-systolic elastance",
"       </td>",
"       <td class=\"centered\">",
"        &darr;",
"       </td>",
"       <td class=\"centered\">",
"        Normal (or &uarr;)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Stress shortening",
"       </td>",
"       <td class=\"centered\">",
"        &darr;",
"       </td>",
"       <td class=\"centered\">",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Preload reserve",
"       </td>",
"       <td class=\"centered\">",
"        Exhausted",
"       </td>",
"       <td class=\"centered\">",
"        Limited",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        LV diastolic properties",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        End diastolic pressure",
"       </td>",
"       <td class=\"centered\">",
"        &uarr;",
"       </td>",
"       <td class=\"centered\">",
"        &uarr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tau",
"       </td>",
"       <td class=\"centered\">",
"        &uarr;",
"       </td>",
"       <td class=\"centered\">",
"        &uarr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chamber stiffness",
"       </td>",
"       <td class=\"centered\">",
"        &darr;",
"       </td>",
"       <td class=\"centered\">",
"        &uarr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myocardial stiffness",
"       </td>",
"       <td class=\"centered\">",
"        Normal (or &uarr;)",
"       </td>",
"       <td class=\"centered\">",
"        &uarr;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Michael Zile.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_55_10109=[""].join("\n");
var outline_f9_55_10109=null;
var title_f9_55_10110="Physiologic anemia of pregnancy";
var content_f9_55_10110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Physiologic anemia of pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 271px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representations of the increases in intravascular volume that occur during pregnancy. Plasma volume increases more than the total red cell volume (50 versus 25 percent), resulting in a 40 percent rise in blood volume and a dilutional fall in the hematocrit.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_55_10110=[""].join("\n");
var outline_f9_55_10110=null;
var title_f9_55_10111="Fixation of proximal humerus fracture";
var content_f9_55_10111=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Surgical fixation of a proximal humerus fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This postoperative anteroposterior radiograph shows the result of an open reduction and internal fixation of a displaced proximal humerus fracture. Preoperatively, this&nbsp;injury was&nbsp;categorized as \"two-part\" fracture using the Neer classification system.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_55_10111=[""].join("\n");
var outline_f9_55_10111=null;
